Pharmaceutical formulations of a bruton&#39;s tyrosine kinase inhibitor

ABSTRACT

Described herein are pharmaceutical formulations of Bruton&#39;s tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No.15/862,995, filed Jan. 5, 2018, which is a continuation of U.S. patentapplication Ser. No. 15/467,414, filed Mar. 23, 2017, now abandoned,which is a continuation of U.S. patent application Ser. No. 15/060,010,filed Mar. 3, 2016, now U.S. Pat. No. 9,655,857, issued May 23, 2017,which claims the benefit of U.S. Provisional Application No. 62/127,717,filed Mar. 3, 2015, and U.S. Provisional Application No. 62/193,518,filed Jul. 16, 2015, which are each incorporated herein by reference intheir entireties.

FIELD OF THE INVENTION

Described herein is the Bruton's tyrosine kinase (Btk) inhibitor1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,including pharmaceutical compositions, solvates and pharmaceuticallyacceptable salts thereof, as well as pharmaceutical formulations thatinclude the Btk inhibitor and methods of using the Btk inhibitorcompositions or formulations in the treatment of diseases or conditionsthat would benefit from inhibition of Btk activity.

BACKGROUND OF THE INVENTION

Bruton's tyrosine kinase (Btk), a member of the Tec family ofnon-receptor tyrosine kinases, is a key signaling enzyme expressed inall hematopoietic cells types except T lymphocytes and natural killercells. Btk plays an essential role in the B-cell signaling pathwaylinking cell surface B-cell receptor (BCR) stimulation to downstreamintracellular responses.

Btk is a key regulator of B-cell development, activation, signaling, andsurvival. In addition, Btk plays a role in a number of otherhematopoietic cell signaling pathways, e.g., Toll like receptor (TLR)and cytokine receptor-mediated TNF-α production in macrophages, IgEreceptor (FcepsilonRI) signaling in Mast cells, inhibition of Fas/APO-1apoptotic signaling in B-lineage lymphoid cells, and collagen-stimulatedplatelet aggregation.

1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-oneis also known by its IUPAC name as1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-oneor 2-Propen-1-one,1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl-,and has been given the USAN name, ibrutinib. The various names given foribrutinib are used interchangeably herein.

SUMMARY OF THE INVENTION

Described herein is the Btk inhibitor1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,including pharmaceutically acceptable compositions, formulations, andmethods of uses thereof. Also described are pharmaceutically acceptablecompositions and formulations of the Btk inhibitor,1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,used in the manufacture of medicaments for the treatment of diseases orconditions that are associated with Btk activity.1-((R)-3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-oneis an irreversible Btk inhibitor. Further described are pharmaceuticalcompositions and formulations of the Btk inhibitor,1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,and methods of using the Btk inhibitor in the treatment of diseases orconditions (including diseases or conditions wherein irreversibleinhibition of Btk provides therapeutic benefit to a mammal having thedisease or condition).

Also described herein is a process for preparing a pharmaceuticalcomposition of1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-oneby a wet granulation method. Further described are pharmaceuticalformulations that include a pharmaceutical composition of1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-oneprepared by a wet granulation method.

In one aspect is a pharmaceutical composition comprising ibrutinib,wherein ibrutinib is a compound with the structure of Compound 1,

and wherein the pharmaceutical composition comprises at least 50% w/w ofibrutinib.

In another embodiment is a pharmaceutical composition comprisingibrutinib, wherein the pharmaceutical composition comprises about 50%w/w to about 90% w/w of ibrutinib. In another embodiment is apharmaceutical composition comprising ibrutinib, wherein thepharmaceutical composition comprises about 50% w/w to about 80% w/w ofibrutinib. In another embodiment is a pharmaceutical compositioncomprising ibrutinib, wherein the pharmaceutical composition comprisesabout 60% w/w to about 80% w/w of ibrutinib. In another embodiment is apharmaceutical composition comprising ibrutinib, wherein thepharmaceutical composition comprises about 60% w/w to about 75% w/w ofibrutinib. In another embodiment is a pharmaceutical compositioncomprising at least 50% w/w of ibrutinib, wherein the pharmaceuticalcomposition comprises intragranular and extragranular ingredients. Inanother embodiment is a pharmaceutical composition comprising at least50% w/w of ibrutinib, wherein the pharmaceutical composition is preparedusing a wet granulation method. In another embodiment is apharmaceutical composition comprising at least 50% w/w of ibrutinib,further comprising at least one pharmaceutically acceptable excipient.

In another embodiment is a high-load solid tablet formulation comprisinga pharmaceutical composition comprising at least 50% w/w of ibrutinib,about 50% w/w to about 90% w/w of ibrutinib, about 50% w/w to about 80%w/w of ibrutinib, about 60% w/w to about 80% w/w of ibrutinib, or about60% w/w to about 75% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients. In another embodiment is a high-load solid tabletformulation comprising a pharmaceutical composition comprising at least50% w/w of ibrutinib, about 50% w/w to about 90% w/w of ibrutinib, about50% w/w to about 80% w/w of ibrutinib, about 60% w/w to about 80% w/w ofibrutinib, or about 60% w/w to about 75% w/w of ibrutinib, and one ormore pharmaceutically acceptable excipients wherein the one or moreexcipients are present in an amount from about 10% w/w to about 50% w/w.

In another embodiment is a high-load solid tablet formulation comprisingat least 50% w/w of ibrutinib, about 50% w/w to about 90% w/w ofibrutinib, about 50% w/w to about 80% w/w of ibrutinib, about 60% w/w toabout 80% w/w of ibrutinib, or about 60% w/w to about 75% w/w ofibrutinib, and one or more pharmaceutically acceptable excipientswherein the one or more excipients are selected from the groupconsisting of diluents, binders, disintegrating agents, lubricants,glidants, and surfactants. In some embodiments, at least one excipientis a diluent. In some embodiments, the diluent is selected from thegroup consisting of lactose, sucrose, dextrose, dextrates, maltodextrin,mannitol, xylitol, sorbitol, cyclodextrins, calcium phosphate, calciumsulfate, starches, modified starches, cellulose, microcrystallinecellulose, microcellulose, and talc. In some embodiments, the diluent iscellulose. In some embodiments, the diluent is the diluent is lactose;and lactose is present in an amount from about 5% w/w to about 20% w/w,about 8% w/w to about 20% w/w, or about 8% w/w to about 15% w/w. In someembodiments, the diluent is lactose; and lactose is present in an amountof about 8.5% w/w or about 14% w/w. In some embodiments, the diluent ismicrocrystalline cellulose. In some embodiments, the diluent ismicrocrystalline cellulose and the microcrystalline cellulose is presentin an amount from about 1% w/w to about 20% w/w, about 1% w/w to about10% w/w, about 1% w/w to about 5% w/w, 1% w/w to about 2% w/w, about 5%w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w toabout 15% w/w. In some embodiments, the diluent is microcrystallinecellulose and the microcrystalline cellulose is present in an amountfrom about 1% w/w to about 6% w/w or about 8.5% w/w or about 14% w/w. Insome embodiments, the diluent comprises lactose and microcrystallinecellulose. In some embodiments, the lactose is present in an amount ofabout 10% w/w to about 15% w/w and microcrystalline cellulose is presentin an amount from about 1% w/w to about 6% w/w. In some embodiments, thelactose is present in an amount of about 14% w/w and microcrystallinecellulose is present in an amount from about 2% w/w to about 5% w/w. Insome embodiments, at least one excipient is a disintegrating agent. Insome embodiments, the disintegrating agent is selected from the groupconsisting of natural starch, a pregelatinized starch, a sodium starch,methylcrystalline cellulose, methylcellulose, croscarmellose,croscarmellose sodium, cross-linked sodium carboxymethylcellulose,cross-linked carboxymethylcellulose, cross-linked croscarmellose,cross-linked starch such as sodium starch glycolate, cross-linkedpolymer such as crospovidone, cross-linked polyvinylpyrrolidone, sodiumalginate, a clay, and a gum. In some embodiments, the disintegratingagent is croscarmellose sodium; and croscarmellose sodium is present inan amount from about 0 to about 20% w/w, about 1% w/w to about 10% w/w,about 5% w/w to about 10% w/w, about 6% w/w to about 8% w/w, about 4%w/w to about 6% w/w, or about 2% w/w to about 4% w/w. In someembodiments, at least one excipient is a binder. In some embodiments,the binder is hydroxypropyl cellulose; and hydroxypropyl cellulose ispresent in an amount from about 0 to about 10% w/w, about 0 to about 5%w/w, about 0 to about 2% w/w, about 0.1% w/w to about 1.1% w/w, or about0.1% w/w to about 1% w/w. In some embodiments, the binder ispolyvinylpyrrolidone. In some embodiments, the polyvinylpyrrolidone ispresent in an amount from about 0 to about 10% w/w, about 1 to about 5%w/w, or about 2% w/w. In some embodiments, the formulation compriseslactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose. In some embodiments, at least one excipient isa surfactant. In some embodiments, the surfactant is sodium laurylsulfate. In some embodiments, the surfactant is sodium lauryl sulfate inan amount from about 0 to about 10% w/w, about 0.5 to about 5% w/w,about 1 to about 4% w/w, about 4% w/w to about 8% w/w, or about 5% w/wto about 6% w/w. In some embodiments, at least one excipient is aglidant. In some embodiments, the glidant is silica (colloidal silicondioxide). In some embodiments, the glidant is silica (colloidal silicondioxide) and the silica (colloidal silicon dioxide) is present in anamount from about 0 to about 5% w/w, 0.1% w/w to about 1.5% w/w, about0.4% w/w to about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, at least one excipient is a lubricant. In some embodiments,the lubricant is magnesium stearate. In some embodiments, the lubricantis magnesium stearate and the magnesium stearate is present in an amountfrom about 0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1%w/w to about 0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, the excipients comprise, consist essentially of, orconsist, lactose, microcrystalline cellulose, polyvinylpyrrolidone,croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxideand magnesium stearate. In another embodiment, the excipients comprise,consist essentially of, or consist, lactose, polyvinylpyrrolidone,sodium lauryl sulfate, crospovidone, colloidal silicon dioxide, andmagnesium stearate.

In another embodiment is a high-load solid tablet formulation comprisingat least 50% w/w of ibrutinib, about 50% w/w to about 90% w/w ofibrutinib, about 50% w/w to about 80% w/w of ibrutinib, about 60% w/w toabout 80% w/w of ibrutinib, or about 60% w/w to about 75% w/w ofibrutinib, and intragranular and extragranular excipients; wherein theintragranular excipients comprise, consist essentially of, or consistlactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose; and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment is a high-load solidtablet formulation comprising at least 50% w/w of ibrutinib, about 50%w/w to about 90% w/w of ibrutinib, about 50% w/w to about 80% w/w ofibrutinib, about 60% w/w to about 80% w/w of ibrutinib, or about 60% w/wto about 75% w/w of ibrutinib, wherein the intragranular excipientscomprise

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0 to about 10%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 4%        w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.1% w/w to about        1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5% w/w to        about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprisingat least 50% w/w of ibrutinib, about 50% w/w to about 90% w/w ofibrutinib, about 50% w/w to about 80% w/w of ibrutinib, about 60% w/w toabout 80% w/w of ibrutinib, or about 60% w/w to about 75% w/w ofibrutinib, and intragranular and extragranular excipients; wherein theintragranular excipients comprise lactose, microcrystalline cellulose,sodium lauryl sulfate, polyvinylpyrrolidone and croscarmellose sodium;and the extragranular excipients comprise croscarmellose sodium, sodiumlauryl sulfate, colloidal silicon dioxide, and magnesium stearate. Inanother embodiment is a high-load solid tablet formulation comprising atleast 50% w/w of ibrutinib, about 50% w/w to about 90% w/w of ibrutinib,about 50% w/w to about 80% w/w of ibrutinib, about 60% w/w to about 80%w/w of ibrutinib, or about 60% w/w to about 75% w/w of ibrutinib,wherein the intragranular excipients comprise

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0 to about 2% w/w,        about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0 to about 5% w/w,        about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0 to about 10% w/w        or about 0% w/w to about 4% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprising

-   -   a) about 69% w/w to about 71% w/w of ibrutinib,    -   b) about 13% w/w to about 15% w/w of lactose,    -   c) about 2% w/w to about 5% w/w of microcrystalline cellulose,    -   d) about 1% w/w to about 3% w/w of polyvinylpyrrolidone,    -   e) about 6% w/w to about 8% w/w of croscarmellose sodium,    -   f) about 1% w/w to about 4% w/w of sodium lauryl sulfate,    -   g) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   h) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In another embodiment is a high-load solid tablet formulation comprising

-   -   a) about 70% w/w of ibrutinib,    -   b) about 14% w/w of lactose monohydrate,    -   c) about 5% w/w of microcrystalline cellulose,    -   d) about 2% w/w of polyvinylpyrrolidone,    -   e) about 7% w/w of croscarmellose sodium,    -   f) about 1% w/w of sodium lauryl sulfate,    -   g) about 0.5% w/w of colloidal silicon dioxide, and    -   h) about 0.5% w/w of magnesium stearate.

In another embodiment is a high-load solid tablet formulation comprising

-   -   a) about 70% w/w of ibrutinib,    -   b) about 14% w/w of lactose monohydrate,    -   c) about 2% w/w of microcrystalline cellulose,    -   d) about 2% w/w of polyvinylpyrrolidone,    -   e) about 7% w/w of croscarmellose sodium,    -   f) about 4% w/w of sodium lauryl sulfate,    -   g) about 0.5% w/w of colloidal silicon dioxide, and    -   h) about 0.5% w/w of magnesium stearate.

In another embodiment is a high-load solid tablet formulation comprising

-   -   a) about 70% w/w of ibrutinib,    -   b) about 16% w/w of lactose,    -   c) about 2% w/w of polyvinylpyrrolidone,    -   d) about 1% w/w of sodium lauryl sulfate,    -   e) about 10% w/w of crospovidone,    -   f) about 0.5% w/w of colloidal silicon dioxide, and    -   g) about 0.5% w/w of magnesium stearate.

In another embodiment is a high-load solid tablet formulation comprising

-   -   a) about 59% w/w to about 61% w/w of ibrutinib,    -   b) about 13% w/w to about 15% w/w of lactose,    -   c) about 13% w/w to about 15% w/w of microcrystalline cellulose,    -   d) about 4% w/w to about 6% w/w of croscarmellose sodium,    -   e) about 5% w/w to about 7% w/w of sodium lauryl sulfate,    -   f) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   g) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In some embodiments, the total weight of a tablet is about 934 mg.

In another embodiment is a high-load solid tablet formulation comprising

-   -   a) about 59% w/w to about 61% w/w of ibrutinib,    -   b) about 13% w/w to about 14% w/w of lactose,    -   c) about 13% w/w to about 14% w/w of microcrystalline cellulose,    -   d) about 2% w/w to about 3% w/w of croscarmellose sodium        (intragranular),    -   e) about 0.8% w/w to about 1.2% w/w of hydroxypropyl cellulose,    -   f) about 2% w/w to about 3% w/w of croscarmellose sodium        (extragranular),    -   g) about 5.5 to about 6.5% w/w of sodium lauryl sulfate,    -   h) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   i) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In some embodiments, the total weight of a tablet is about 934 mg.

In another embodiment is a high-load solid tablet formulation comprising

-   -   a) about 69% w/w to about 71% w/w of ibrutinib,    -   b) about 8% w/w to about 9% w/w of lactose,    -   c) about 8 to about 9% w/w of microcrystalline cellulose,    -   d) about 2.5 to about 3.5% w/w of croscarmellose sodium        (intragranular),    -   e) about 2.5 to about 3.5% w/w of croscarmellose sodium        (extragranular),    -   g) about 5.5 to about 6.5% w/w of sodium lauryl sulfate,    -   h) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   i) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

Lactose used herein may be anhydrous lactose and/or hydrous lactose,such as lactose monohydrate. In some embodiments, the lactose isanhydrous lactose. In some particular embodiments, the lacose is hydrouslactose. In more particular embodiments, the lacose is lactosemonohydrate.

In some embodiments, the total weight of a tablet is about 800 mg.

In some embodiments of the high-load solid tablet formulations describedherein, the ibrutinib is in an amount of about 35 mg to about 840 mg pertablet. In some embodiments of the high-load solid tablet formulationsdescribed herein, the ibrutinib is in an amount of about 140 mg to about840 mg per tablet. In some embodiments of the high-load solid tabletformulations described herein, the ibrutinib is in an amount of about140 mg, about 280 mg, about 420 mg, about 560 mg, or about 840 mg pertablet, or any range between any two of the values, end pointsinclusive. In some embodiments of the high-load solid tabletformulations described herein, the ibrutinib is in an amount of about560 mg. In some embodiments of the high-load solid tablet formulationsdescribed herein, the ibrutinib is in micronized form. In someembodiments of the high-load solid tablet formulations described herein,the formulation is used for once a day dosing. In some embodiments ofthe high-load solid tablet formulations described herein, theformulation is in an oral dosage form containing a therapeuticallyeffective amount of ibrutinib.

In another embodiment is a method of treating a disease in a patient inneed of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein.

In another embodiment is a method of treating an autoimmune disease in apatient in need of such treatment, comprising administering to thepatient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein. In some embodiments, theautoimmune disease is rheumatoid arthritis or lupus.

In another embodiment is a method of treating a heteroimmune disease ina patient in need of such treatment, comprising administering to thepatient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein.

In another embodiment is a method of treating cancer in a patient inneed of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein. In some embodiments, the cancer is aB-cell proliferative disorder. In some embodiments, the cancer is aB-cell proliferative disorder and the B-cell proliferative disorder isdiffuse large B cell lymphoma, follicular lymphoma or chroniclymphocytic leukemia. In some embodiments, the cancer is a B cellmalignancy. In some embodiments, the cancer is a B cell malignancy andthe B cell malignancy selected from chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL),diffuse large B Cell lymphoma (DLBCL), and multiple myeloma. In someembodiments, the cancer is a lymphoma, leukemia or a solid tumor. Insome embodiments, the cancer is diffuse large B cell lymphoma,follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocyticleukemia, B-cell prolymphocytic leukemia, lymphoplasmacyticlymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma,plasma cell myeloma, plasmacytoma, extranodal marginal zone B celllymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma,mediastinal (thymic) large B cell lymphoma, intravascular large B celllymphoma, primary effusion lymphoma, burkitt lymphoma/leukemia, orlymphomatoid granulomatosis.

In another embodiment is a method of treating mastocytosis in a patientin need of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein.

In another embodiment is a method of treating osteoporosis or boneresorption disorders in a patient in need of such treatment, comprisingadministering to the patient a therapeutically effective amount of apharmaceutical composition or formulation described herein.

In another embodiment is a method of treating an inflammatory disease orcondition in a patient in need of such treatment, comprisingadministering to the patient a therapeutically effective amount of apharmaceutical composition or formulation described herein.

In another embodiment is a method of treating lupus in a patient in needof such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein.

In some embodiments, the formulations and methods described herein canbe used to treat carcinoma of the brain, kidney, liver, adrenal gland,bladder, breast, stomach, gastric tumors, ovaries, colon, rectum,prostate, pancreas, lung, vagina, cervix, testis, genitourinary tract,esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastomas,neuroblastomas, multiple myeloma, gastrointestinal cancer, especiallycolon carcinoma or colorectal adenoma, a tumor of the neck and head, anepidermal hyperproliferation, psoriasis, prostate hyperplasia, aneoplasia, a neoplasia of epithelial character, adenoma, adenocarcinoma,keratoacanthoma, epidermoid carcinoma, large cell carcinoma,non-small-cell lung carcinoma, lymphomas, Hodgkins and Non-Hodgkins, amammary carcinoma, follicular carcinoma, undifferentiated carcinoma,papillary carcinoma, seminoma, melanoma, or Smoldering of indolentmultiple myeloma.

In some embodiments, the formulations and methods described herein canbe used to treat a central nervous system (CNS) malignancy. In someembodiments, the CNS malignancy is a primary CNS lymphoma. In someembodiments the primary CNS lymphoma is a glioma. In some embodimentsthe glioma is astrocytomas, ependymomas, oligodendrogliomas. In someembodiments the CNS malignancy is astrocytic tumors such as juvenilepilocytic, subependymal, well differentiated or moderatelydifferentiated anaplastic astrocytoma; anaplastic astrocytoma;glioblastoma multiforme; ependymal tumors such as myxopapillary andwell-differentiated ependymoma, anaplastic ependymoma, ependymoblastoma;oligodendroglial tumors including well-differentiated oligodendrogliomaand anaplastic oligodendroglioma; mixed tumors such as mixedastrocytoma-ependymoma, mixed astrocytoma-oligodendroglioma, mixedastrocytomaependymoma-oligodendroglioma; or medulloblastoma.

In some embodiments, the formulations and methods described herein canbe used to treat hematological malignancies such as, but not limited to,a leukemia, a lymphoma, a myeloma, a non-Hodgkin's lymphoma, a Hodgkin'slymphoma, a T-cell malignancy, or a B-cell malignancy. In someembodiments, the hematological malignancy is a treatment naïvehematological malignancy. In some embodiments the hematologicalmalignancy is a relapsed or refractory hematological malignancy.

In some embodiments, the hematologic malignancy is a T-cell malignancy.In some embodiments, the T-cell malignancy is peripheral T-cell lymphomanot otherwise specified (PTCL-NOS), anaplastic large cell lymphoma,angioimmunoblastic lymphoma, cutaneous T-cell lymphoma, adult T-cellleukemia/lymphoma (ATLL), blastic NK-cell lymphoma, enteropathy-typeT-cell lymphoma, hematosplenic gamma-delta T-cell lymphoma,lymphoblastic lymphoma, nasal NK/T-cell lymphomas, or treatment-relatedT-cell lymphomas. In some embodiments, the T-cell malignancy is arelapsed or refractory T-cell malignancy. In some embodiments, theT-cell malignancy is a treatment naïve T-cell malignancy.

In some embodiments, the hematologic malignancy is a B-cellproliferative disorder. In some embodiments, the cancer is chroniclymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high riskCLL, a non-CLL/SLL lymphoma, or prolymphocytic leukemia (PLL). In someembodiments, the cancer is follicular lymphoma (FL), diffuse largeB-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom'smacroglobulinemia, multiple myeloma, extranodal marginal zone B celllymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma,non-Burkitt high grade B cell lymphoma, primary mediastinal B-celllymphoma (PMBL), immunoblastic large cell lymphoma, precursorB-lymphoblastic lymphoma, B cell prolymphocytic leukemia,lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cellmyeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma,intravascular large B cell lymphoma, primary effusion lymphoma, orlymphomatoid granulomatosis. In some embodiments, DLBCL is furtherdivided into subtypes: activated B-cell diffuse large B-cell lymphoma(ABC-DLBCL), germinal center diffuse large B-cell lymphoma (GCB DLBCL),and Double-Hit (DH) DLBCL. In some embodiments, ABC-DLBCL ischaracterized by a CD79B mutation. In some embodiments, ABC-DLBCL ischaracterized by a CD79A mutation. In some embodiments, the ABC-DLBCL ischaracterized by a mutation in MyD88, A20, or a combination thereof. Insome embodiments, the cancer is acute or chronic myelogenous (ormyeloid) leukemia, myelodysplastic syndrome, or acute lymphoblasticleukemia. In some embodiments, the B-cell proliferative disorder is arelapsed and refractory B-cell proliferative disorder. In someembodiments, the B-cell proliferative disorder is a treatment naïveB-cell proliferative disorder.

In some embodiments, the formulations and methods described herein canbe used to treat fibrosis. In some embodiments, the fibrosis is notassociated with graft versus host disease (GVHD). In some embodiments,the fibrosis is not associated with sclerodermatous GVHD, lung chronicGVHD, or liver chronic GVHD. In some embodiments, the fibrosis is of theliver, lung, pancreas, kidney, bone marrow, heart, skin, intestine, orjoints. In some embodiments, the fibrosis is of the liver. In someembodiments, the fibrosis is of the lung. In some embodiments, thefibrosis is of the pancreas. In some embodiments, the patient hascirrhosis, chronic pancreatitis, or cystic fibrosis.

In another aspect is a process for preparing a pharmaceuticalcomposition or tablet formulation comprising ibrutinib as describedherein, wherein the process comprises a wet granulation method.

In another aspect is a high-load solid tablet formulation comprisingibrutinib, wherein ibrutinib is a compound with the structure ofCompound 1,

and the tablet comprises about 560 mg of ibrutinib.

In another embodiment is a high-load solid tablet formulation, whereinibrutinib is in micronized form. In another embodiment, ibrutinib is inspray-dried form. In another embodiment, ibrutinib is not in spray-driedform. In another embodiment, the particle size is about or less than 30micron. In one embodiment, ibrutinib is in micronized form and theparticle size is about 1-30 micron. In another embodiment, the particlesize is about or less than 10 micron. In another embodiment, theparticle size is <1 micron. In another embodiment is a high-load solidtablet formulation, wherein the tablet is used for once a day oraldosing.

In another aspect, provided herein are methods for treating a patient byadministering Compound 1. In some embodiments, provided herein is amethod of inhibiting the activity of tyrsoine kinase(s), such as Btk, orof treating a disease, disorder, or condition, which would benefit frominhibition of tyrosine kinase(s), such as Btk, in a mammal, whichincludes administering to the mammal a therapeutically effective amountof Compound 1, or pharmaceutically acceptable salt, pharmaceuticallyactive metabolite, pharmaceutically acceptable prodrug, orpharmaceutically acceptable solvate.

In another aspect, provided herein is the use of Compound 1 forinhibiting Bruton's tyrosine kinase (Btk) activity or for the treatmentof a disease, disorder, or condition, which would benefit frominhibition of Bruton's tyrosine kinase (Btk) activity.

In some embodiments, a pharmaceutical composition comprising crystallineCompound 1 is administered to a human. In some embodiments, apharmaceutical composition comprising amorphous Compound 1 isadministered to a human.

In some embodiments, a pharmaceutical composition comprising crystallineCompound 1 is orally administered. In some embodiments, a pharmaceuticalcomposition comprising amorphous Compound 1 is orally administered.

In some embodiments, a pharmaceutical composition comprising crystallineCompound 1 is used for the formulation of a medicament for theinhibition of tyrosine kinase activity. In some other embodiments, apharmaceutical composition comprising crystalline Compound 1 is used forthe formulation of a medicament for the inhibition of Bruton's tyrosinekinase (Btk) activity. In some embodiments, a pharmaceutical compositioncomprising amorphous Compound 1 is used for the formulation of amedicament for the inhibition of tyrosine kinase activity. In some otherembodiments, a pharmaceutical composition comprising amorphous Compound1 is used for the formulation of a medicament for the inhibition ofBruton's tyrosine kinase (Btk) activity.

In some embodiments, in any of the embodiments disclosed herein(including compositions, methods, uses, formulations, combinationtherapy, etc.), Compound 1, or a pharmaceutically acceptable salt orsolvate thereof, is optically pure (i.e. greater than 99% chiral purityby HPLC). In some embodiments, in any of the embodiments disclosedherein (including compositions, methods, uses, formulations, combinationtherapy, etc.), Compound 1, or a pharmaceutically acceptable salt orsolvate thereof, is replaced with: a) Compound 1, or a pharmaceuticallyacceptable salt or solvate thereof, of lower chiral purity; b)1-((S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,or a pharmaceutically acceptable salt or solvate thereof of any opticalpurity; or c) racemic1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,or a pharmaceutically acceptable salt or solvate thereof.

In any of the embodiments disclosed herein (including compositions,methods, uses, formulations, combination therapy, etc.), amorphousCompound 1 is used. In any of the embodiments disclosed herein(including compositions, methods, uses, formulations, combinationtherapy, etc.), crystalline Compound 1 is used.

In some embodiments, in any of the embodiments disclosed herein(including compositions, methods, uses, formulations, combinationtherapy, etc.), Compound 1, or a pharmaceutically acceptable saltthereof, is replaced with an active metabolite of Compound 1. In someembodiments, the active metabolite is in a crystalline form. In someembodiments, the active metabolite is in an amorphous phase. In furtherembodiments the metabolite is isolated. In some embodiments, in any ofthe embodiments disclosed herein (including compositions, methods, uses,formulations, combination therapy, etc.), Compound 1, or apharmaceutically acceptable salt thereof, is replaced with a prodrug ofCompound 1, or a deuterated analog of Compound 1, or a pharmaceuticallyacceptable salt thereof.

Other objects, features and advantages of the methods and compositionsdescribed herein will become apparent from the following detaileddescription. It should be understood, however, that the detaileddescription and the specific examples, while indicating specificembodiments, are given by way of illustration only, since variouschanges and modifications within the spirit and scope of the presentdisclosure will become apparent to those skilled in the art from thisdetailed description. The section headings used herein are fororganizational purposes only and are not to be construed as limiting thesubject matter described. All documents, or portions of documents, citedin the application including, but not limited to, patents, patentapplications, articles, books, manuals, and treatises are herebyexpressly incorporated by reference in their entirety for any purpose.

INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specificationare herein incorporated by reference to the extent applicable andrelevant.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows mean plasma concentration-time profiles of ibrutinibfollowing single oral dose administration of a capsule formulationversus three different wet tablet formulations to fasted beagle dogs(Dose=140 mg).

FIG. 2 shows mean plasma concentration-time profiles of ibrutinibfollowing single oral dose administration of a capsule formulationversus two different dry tablet formulations to fasted beagle dogs(Dose=140 mg).

FIG. 3 is a photo of examples: (A) a capsule comprising 140 mg ibrutinib(Formulation A), and tablets of the invention (B-E) designed to comprise560 mg, 420 mg, 280 mg, and 140 mg of ibrutinib, respectively.

DETAILED DESCRIPTION OF THE INVENTION

The diverse roles played by Btk signaling in various hematopoietic cellfunctions, e.g., B-cell receptor activation, suggests that smallmolecule Btk inhibitors, such as Compound 1, are useful for reducing therisk of or treating a variety of diseases affected by or affecting manycell types of the hematopoietic lineage including, e.g., autoimmunediseases, heteroimmune conditions or diseases, inflammatory diseases,cancer (e.g., B-cell proliferative disorders), and thromboembolicdisorders. Further, irreversible Btk inhibitor compounds, such asCompound 1, can be used to inhibit a small subset of other tyrosinekinases that share homology with Btk by having a cysteine residue(including a Cys 481 residue) that can form a covalent bond with theirreversible inhibitor.

In some embodiments, the compositions or tablet formulations comprisingCompound 1 can be used in the treatment of an autoimmune disease in amammal, which includes, but is not limited to, rheumatoid arthritis,psoriatic arthritis, osteoarthritis, Still's disease, juvenilearthritis, lupus, diabetes, myasthenia gravis, Hashimoto's thyroiditis,Ord's thyroiditis, Graves' disease Sjögren's syndrome, multiplesclerosis, Guillain-Barrd syndrome, acute disseminatedencephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome,ankylosing spondylitisis, antiphospholipid antibody syndrome, aplasticanemia, autoimmune hepatitis, coeliac disease, Goodpasture's syndrome,idiopathic thrombocytopenic purpura, optic neuritis, scleroderma,primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis,temporal arteritis, warm autoimmune hemolytic anemia, Wegener'sgranulomatosis, psoriasis, alopecia universalis, Behçet's disease,chronic fatigue, dysautonomia, endometriosis, interstitial cystitis,neuromyotonia, scleroderma, and vulvodynia.

In some embodiments, the compositions or tablet formulations comprisingCompound 1 can be used in the treatment of a heteroimmune disease orcondition in a mammal, which include, but are not limited to graftversus host disease, transplantation, transfusion, anaphylaxis,allergies (e.g., allergies to plant pollens, latex, drugs, foods, insectpoisons, animal hair, animal dander, dust mites, or cockroach calyx),type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, andatopic dermatitis.

In some embodiments, the compositions or tablet formulations comprisingCompound 1 can be used in the treatment of an inflammatory disease in amammal, which includes, but is not limited to asthma, inflammatory boweldisease, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis,cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis,cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis,endocarditis, endometritis, enteritis, enterocolitis, epicondylitis,epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis,hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis,myelitis myocarditis, myositis, nephritis, oophoritis, orchitis,osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis,pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, proctitis,prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis,stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis,vasculitis, and vulvitis. In some embodiments, the inflammatory diseaseis asthma, appendicitis, blepharitis, bronchiolitis, bronchitis,bursitis, cervicitis, cholangitis, cholecystitis, colitis,conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis,encephalitis, endocarditis, endometritis, enteritis, enterocolitis,epicondylitis, epididymitis, fasciitis, fibrositis, gastritis,gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis,mastitis, meningitis, myelitis myocarditis, myositis, nephritis,oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis,pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis,pneumonitis, pneumonia, proctitis, prostatitis, pyelonephritis,rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis,tonsillitis, uveitis, vaginitis, vasculitis, or vulvitis. In someembodiments, the autoimmune disease is inflammatory bowel disease,arthritis, lupus, rheumatoid arthritis, psoriatic arthritis,osteoarthritis, Still's disease, juvenile arthritis, diabetes,myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves'disease Sjögren's syndrome, multiple sclerosis, Guillain-Barre syndrome,acute disseminated encephalomyelitis, Addison's disease,opsoclonus-myoclonus syndrome, ankylosing spondylitisis,antiphospholipid antibody syndrome, aplastic anemia, autoimmunehepatitis, coeliac disease, Goodpasture's syndrome, idiopathicthrombocytopenic purpura, optic neuritis, scleroderma, primary biliarycirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis,warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis,alopecia universalis, Behçet's disease, chronic fatigue, dysautonomia,endometriosis, interstitial cystitis, neuromyotonia, scleroderma, orvulvodynia.

In yet other embodiments, the methods described herein can be used totreat a cancer, e.g., B-cell proliferative disorders, which include, butare not limited to diffuse large B cell lymphoma, follicular lymphoma,chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cellprolymphocytic leukemia, lymphoplasmacytic lymphoma/Waldenstrommacroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma,plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginalzone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large Bcell lymphoma, intravascular large B cell lymphoma, primary effusionlymphoma, burkitt lymphoma/leukemia, and lymphomatoid granulomatosis.

In further embodiments, the methods described herein can be used totreat thromboembolic disorders, which include, but are not limited tomyocardial infarct, angina pectoris (including unstable angina),reocclusions or restenoses after angioplasty or aortocoronary bypass,stroke, transitory ischemia, peripheral arterial occlusive disorders,pulmonary embolisms, and deep venous thromboses.

Hematological Malignancies

Disclosed herein, in certain embodiments, is a method for treating ahematological malignancy in an individual in need thereof, comprising:administering to the individual a composition or tablet formulationdescribed herein comprising an amount of Compound 1.

In some embodiments, the hematological malignancy is a non-Hodgkin'slymphoma (NHL). In some embodiments, the hematological malignancy is achronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL),high risk CLL, or a non-CLL/SLL lymphoma. In some embodiments, thehematological malignancy is follicular lymphoma (FL), diffuse largeB-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom'smacroglobulinemia, multiple myeloma (MM), marginal zone lymphoma,Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, orextranodal marginal zone B cell lymphoma. In some embodiments, thehematological malignancy is acute or chronic myelogenous (or myeloid)leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, orprecursor B-cell acute lymphoblastic leukemia. In some embodiments, thehematological malignancy is chronic lymphocytic leukemia (CLL). In someembodiments, the hematological malignancy is mantle cell lymphoma (MCL).In some embodiments, the hematological malignancy is diffuse largeB-cell lymphoma (DLBCL). In some embodiments, the hematologicalmalignancy is diffuse large B-cell lymphoma (DLBCL), ABC subtype. Insome embodiments, the hematological malignancy is diffuse large B-celllymphoma (DLBCL), GCB subtype. In some embodiments, the hematologicalmalignancy is Waldenstrom's macroglobulinemia (WM). In some embodiments,the hematological malignancy is multiple myeloma (MM). In someembodiments, the hematological malignancy is Burkitt's lymphoma. In someembodiments, the hematological malignancy is follicular lymphoma (FL).In some embodiments, the hematological malignancy is transformedfollicular lymphoma. In some embodiments, the hematological malignancyis marginal zone lymphoma.

In some embodiments, the hematological malignancy is relapsed orrefractory non-Hodgkin's lymphoma (NHL). In some embodiments, thehematological malignancy is relapsed or refractory diffuse large B-celllymphoma (DLBCL), relapsed or refractory mantle cell lymphoma (MCL),relapsed or refractory follicular lymphoma (FL), relapsed or refractoryCLL, relapsed or refractory SLL, relapsed or refractory multiplemyeloma, relapsed or refractory Waldenstrom's macroglobulinemia,relapsed or refractory multiple myeloma (MM), relapsed or refractorymarginal zone lymphoma, relapsed or refractory Burkitt's lymphoma,relapsed or refractory non-Burkitt high grade B cell lymphoma, relapsedor refractory extranodal marginal zone B cell lymphoma. In someembodiments, the hematological malignancy is a relapsed or refractoryacute or chronic myelogenous (or myeloid) leukemia, relapsed orrefractory myelodysplastic syndrome, relapsed or refractory acutelymphoblastic leukemia, or relapsed or refractory precursor B-cell acutelymphoblastic leukemia. In some embodiments, the hematologicalmalignancy is relapsed or refractory chronic lymphocytic leukemia (CLL).In some embodiments, the hematological malignancy is relapsed orrefractory mantle cell lymphoma (MCL). In some embodiments, thehematological malignancy is relapsed or refractory diffuse large B-celllymphoma (DLBCL). In some embodiments, the hematological malignancy isrelapsed or refractory diffuse large B-cell lymphoma (DLBCL), ABCsubtype. In some embodiments, the hematological malignancy is relapsedor refractory diffuse large B-cell lymphoma (DLBCL), GCB subtype. Insome embodiments, the hematological malignancy is relapsed or refractoryWaldenstrom's macroglobulinemia (WM). In some embodiments, thehematological malignancy is relapsed or refractory multiple myeloma(MM). In some embodiments, the hematological malignancy is relapsed orrefractory Burkitt's lymphoma. In some embodiments, the hematologicalmalignancy is relapsed or refractory follicular lymphoma (FL).

In some embodiments, the hematological malignancy is a hematologicalmalignancy that is classified as high-risk. In some embodiments, thehematological malignancy is high risk CLL or high risk SLL.

B-cell lymphoproliferative disorders (BCLDs) are neoplasms of the bloodand encompass, inter alia, non-Hodgkin lymphoma, multiple myeloma, andleukemia. BCLDs can originate either in the lymphatic tissues (as in thecase of lymphoma) or in the bone marrow (as in the case of leukemia andmyeloma), and they all are involved with the uncontrolled growth oflymphocytes or white blood cells. There are many subtypes of BCLD, e.g.,chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Thedisease course and treatment of BCLD is dependent on the BCLD subtype;however, even within each subtype the clinical presentation, morphologicappearance, and response to therapy is heterogeneous.

Malignant lymphomas are neoplastic transformations of cells that residepredominantly within lymphoid tissues. Two groups of malignant lymphomasare Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL). Both types oflymphomas infiltrate reticuloendothelial tissues. However, they differin the neoplastic cell of origin, site of disease, presence of systemicsymptoms, and response to treatment (Freedman et al., “Non-Hodgkin'sLymphomas” Chapter 134, Cancer Medicine, (an approved publication of theAmerican Cancer Society, B.C. Decker Inc., Hamilton, Ontario, 2003).

Non-Hodgkin's Lymphomas

Disclosed herein, in certain embodiments, is a method for treating anon-Hodgkin's lymphoma in an individual in need thereof, comprising:administering to the individual a composition or tablet formulationdescribed herein comprising an amount of Compound 1.

Further disclosed herein, in certain embodiments, is a method fortreating relapsed or refractory non-Hodgkin's lymphoma in an individualin need thereof, comprising: administering to the individual atherapeutically-effective amount of Compound 1. In some embodiments, thenon-Hodgkin's lymphoma is relapsed or refractory diffuse large B-celllymphoma (DLBCL), relapsed or refractory mantle cell lymphoma, relapsedor refractory follicular lymphoma, or relapsed or refractory CLL.

Non-Hodgkin lymphomas (NHL) are a diverse group of malignancies that arepredominately of B-cell origin. NHL may develop in any organs associatedwith lymphatic system such as spleen, lymph nodes or tonsils and canoccur at any age. NHL is often marked by enlarged lymph nodes, fever,and weight loss. NHL is classified as either B-cell or T-cell NHL.Lymphomas related to lymphoproliferative disorders following bone marrowor stem cell transplantation are usually B-cell NHL. In the WorkingFormulation classification scheme, NHL has been divided into low-,intermediate-, and high-grade categories by virtue of their naturalhistories (see “The Non-Hodgkin's Lymphoma Pathologic ClassificationProject,” Cancer 49(1982):2112-2135). The low-grade lymphomas areindolent, with a median survival of 5 to 10 years (Homing and Rosenberg(1984) N. Engl. J. Med. 311:1471-1475). Although chemotherapy can induceremissions in the majority of indolent lymphomas, cures are rare andmost patients eventually relapse, requiring further therapy. Theintermediate- and high-grade lymphomas are more aggressive tumors, butthey have a greater chance for cure with chemotherapy. However, asignificant proportion of these patients will relapse and requirefurther treatment.

A non-limiting list of the B-cell NHL includes Burkitt's lymphoma (e.g.,Endemic Burkitt's Lymphoma and Sporadic Burkitt's Lymphoma), CutaneousB-Cell Lymphoma, Cutaneous Marginal Zone Lymphoma (MZL), Diffuse LargeCell Lymphoma (DLBCL), Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Small Cleaved Cell, Diffuse Small Lymphocytic Lymphoma,Extranodal Marginal Zone B-cell lymphoma, follicular lymphoma,Follicular Small Cleaved Cell (Grade 1), Follicular Mixed Small Cleavedand Large Cell (Grade 2), Follicular Large Cell (Grade 3), IntravascularLarge B-Cell Lymphoma, Intravascular Lymphomatosis, Large CellImmunoblastic Lymphoma, Large Cell Lymphoma (LCL), LymphoblasticLymphoma, MALT Lymphoma, Mantle Cell Lymphoma (MCL), immunoblastic largecell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma,chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL),extranodal marginal zone B-cell lymphoma-mucosa-associated lymphoidtissue (MALT) lymphoma, Mediastinal Large B-Cell Lymphoma, nodalmarginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma,primary mediastinal B-cell lymphoma, lymphoplasmocytic lymphoma, hairycell leukemia, Waldenstrom's Macroglobulinemia, and primary centralnervous system (CNS) lymphoma. Additional non-Hodgkin's lymphomas arecontemplated within the scope of the present invention and apparent tothose of ordinary skill in the art.

DLBCL

Disclosed herein, in certain embodiments, is a method for treating aDLCBL in an individual in need thereof, comprising: administering to theindividual a composition or tablet formulation described hereincomprising an amount of Compound 1. Further disclosed herein, in certainembodiments, is a method for treating relapsed or refractory DLCBL in anindividual in need thereof, comprising: administering to the individuala composition or tablet formulation described herein comprising atherapeutically-effective amount of Compound 1.

As used herein, the term “Diffuse large B-cell lymphoma (DLBCL)” refersto a neoplasm of the germinal center B lymphocytes with a diffuse growthpattern and a high-intermediate proliferation index. DLBCLs representapproximately 30% of all lymphomas and may present with severalmorphological variants including the centroblastic, immunoblastic,T-cell/histiocyte rich, anaplastic and plasmoblastic subtypes. Genetictests have shown that there are different subtypes of DLBCL. Thesesubtypes seem to have different outlooks (prognoses) and responses totreatment. DLBCL can affect any age group but occurs mostly in olderpeople (the average age is mid-60s).

Disclosed herein, in certain embodiments, is a method for treatingdiffuse large B-cell lymphoma, activated B cell-like subtype(ABC-DLBCL), in an individual in need thereof, comprising: administeringto the individual an irreversible Btk inhibitor in an amount from 300mg/day up to, and including, 1000 mg/day. The ABC subtype of diffuselarge B-cell lymphoma (ABC-DLBCL) is thought to arise from post germinalcenter B cells that are arrested during plasmatic differentiation. TheABC subtype of DLBCL (ABC-DLBCL) accounts for approximately 30% totalDLBCL diagnoses. It is considered the least curable of the DLBCLmolecular subtypes and, as such, patients diagnosed with the ABC-DLBCLtypically display significantly reduced survival rates compared withindividuals with other types of DLCBL. ABC-DLBCL is most commonlyassociated with chromosomal translocations deregulating the germinalcenter master regulator BCL6 and with mutations inactivating the PRDM1gene, which encodes a transcriptional repressor required for plasma celldifferentiation.

A particularly relevant signaling pathway in the pathogenesis ofABC-DLBCL is the one mediated by the nuclear factor (NF)-κBtranscription complex. The NF-κB family comprises 5 members (p50, p52,p65, c-rel and RelB) that form homo- and heterodimers and function astranscriptional factors to mediate a variety of proliferation,apoptosis, inflammatory and immune responses and are critical for normalB-cell development and survival. NF-κB is widely used by eukaryoticcells as a regulator of genes that control cell proliferation and cellsurvival. As such, many different types of human tumors havemisregulated NF-κB: that is, NF-κd is constitutively active. ActiveNF-κd turns on the expression of genes that keep the cell proliferatingand protect the cell from conditions that would otherwise cause it todie via apoptosis.

The dependence of ABC DLBCLs on NF-kB depends on a signaling pathwayupstream of IkB kinase comprised of CARD11, BCL10 and MALT1 (the CBMcomplex). Interference with the CBM pathway extinguishes NF-kB signalingin ABC DLBCL cells and induces apoptosis. The molecular basis forconstitutive activity of the NF-kB pathway is a subject of currentinvestigation but some somatic alterations to the genome of ABC DLBCLsclearly invoke this pathway. For example, somatic mutations of thecoiled-coil domain of CARD11 in DLBCL render this signaling scaffoldprotein able to spontaneously nucleate protein-protein interaction withMALT1 and BCL10, causing IKK activity and NF-kB activation. Constitutiveactivity of the B cell receptor signaling pathway has been implicated inthe activation of NF-kB in ABC DLBCLs with wild type CARD11, and this isassociated with mutations within the cytoplasmic tails of the B cellreceptor subunits CD79A and CD79B. Oncogenic activating mutations in thesignaling adapter MYD88 activate NF-kB and synergize with B cellreceptor signaling in sustaining the survival of ABC DLBCL cells. Inaddition, inactivating mutations in a negative regulator of the NF-kBpathway, A20, occur almost exclusively in ABC DLBCL.

Indeed, genetic alterations affecting multiple components of the NF-κBsignaling pathway have been recently identified in more than 50% ofABC-DLBCL patients, where these lesions promote constitutive NF-κBactivation, thereby contributing to lymphoma growth. These includemutations of CARD11 (˜10% of the cases), a lymphocyte-specificcytoplasmic scaffolding protein that—together with MALT1 and BCL10—formsthe BCR signalosome, which relays signals from antigen receptors to thedownstream mediators of NF-κB activation. An even larger fraction ofcases (˜30%) carry biallelic genetic lesions inactivating the negativeNF-κB regulator A20. Further, high levels of expression of NF-κB targetgenes have been observed in ABC-DLBCL tumor samples. See, e.g., U. Kleinet al., (2008), Nature Reviews Immunology 8:22-23; R. E. Davis et al.,(2001), Journal of Experimental Medicine 194:1861-1874; G. Lentz et al.,(2008), Science 319:1676-1679; M. Compagno et al., (2009), Nature459:712-721; and L. Srinivasan et al., (2009), Cell 139:573-586).

DLBCL cells of the ABC subtype, such as OCI-Ly10, have chronic activeBCR signaling and are very sensitive to the Btk inhibitor describedherein. The irreversible Btk inhibitor described herein potently andirreversibly inhibits the growth of OCI-Ly10 (EC₅₀ continuousexposure=10 nM, EC₅₀ 1 hour pulse=50 nM). In addition, induction ofapoptosis, as shown by capsase activation, Annexin-V flow cytometry andincrease in sub-GO fraction is observed in OCILy 10. Both sensitive andresistant cells express Btk at similar levels, and the active site ofBtk is fully occupied by the inhibitor in both as shown using afluorescently labeled affinity probe. OCI-Ly10 cells are shown to havechronically active BCR signaling to NF-kB which is dose dependentlyinhibited by the Btk inhibitors described herein. The activity of Btkinhibitors in the cell lines studied herein are also characterized bycomparing signal transduction profiles (Btk, PLCγ, ERK, NF-kB, AKT),cytokine secretion profiles and mRNA expression profiles, both with andwithout BCR stimulation, and observed significant differences in theseprofiles that lead to clinical biomarkers that identify the mostsensitive patient populations to Btk inhibitor treatment. See U.S. Pat.No. 7,711,492 and Staudt et al., Nature, Vol. 463, Jan. 7, 2010, pp.88-92, the contents of which are incorporated by reference in theirentirety.

Follicular Lymphoma

Disclosed herein, in certain embodiments, is a method for treating afollicular lymphoma in an individual in need thereof, comprising:administering to the individual a composition or tablet formulationdescribed herein comprising an amount of Compound 1. Further disclosedherein, in certain embodiments, is a method for treating relapsed orrefractory follicular lymphoma in an individual in need thereof,comprising: administering to the individual a composition or tabletformulation described herein comprising a therapeutically-effectiveamount of Compound 1.

As used herein, the term “follicular lymphoma” refers to any of severaltypes of non-Hodgkin's lymphoma in which the lymphomatous cells areclustered into nodules or follicles. The term follicular is used becausethe cells tend to grow in a circular, or nodular, pattern in lymphnodes. The average age for people with this lymphoma is about 60.

CLL/SLL

Disclosed herein, in certain embodiments, is a method for treating a CLLor SLL in an individual in need thereof, comprising: administering tothe individual a composition or tablet formulation described hereincomprising an amount of Compound 1. Further disclosed herein, in certainembodiments, is a method for treating relapsed or refractory CLL or SLLin an individual in need thereof, comprising: administering to theindividual a composition or tablet formulation described hereincomprising a therapeutically-effective amount of Compound 1.

Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)are commonly thought as the same disease with slightly differentmanifestations. Where the cancerous cells gather determines whether itis called CLL or SLL. When the cancer cells are primarily found in thelymph nodes, lima bean shaped structures of the lymphatic system (asystem primarily of tiny vessels found in the body), it is called SLL.SLL accounts for about 5% to 10% of all lymphomas. When most of thecancer cells are in the bloodstream and the bone marrow, it is calledCLL.

Both CLL and SLL are slow-growing diseases, although CLL, which is muchmore common, tends to grow slower. CLL and SLL are treated the same way.They are usually not considered curable with standard treatments, butdepending on the stage and growth rate of the disease, most patientslive longer than 10 years. Occasionally over time, these slow-growinglymphomas may transform into a more aggressive type of lymphoma.

Chronic lymphoid leukemia (CLL) is the most common type of leukemia. Itis estimated that 100,760 people in the United States are living with orare in remission from CLL. Most (>75%) people newly diagnosed with CLLare over the age of 50. Currently CLL treatment focuses on controllingthe disease and its symptoms rather than on an outright cure. CLL istreated by chemotherapy, radiation therapy, biological therapy, or bonemarrow transplantation. Symptoms are sometimes treated surgically(splenectomy removal of enlarged spleen) or by radiation therapy(“de-bulking” swollen lymph nodes). Though CLL progresses slowly in mostcases, it is considered generally incurable. Certain CLLs are classifiedas high-risk. As used herein, “high risk CLL” means CLL characterized byat least one of the following 1) 17p13-; 2) 11q22-; 3) unmutated IgVHtogether with ZAP-70+ and/or CD38+; or 4) trisomy 12.

CLL treatment is typically administered when the patient's clinicalsymptoms or blood counts indicate that the disease has progressed to apoint where it may affect the patient's quality of life.

Small lymphocytic leukemia (SLL) is very similar to CLL described supra,and is also a cancer of B-cells. In SLL the abnormal lymphocytes mainlyaffect the lymph nodes. However, in CLL the abnormal cells mainly affectthe blood and the bone marrow. The spleen may be affected in bothconditions. SLL accounts for about 1 in 25 of all cases of non-Hodgkinlymphoma. It can occur at any time from young adulthood to old age, butis rare under the age of 50. SLL is considered an indolent lymphoma.This means that the disease progresses very slowly, and patients tend tolive many years after diagnosis. However, most patients are diagnosedwith advanced disease, and although SLL responds well to a variety ofchemotherapy drugs, it is generally considered to be incurable. Althoughsome cancers tend to occur more often in one gender or the other, casesand deaths due to SLL are evenly split between men and women. Theaverage age at the time of diagnosis is 60 years.

Although SLL is indolent, it is persistently progressive. The usualpattern of this disease is one of high response rates to radiationtherapy and/or chemotherapy, with a period of disease remission. This isfollowed months or years later by an inevitable relapse. Re-treatmentleads to a response again, but again the disease will relapse. Thismeans that although the short-term prognosis of SLL is quite good, overtime, many patients develop fatal complications of recurrent disease.Considering the age of the individuals typically diagnosed with CLL andSLL, there is a need in the art for a simple and effective treatment ofthe disease with minimum side-effects that do not impede on thepatient's quality of life. The instant invention fulfills this longstanding need in the art.

Mantle Cell Lymphoma

Disclosed herein, in certain embodiments, is a method for treating aMantle cell lymphoma in an individual in need thereof, comprising:administering to the individual a composition or tablet formulationdescribed herein comprising an amount of Compound 1. Further disclosedherein, in certain embodiments, is a method for treating relapsed orrefractory Mantle cell lymphoma in an individual in need thereof,comprising: administering to the individual a composition or tabletformulation described herein comprising a therapeutically-effectiveamount of Compound 1.

As used herein, the term, “Mantle cell lymphoma” refers to a subtype ofB-cell lymphoma, due to CD5 positive antigen-naive pregerminal centerB-cell within the mantle zone that surrounds normal germinal centerfollicles. MCL cells generally over-express cyclin D1 due to a t(11:14)chromosomal translocation in the DNA. More specifically, thetranslocation is at t(11;14)(q13;q32). Only about 5% of lymphomas are ofthis type. The cells are small to medium in size. Men are affected mostoften. The average age of patients is in the early 60s. The lymphoma isusually widespread when it is diagnosed, involving lymph nodes, bonemarrow, and, very often, the spleen. Mantle cell lymphoma is not a veryfast growing lymphoma, but is difficult to treat.

Marginal Zone B-Cell Lymphoma

Disclosed herein, in certain embodiments, is a method for treating amarginal zone B-cell lymphoma in an individual in need thereof,comprising: administering to the individual a composition or tabletformulation described herein comprising an amount of Compound 1. Furtherdisclosed herein, in certain embodiments, is a method for treatingrelapsed or refractory marginal zone B-cell lymphoma in an individual inneed thereof, comprising: administering to the individual a compositionor tablet formulation described herein comprising atherapeutically-effective amount of Compound 1.

As used herein, the term “marginal zone B-cell lymphoma” refers to agroup of related B-cell neoplasms that involve the lymphoid tissues inthe marginal zone, the patchy area outside the follicular mantle zone.Marginal zone lymphomas account for about 5% to 10% of lymphomas. Thecells in these lymphomas look small under the microscope. There are 3main types of marginal zone lymphomas including extranodal marginal zoneB-cell lymphomas, nodal marginal zone B-cell lymphoma, and splenicmarginal zone lymphoma.

MALT

Disclosed herein, in certain embodiments, is a method for treating aMALT in an individual in need thereof, comprising: administering to theindividual an amount of Compound 1. Further disclosed herein, in certainembodiments, is a method for treating relapsed or refractory MALT in anindividual in need thereof, comprising: administering to the individuala composition or tablet formulation described herein comprising atherapeutically-effective amount of Compound 1.

The term “mucosa-associated lymphoid tissue (MALT) lymphoma”, as usedherein, refers to extranodal manifestations of marginal-zone lymphomas.Most MALT lymphoma are a low grade, although a minority either manifestinitially as intermediate-grade non-Hodgkin lymphoma (NHL) or evolvefrom the low-grade form. Most of the MALT lymphoma occur in the stomach,and roughly 70% of gastric MALT lymphoma are associated withHelicobacter pylori infection. Several cytogenetic abnormalities havebeen identified, the most common being trisomy 3 or t(11;18). Many ofthese other MALT lymphoma have also been linked to infections withbacteria or viruses. The average age of patients with MALT lymphoma isabout 60.

Nodal Marginal Zone B-Cell Lymphoma

Disclosed herein, in certain embodiments, is a method for treating anodal marginal zone B-cell lymphoma in an individual in need thereof,comprising: administering to the individual a composition or tabletformulation described herein comprising an amount of Compound 1. Furtherdisclosed herein, in certain embodiments, is a method for treatingrelapsed or refractory nodal marginal zone B-cell lymphoma in anindividual in need thereof, comprising: administering to the individuala composition or tablet formulation described herein comprising atherapeutically-effective amount of Compound 1.

The term “nodal marginal zone B-cell lymphoma” refers to an indolentB-cell lymphoma that is found mostly in the lymph nodes. The disease israre and only accounts for 1% of all Non-Hodgkin's Lymphomas (NHL). Itis most commonly diagnosed in older patients, with women moresusceptible than men. The disease is classified as a marginal zonelymphoma because the mutation occurs in the marginal zone of theB-cells. Due to its confinement in the lymph nodes, this disease is alsoclassified as nodal.

Splenic Marginal Zone B-Cell Lymphoma

Disclosed herein, in certain embodiments, is a method for treating asplenic marginal zone B-cell lymphoma in an individual in need thereof,comprising: administering to the individual a composition or tabletformulation described herein comprising an amount of Compound 1. Furtherdisclosed herein, in certain embodiments, is a method for treatingrelapsed or refractory splenic marginal zone B-cell lymphoma in anindividual in need thereof, comprising: administering to the individuala composition or tablet formulation described herein comprising atherapeutically-effective amount of Compound 1.

The term “splenic marginal zone B-cell lymphoma” refers to specificlow-grade small B-cell lymphoma that is incorporated in the World HealthOrganization classification. Characteristic features are splenomegaly,moderate lymphocytosis with villous morphology, intrasinusoidal patternof involvement of various organs, especially bone marrow, and relativeindolent course. Tumor progression with increase of blastic forms andaggressive behavior are observed in a minority of patients. Molecularand cytogenetic studies have shown heterogeneous results probablybecause of the lack of standardized diagnostic criteria.

Burkitt Lymphoma

Disclosed herein, in certain embodiments, is a method for treating aBurkitt lymphoma in an individual in need thereof, comprising:administering to the individual a composition or tablet formulationdescribed herein comprising an amount of Compound 1. Further disclosedherein, in certain embodiments, is a method for treating relapsed orrefractory Burkitt lymphoma in an individual in need thereof,comprising: administering to the individual a composition or tabletformulation described herein comprising a therapeutically-effectiveamount of Compound 1.

The term “Burkitt lymphoma” refers to a type of Non-Hodgkin Lymphoma(NHL) that commonly affects children. It is a highly aggressive type ofB-cell lymphoma that often starts and involves body parts other thanlymph nodes. In spite of its fast-growing nature, Burkitt's lymphoma isoften curable with modern intensive therapies. There are two broad typesof Burkitt's lymphoma—the sporadic and the endemic varieties:

Endemic Burkitt's lymphoma: The disease involves children much more thanadults, and is related to Epstein Barr Virus (EBV) infection in 95%cases. It occurs primarily is equatorial Africa, where about half of allchildhood cancers are Burkitt's lymphoma. It characteristically has ahigh chance of involving the jawbone, a rather distinctive feature thatis rare in sporadic Burkitt's. It also commonly involves the abdomen.

Sporadic Burkitt's lymphoma: The type of Burkitt's lymphoma that affectsthe rest of the world, including Europe and the Americas is the sporadictype. Here too, it's mainly a disease in children. The link betweenEpstein Barr Virus (EBV) is not as strong as with the endemic variety,though direct evidence of EBV infection is present in one out of fivepatients. More than the involvement of lymph nodes, it is the abdomenthat is notably affected in more than 90% of the children. Bone marrowinvolvement is more common than in the sporadic variety.

Waldenstrom Macroglobulinemia

Disclosed herein, in certain embodiments, is a method for treating aWaldenstrom macroglobulinemia in an individual in need thereof,comprising: administering to the individual a composition or tabletformulation described herein comprising an amount of Compound 1. Furtherdisclosed herein, in certain embodiments, is a method for treatingrelapsed or refractory Waldenstrom macroglobulinemia in an individual inneed thereof, comprising: administering to the individual a compositionor tablet formulation described herein comprising atherapeutically-effective amount of Compound 1.

The term “Waldenstrom macroglobulinemia”, also known aslymphoplasmacytic lymphoma, is cancer involving a subtype of white bloodcells called lymphocytes. It is characterized by an uncontrolled clonalproliferation of terminally differentiated B lymphocytes. It is alsocharacterized by the lymphoma cells making an antibody calledimmunoglobulin M (IgM). The IgM antibodies circulate in the blood inlarge amounts, and cause the liquid part of the blood to thicken, likesyrup. This can lead to decreased blood flow to many organs, which cancause problems with vision (because of poor circulation in blood vesselsin the back of the eyes) and neurological problems (such as headache,dizziness, and confusion) caused by poor blood flow within the brain.Other symptoms can include feeling tired and weak, and a tendency tobleed easily. The underlying etiology is not fully understood but anumber of risk factors have been identified, including the locus 6p21.3on chromosome 6. There is a 2- to 3-fold risk increase of developing WMin people with a personal history of autoimmune diseases withautoantibodies and particularly elevated risks associated withhepatitis, human immunodeficiency virus, and rickettsiosis.

Multiple Myeloma

Disclosed herein, in certain embodiments, is a method for treating amyeloma in an individual in need thereof, comprising: administering tothe individual a composition or tablet formulation described hereincomprising an amount of Compound 1. Further disclosed herein, in certainembodiments, is a method for treating relapsed or refractory myeloma inan individual in need thereof, comprising: administering to theindividual a composition or tablet formulation described hereincomprising a therapeutically-effective amount of Compound 1.

Multiple myeloma, also known as MM, myeloma, plasma cell myeloma, or asKahler's disease (after Otto Kahler) is a cancer of the white bloodcells known as plasma cells. A type of B cell, plasma cells are acrucial part of the immune system responsible for the production ofantibodies in humans and other vertebrates. They are produced in thebone marrow and are transported through the lymphatic system.

Leukemia

Disclosed herein, in certain embodiments, is a method for treating aleukemia in an individual in need thereof, comprising: administering tothe individual a composition or tablet formulation described hereincomprising an amount of Compound 1. Further disclosed herein, in certainembodiments, is a method for treating relapsed or refractory leukemia inan individual in need thereof, comprising: administering to theindividual a composition or tablet formulation described hereincomprising a therapeutically-effective amount of Compound 1.

Leukemia is a cancer of the blood or bone marrow characterized by anabnormal increase of blood cells, usually leukocytes (white bloodcells). Leukemia is a broad term covering a spectrum of diseases. Thefirst division is between its acute and chronic forms: (i) acuteleukemia is characterized by the rapid increase of immature blood cells.This crowding makes the bone marrow unable to produce healthy bloodcells. Immediate treatment is required in acute leukemia due to therapid progression and accumulation of the malignant cells, which thenspill over into the bloodstream and spread to other organs of the body.Acute forms of leukemia are the most common forms of leukemia inchildren; (ii) chronic leukemia is distinguished by the excessive buildup of relatively mature, but still abnormal, white blood cells.Typically taking months or years to progress, the cells are produced ata much higher rate than normal cells, resulting in many abnormal whiteblood cells in the blood. Chronic leukemia mostly occurs in olderpeople, but can theoretically occur in any age group. Additionally, thediseases are subdivided according to which kind of blood cell isaffected. This split divides leukemias into lymphoblastic or lymphocyticleukemias and myeloid or myelogenous leukemias: (i) lymphoblastic orlymphocytic leukemias, the cancerous change takes place in a type ofmarrow cell that normally goes on to form lymphocytes, which areinfection-fighting immune system cells; (ii) myeloid or myelogenousleukemias, the cancerous change takes place in a type of marrow cellthat normally goes on to form red blood cells, some other types of whitecells, and platelets.

Within these main categories, there are several subcategories including,but not limited to, Acute lymphoblastic leukemia (ALL), precursor B-cellacute lymphoblastic leukemia (precursor B-ALL; also called precursorB-lymphoblastic leukemia), Acute myelogenous leukemia (AML), Chronicmyelogenous leukemia (CML), and Hairy cell leukemia (HCL). Accordingly,disclosed herein, in certain embodiments, is a method for treating Acutelymphoblastic leukemia (ALL), precursor B-cell acute lymphoblasticleukemia (precursor B-ALL; also called precursor B-lymphoblasticleukemia), Acute myelogenous leukemia (AML), Chronic myelogenousleukemia (CML), or Hairy cell leukemia (HCL) in an individual in needthereof, comprising: administering to the individual an amount ofCompound 1. In some embodiments, the leukemia is a relapsed orrefractory leukemia. In some embodiments, the leukemia is a relapsed orrefractory Acute lymphoblastic leukemia (ALL), relapsed or refractoryprecursor B-cell acute lymphoblastic leukemia (precursor B-ALL; alsocalled precursor B-lymphoblastic leukemia), relapsed or refractory Acutemyelogenous leukemia (AML), relapsed or refractory Chronic myelogenousleukemia (CML), or relapsed or refractory Hairy cell leukemia (HCL).

Symptoms, diagnostic tests, and prognostic tests for each of theabove-mentioned conditions are known. See, e.g., Harrison's Principlesof Internal Medicine©,” 16th ed., 2004, The McGraw-Hill Companies, Inc.Dey et al. (2006), Cytojournal 3(24), and the “Revised European AmericanLymphoma” (REAL) classification system (see, e.g., the websitemaintained by the National Cancer Institute).

A number of animal models of are useful for establishing a range oftherapeutically effective doses of irreversible Btk inhibitor compounds,such as Compound 1, for treating any of the foregoing diseases.

The therapeutic efficacy of Compound 1 for any one of the foregoingdiseases can be optimized during a course of treatment. For example, asubject being treated can undergo a diagnostic evaluation to correlatethe relief of disease symptoms or pathologies to inhibition of in vivoBtk activity achieved by administering a given dose of Compound 1.Cellular assays known in the art can be used to determine in vivoactivity of Btk in the presence or absence of an irreversible Btkinhibitor. For example, since activated Btk is phosphorylated attyrosine 223 (Y223) and tyrosine 551 (Y551), phospho-specificimmunocytochemical staining of P-Y223 or P-Y551-positive cells can beused to detect or quantify activation of Btk in a population of cells(e.g., by FACS analysis of stained vs unstained cells). See, e.g.,Nisitani et al. (1999), Proc. Natl. Acad. Sci, USA 96:2221-2226. Thus,the amount of the Btk inhibitor compound that is administered to asubject can be increased or decreased as needed so as to maintain alevel of Btk inhibition optimal for treating the subject's diseasestate.

Compound 1 can irreversibly inhibit Btk and may be used to treat mammalssuffering from Bruton's tyrosine kinase-dependent or Bruton's tyrosinekinase mediated conditions or diseases, including, but not limited to,cancer, autoimmune and other inflammatory diseases. Compound 1 has shownefficacy is a wide variety of diseases and conditions that are describedherein.

In some embodiments, Compound 1 is used for the manufacture of amedicament for treating any of the foregoing conditions (e.g.,autoimmune diseases, inflammatory diseases, allergy disorders, B-cellproliferative disorders, or thromboembolic disorders).

Compound 1, and Pharmaceutically Acceptable Salts Thereof

The Btk inhibitor compound described herein (i.e. Compound 1) isselective for Btk and kinases having a cysteine residue in an amino acidsequence position of the tyrosine kinase that is homologous to the aminoacid sequence position of cysteine 481 in Btk. The Btk inhibitorcompound can form a covalent bond with Cys 481 of Btk (e.g., via aMichael reaction).

“Compound 1” or“1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one”or“1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one”or “2-Propen-1-one,1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl-”or ibrutinib or any other suitable name refers to the compound with thefollowing structure:

A wide variety of pharmaceutically acceptable salts is formed fromCompound 1 and includes:

-   -   acid addition salts formed by reacting Compound 1 with an        organic acid, which includes aliphatic mono- and dicarboxylic        acids, phenyl-substituted alkanoic acids, hydroxyl alkanoic        acids, alkanedioic acids, aromatic acids, aliphatic and aromatic        sulfonic acids, amino acids, etc. and include, for example,        acetic acid, trifluoroacetic acid, propionic acid, glycolic        acid, pyruvic acid, oxalic acid, maleic acid, malonic acid,        succinic acid, fumaric acid, tartaric acid, citric acid, benzoic        acid, cinnamic acid, mandelic acid, methanesulfonic acid,        ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and        the like;    -   acid addition salts formed by reacting Compound 1 with an        inorganic acid, which includes hydrochloric acid, hydrobromic        acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic        acid, hydrofluoric acid, phosphorous acid, and the like.

The term “pharmaceutically acceptable salts” in reference to Compound 1refers to a salt of Compound 1, which does not cause significantirritation to a mammal to which it is administered and does notsubstantially abrogate the biological activity and properties of thecompound.

It should be understood that a reference to a pharmaceuticallyacceptable salt includes the solvent addition forms (solvates). Solvatescontain either stoichiometric or non-stoichiometric amounts of asolvent, and are formed during the process of product formation orisolation with pharmaceutically acceptable solvents such as water,ethanol, methanol, methyl tert-butyl ether (MTBE), diisopropyl ether(DIPE), ethyl acetate, isopropyl acetate, isopropyl alcohol, methylisobutyl ketone (MIBK), methyl ethyl ketone (MEK), acetone,nitromethane, tetrahydrofuran (THF), dichloromethane (DCM), dioxane,heptanes, toluene, anisole, acetonitrile, and the like. In one aspect,solvates are formed using, but not limited to, Class 3 solvent(s).Categories of solvents are defined in, for example, the InternationalConference on Harmonization of Technical Requirements for Registrationof Pharmaceuticals for Human Use (ICH), “Impurities: Guidelines forResidual Solvents, Q3C(R3), (November 2005). Hydrates are formed whenthe solvent is water, or alcoholates are formed when the solvent isalcohol. In some embodiments, solvates of Compound 1, orpharmaceutically acceptable salts thereof, are conveniently prepared orformed during the processes described herein. In some embodiments,solvates of Compound 1 are anhydrous. In some embodiments, Compound 1,or pharmaceutically acceptable salts thereof, exist in unsolvated form.In some embodiments, Compound 1, or pharmaceutically acceptable saltsthereof, exist in unsolvated form and are anhydrous.

In yet other embodiments, Compound 1, or a pharmaceutically acceptablesalt thereof, is prepared in various forms, including but not limitedto, amorphous phase, crystalline forms, milled forms andnano-particulate forms. In some embodiments, Compound 1, or apharmaceutically acceptable salt thereof, is amorphous. In someembodiments, Compound 1, or a pharmaceutically acceptable salt thereof,is amorphous and anhydrous. In some embodiments, Compound 1, or apharmaceutically acceptable salt thereof, is crystalline. In someembodiments, Compound 1, or a pharmaceutically acceptable salt thereof,is crystalline and anhydrous.

In some embodiments, Compound 1 is prepared as outlined in U.S. Pat. No.7,514,444.

Certain Terminology

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of skill in theart to which the claimed subject matter belongs. It is to be understoodthat the foregoing general description and the following detaileddescription are exemplary and explanatory only and are not restrictiveof any subject matter claimed. In this application, the use of thesingular includes the plural unless specifically stated otherwise. Itmust be noted that, as used in the specification and the appendedclaims, the singular forms “a,” “an” and “the” include plural referentsunless the context clearly dictates otherwise. In this application, theuse of “or” means “and/or” unless stated otherwise. Furthermore, use ofthe term “including” as well as other forms, such as “include”,“includes,” and “included,” is not limiting.

The section headings used herein are for organizational purposes onlyand are not to be construed as limiting the subject matter described.All documents, or portions of documents, cited in the applicationincluding, but not limited to, patents, patent applications, articles,books, manuals, and treatises are hereby expressly incorporated byreference in their entirety for any purpose.

The term “about” when used before a numerical value indicates that thevalue may vary within a reasonable range, such as within +10%, +5% or+1% of the stated value.

As used herein, the term “comprising” or its grammatic variants isintended to mean that the compositions and methods, etc., include therecited elements, but do not exclude others. “Consisting essentially of”or its grammatic variants when used to define compositions and methods,shall mean excluding other elements of any essential significance to thecombination for the intended use, but not excluding elements that do notmaterially affect the characteristic(s) of the compositions or methods.“Consisting of” or its grammatic variants shall mean excluding elementsnot specifically recited. Embodiments defined by each of thesetransition terms are within the scope of this invention. For example,when a formulation is described as comprising ingredients A, B and C, aformulation consisting essentially of A, B and C, and a formulationconsisting of A, B and C are independently within the scope of thisinvention.

The term “acceptable” or “pharmaceutically acceptable”, with respect toa formulation, composition or ingredient, as used herein, means havingno persistent detrimental effect on the general health of the subjectbeing treated or does not abrogate the biological activity or propertiesof the compound, and is relatively nontoxic.

As used herein, the term “agonist” refers to a compound, the presence ofwhich results in a biological activity of a protein that is the same asthe biological activity resulting from the presence of a naturallyoccurring ligand for the protein, such as, for example, Btk.

As used herein, the term “partial agonist” refers to a compound thepresence of which results in a biological activity of a protein that isof the same type as that resulting from the presence of a naturallyoccurring ligand for the protein, but of a lower magnitude.

As used herein, the term “antagonist” refers to a compound, the presenceof which results in a decrease in the magnitude of a biological activityof a protein. In certain embodiments, the presence of an antagonistresults in complete inhibition of a biological activity of a protein,such as, for example, Btk. In certain embodiments, an antagonist is aninhibitor.

As used herein, “amelioration” of the symptoms of a particular disease,disorder or condition by administration of a particular compound orpharmaceutical composition refers to any lessening of severity, delay inonset, slowing of progression, or shortening of duration, whetherpermanent or temporary, lasting or transient that can be attributed toor associated with administration of the compound or composition.

“Bioavailability” refers to the percentage of Compound 1 dosed that isdelivered into the general circulation of the animal or human beingstudied. The total exposure (AUC_((0-∞))) of a drug when administeredintravenously is usually defined as 100% bioavailable (F %). “Oralbioavailability” refers to the extent to which Compound 1 is absorbedinto the general circulation when the pharmaceutical composition istaken orally as compared to intravenous injection.

“Blood plasma concentration” refers to the concentration of Compound 1in the plasma component of blood of a subject. It is understood that theplasma concentration of Compound 1 may vary significantly betweensubjects, due to variability with respect to metabolism and/or possibleinteractions with other therapeutic agents. In accordance with oneembodiment disclosed herein, the blood plasma concentration of Compound1 may vary from subject to subject. Likewise, values such as maximumplasma concentration (C_(max)) or time to reach maximum plasmaconcentration (T_(max)), or total area under the plasma concentrationtime curve (AUC_((0-∞))) may vary from subject to subject. Due to thisvariability, the amount necessary to constitute “a therapeuticallyeffective amount” of Compound 1 may vary from subject to subject.

The term “Bruton's tyrosine kinase,” as used herein, refers to Bruton'styrosine kinase from Homo sapiens, as disclosed in, e.g., U.S. Pat. No.6,326,469 (GenBank Accession No. NP_000052).

The terms “co-administration” or the like, as used herein, are meant toencompass administration of the selected therapeutic agents to a singlepatient, and are intended to include treatment regimens in which theagents are administered by the same or different route of administrationor at the same or different time. In some embodiments, the term“co-administration” or the like, is meant to encompass theadministration of the selected therapeutic agents in the same cycle(s).In these embodiments, the selected therapeutic agents may beadministered on the same or different days of the cycle(s).

The terms “effective amount” or “therapeutically effective amount,” asused herein, refer to a sufficient amount of an agent or a compoundbeing administered which will relieve to some extent one or more of thesymptoms of the disease or condition being treated. The result can bereduction and/or alleviation of the signs, symptoms, or causes of adisease, or any other desired alteration of a biological system. Forexample, an “effective amount” for therapeutic uses is the amount of thecomposition including a compound as disclosed herein required to providea clinically significant decrease in disease symptoms without undueadverse side effects. An appropriate “effective amount” in anyindividual case may be determined using techniques, such as a doseescalation study. The term “therapeutically effective amount” includes,for example, a prophylactically effective amount. An “effective amount”of a compound disclosed herein is an amount effective to achieve adesired pharmacologic effect or therapeutic improvement without undueadverse side effects. It is understood that “an effect amount” or “atherapeutically effective amount” can vary from subject to subject, dueto variation in metabolism of Compound 1, age, weight, general conditionof the subject, the condition being treated, the severity of thecondition being treated, and the judgment of the prescribing physician.By way of example only, therapeutically effective amounts may bedetermined by routine experimentation, including but not limited to adose escalation clinical trial.

The terms “enhance” or “enhancing” means to increase or prolong eitherin potency or duration a desired effect. By way of example, “enhancing”the effect of therapeutic agents refers to the ability to increase orprolong, either in potency or duration, the effect of therapeutic agentson during treatment of a disease, disorder or condition. An“enhancing-effective amount,” as used herein, refers to an amountadequate to enhance the effect of a therapeutic agent in the treatmentof a disease, disorder or condition. When used in a patient, amountseffective for this use will depend on the severity and course of thedisease, disorder or condition, previous therapy, the patient's healthstatus and response to the drugs, and the judgment of the treatingphysician.

The terms “inhibits”, “inhibiting”, or “inhibitor” of a kinase, as usedherein, refer to inhibition of enzymatic phosphotransferase activity.

The term “irreversible inhibitor,” as used herein, refers to a compoundthat, upon contact with a target protein (e.g., a kinase) causes theformation of a new covalent bond with or within the protein, whereby oneor more of the target protein's biological activities (e.g.,phosphotransferase activity) is diminished or abolished notwithstandingthe subsequent presence or absence of the irreversible inhibitor.

The term “irreversible Btk inhibitor,” as used herein, refers to aninhibitor of Btk that can form a covalent bond with an amino acidresidue of Btk. In one embodiment, the irreversible inhibitor of Btk canform a covalent bond with a Cys residue of Btk; in particularembodiments, the irreversible inhibitor can form a covalent bond with aCys 481 residue (or a homolog thereof) of Btk or a cysteine residue inthe homologous corresponding position of another tyrosine kinase.

The term “modulate,” as used herein, means to interact with a targeteither directly or indirectly so as to alter the activity of the target,including, by way of example only, to enhance the activity of thetarget, to inhibit the activity of the target, to limit the activity ofthe target, or to extend the activity of the target.

As used herein, the term “modulator” refers to a compound that alters anactivity of a molecule. For example, a modulator can cause an increaseor decrease in the magnitude of a certain activity of a moleculecompared to the magnitude of the activity in the absence of themodulator. In certain embodiments, a modulator is an inhibitor, whichdecreases the magnitude of one or more activities of a molecule. Incertain embodiments, an inhibitor completely prevents one or moreactivities of a molecule. In certain embodiments, a modulator is anactivator, which increases the magnitude of at least one activity of amolecule. In certain embodiments the presence of a modulator results inan activity that does not occur in the absence of the modulator.

The term “prophylactically effective amount,” as used herein, refersthat amount of a composition applied to a patient which will relieve tosome extent one or more of the symptoms of a disease, condition ordisorder being treated. In such prophylactic applications, such amountsmay depend on the patient's state of health, weight, and the like. It isconsidered well within the skill of the art for one to determine suchprophylactically effective amounts by routine experimentation,including, but not limited to, a dose escalation clinical trial.

The term “individual,” “subject” or “patient” as used herein, refers toan animal which is the object of treatment, observation or experiment.By way of example only, a subject may be, but is not limited to, amammal including, but not limited to, a human.

The term “wet granulation” as used herein, refers to the formation ofgranules using a granulation liquid (water, organic solvent, or asolution).

The term “dry granulation” as used herein, refers to the formation ofgranules without using a granulation liquid (water, organic solvent, ora solution).

The term “high-load solid tablet formulation” as used herein, refers toa solid tablet formulation comprising at least 50% w/w of ibrutinib pertablet.

As used herein, the IC₅₀ refers to an amount, concentration or dosage ofa particular test compound that achieves a 50% inhibition of a maximalresponse, such as inhibition of Btk, in an assay that measures suchresponse.

As used herein, EC₅₀ refers to a dosage, concentration or amount of aparticular test compound that elicits a dose-dependent response at 50%of maximal expression of a particular response that is induced, provokedor potentiated by the particular test compound.

Pharmaceutical Compositions/Formulations

A pharmaceutical composition or pharmaceutical formulation, as usedherein, refers to a mixture of Compound 1 with other chemicalcomponents, such as carriers, stabilizers, diluents, dispersing agents,suspending agents, thickening agents, and/or excipients. Thepharmaceutical composition facilitates administration of the compound toa mammal. The compounds can be used singly or in combination with one ormore therapeutic agents as components of mixtures.

The term “pharmaceutical combination” as used herein, means a productthat results from the mixing or combining of more than one activeingredient and includes both fixed and non-fixed combinations of theactive ingredients. The term “fixed combination” means that the activeingredients, e.g. Compound 1 and a co-agent, are both administered to apatient simultaneously in the form of a single entity or dosage. Theterm “non-fixed combination” means that the active ingredients, e.g.Compound 1 and a co-agent, are administered to a patient as separateentities either simultaneously, concurrently or sequentially with nospecific intervening time limits, wherein such administration provideseffective levels of the two compounds in the body of the patient. Thelatter also applies to cocktail therapy, e.g. the administration ofthree or more active ingredients.

In some embodiments, crystalline Compound 1 is incorporated intopharmaceutical compositions to provide solid oral dosage forms, such aspowders, immediate release formulations, controlled releaseformulations, fast melt formulations, tablets, capsules, pills, delayedrelease formulations, extended release formulations, pulsatile releaseformulations, multiparticulate formulations, and mixed immediate andcontrolled release formulations.

Ibrutinib is currently used in the clinic at a unit dose of 420 mg or560 mg which is administered orally in three or four capsules comprising140 mg ibrutinib per capsule. High load tablet formulations would allowadministration of one tablet per dose. However, high load tabletformulations that meet pharmaceutically acceptable properties, such as,suitable compressibility, compactibility, granulate flowability,granulate density, integrity during manufacture, shipping and storage,proper hardness, stability, swallowbility and disintegration propertieswhen administered, are considerately more difficult to prepare thancapsule formations due to the limited amount of excipients that can beused to adjust the tablet properties. Further, tablet formulations tendto have lower C_(max) as compared with the capsule formulations due tothe process of its disintegration and absorption after administration,especially for ibrutinib which has a very low water solubility. It ischallenging to prepare high load tablet formulations of ibrutinib thatpossess both pharmaceutically acceptable properties and desired PKproperties, such as a high C_(max).

In some embodiments is a pharmaceutical composition comprisingibrutinib, wherein ibrutinib is a compound with the structure ofCompound 1,

and wherein the pharmaceutical composition comprises at least 50% w/w ofibrutinib.

In another embodiment is a pharmaceutical composition comprisingibrutinib, wherein the pharmaceutical composition comprises at leastabout 20% w/w of ibrutinib. In another embodiment is a pharmaceuticalcomposition comprising ibrutinib, wherein the pharmaceutical compositioncomprises about 20% w/w to about 90% w/w of ibrutinib. In anotherembodiment is a pharmaceutical composition comprising ibrutinib, whereinthe pharmaceutical composition comprises about 30% w/w to about 90% w/wof ibrutinib. In another embodiment is a pharmaceutical compositioncomprising ibrutinib, wherein the pharmaceutical composition comprisesabout 40% w/w to about 90% w/w of ibrutinib. In another embodiment is apharmaceutical composition comprising ibrutinib, wherein thepharmaceutical composition comprises about 50% w/w to about 90% w/w ofibrutinib. In another embodiment is a pharmaceutical compositioncomprising ibrutinib, wherein the pharmaceutical composition comprisesabout 40% w/w to about 80% w/w of ibrutinib. In another embodiment is apharmaceutical composition comprising ibrutinib, wherein thepharmaceutical composition comprises about 50% w/w to about 80% w/w ofibrutinib. In another embodiment is a pharmaceutical compositioncomprising ibrutinib, wherein the pharmaceutical composition comprisesabout 60% w/w to about 80% w/w of ibrutinib. In another embodiment is apharmaceutical composition comprising ibrutinib, wherein thepharmaceutical composition comprises about 50% w/w to about 75% w/w ofibrutinib. In another embodiment is a pharmaceutical compositioncomprising ibrutinib, wherein the pharmaceutical composition comprisesabout 60% w/w to about 75% w/w of ibrutinib. In another embodiment is apharmaceutical composition comprising at least 50% w/w of ibrutinib,wherein the pharmaceutical composition comprises intragranular andextragranular ingredients. In another embodiment is a pharmaceuticalcomposition comprising at least 50% w/w of ibrutinib, wherein thepharmaceutical composition is prepared using a wet granulation method.In another embodiment is a pharmaceutical composition comprising atleast 50% w/w of ibrutinib, further comprising at least onepharmaceutically acceptable excipient.

In some embodiments, the pharmaceutical compositions described hereinare prepared by a process comprising a wet granulation method.

In another embodiment is a solid tablet formulation comprisingibrutinib, wherein the solid tablet formulation comprises at least about20% w/w of ibrutinib. In another embodiment is a solid tabletformulation comprising ibrutinib, wherein the solid tablet formulationcomprises about 20% w/w to about 90% w/w of ibrutinib. In anotherembodiment is a high-load solid tablet formulation comprising at least20% w/w or 30% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients. In another embodiment is a high-load solid tabletformulation comprising at least 40% w/w of ibrutinib, and one or morepharmaceutically acceptable excipients. In another embodiment is ahigh-load solid tablet formulation comprising at least 50% w/w ofibrutinib, and one or more pharmaceutically acceptable excipients. Inanother embodiment is a high-load solid tablet formulation comprisingabout 30% w/w to about 90% w/w of ibrutinib, and one or morepharmaceutically acceptable excipients. In another embodiment is ahigh-load solid tablet formulation comprising about 40% w/w to about 90%w/w of ibrutinib, and one or more pharmaceutically acceptableexcipients. In another embodiment is a high-load solid tabletformulation comprising about 50% w/w to about 90% w/w of ibrutinib, andone or more pharmaceutically acceptable excipients. In anotherembodiment is a high-load solid tablet formulation comprising about 40%w/w to about 80% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients. In another embodiment is a high-load solid tabletformulation comprising about 50% w/w to about 80% w/w of ibrutinib, andone or more pharmaceutically acceptable excipients. In anotherembodiment is a high-load solid tablet formulation comprising about 60%w/w to about 80% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients. In another embodiment is a high-load solid tabletformulation comprising about 50% w/w to about 75% w/w of ibrutinib, andone or more pharmaceutically acceptable excipients. In anotherembodiment is a high-load solid tablet formulation comprising about 60%w/w to about 75% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients.

In another embodiment is a high-load solid tablet formulation comprisingat least 50% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients wherein the one or more excipients are present inan amount from about 10% w/w to about 50% w/w. In another embodiment isa high-load solid tablet formulation comprising about 50% w/w to about90% w/w of ibrutinib, and one or more pharmaceutically acceptableexcipients wherein the one or more excipients are present in an amountfrom about 10% w/w to about 50% w/w. In another embodiment is ahigh-load solid tablet formulation comprising about 60% w/w to about 80%w/w of ibrutinib, and one or more pharmaceutically acceptable excipientswherein the one or more excipients are present in an amount from about20% w/w to about 40% w/w. In another embodiment is a high-load solidtablet formulation comprising about 60% w/w to about 75% w/w ofibrutinib, and one or more pharmaceutically acceptable excipientswherein the one or more excipients are present in an amount from about25% w/w to about 40% w/w.

In another embodiment is a high-load solid tablet formulation comprisingat least 50% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients wherein the one or more excipients are selectedfrom the group consisting of diluents, binders, disintegrating agents,lubricants, glidants, and surfactants. In some embodiments, at least oneexcipient is a diluent. In some embodiments, the diluent is selectedfrom the group consisting of lactose, sucrose (e.g., Dipac®), dextrose,dextrates, maltodextrin, mannitol, xylitol (e.g., Xylitab®), sorbitol,cyclodextrins, calcium phosphate, calcium sulfate, starches, modifiedstarches, cellulose, microcrystalline cellulose (e.g., Avicel®),microcellulose, and talc. In some embodiments, the diluent is cellulose.In some embodiments, the diluent is the diluent is lactose; and lactoseis present in an amount from about 5% w/w to about 20% w/w, about 8% w/wto about 20% w/w, or about 8% w/w to about 15% w/w. In some embodiments,the diluent is lactose; and lactose is present in an amount of about8.5% w/w or about 14% w/w. In some embodiments, the diluent ismicrocrystalline cellulose. In some embodiments, the diluent ismicrocrystalline cellulose and the microcrystalline cellulose is presentin an amount from about 1% w/w to about 20% w/w, about 1% w/w to about10% w/w, about 1% w/w to about 5% w/w, 1% w/w to about 2% w/w, about 5%w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w toabout 15% w/w. In some embodiments, the diluent is microcrystallinecellulose and the microcrystalline cellulose is present in an amountfrom about 1% w/w to about 6% w/w or about 8.5% w/w or about 14% w/w. Insome embodiments, the diluent comprises lactose and microcrystallinecellulose. In some embodiments, the lactose is present in an amount ofabout 10% w/w to about 15% w/w and microcrystalline cellulose is presentin an amount from about 1% w/w to about 6% w/w. In some embodiments, thelactose is present in an amount of about 14% w/w and microcrystallinecellulose is present in an amount from about 2% w/w to about 5% w/w. Insome embodiments, at least one excipient is a disintegrating agent. Insome embodiments, the disintegrating agent is selected from the groupconsisting of natural starch, a pregelatinized starch, a sodium starch,methylcrystalline cellulose, methylcellulose (e.g., Methocel®),croscarmellose, croscarmellose sodium, cross-linked sodiumcarboxymethylcellulose, cross-linked carboxymethylcellulose,cross-linked croscarmellose, cross-linked starch such as sodium starchglycolate, cross-linked polymer such as crospovidone, cross-linkedpolyvinylpyrrolidone, sodium alginate, a clay, and a gum. In someembodiments, the disintegrating agent is croscarmellose sodium; andcroscarmellose sodium is present in an amount from about 0 to about 20%w/w, about 1% w/w to about 10% w/w, about 5% w/w to about 10% w/w, about6% w/w to about 8% w/w, about 4% w/w to about 6% w/w, or about 2% w/w toabout 4% w/w. In some embodiments, at least one excipient is a binder.In some embodiments, the binder is polyvinylpyrrolidone (e.g., PVP K15,PVP K19, PVP K25, PVP K30, Povidone® CL, Kollidon® CL, Polyplasdone®XL-10, and Povidone® K-12). In some embodiments, thepolyvinylpyrrolidone is present in an amount from about 0 to about 10%w/w, about 1 to about 5% w/w, or about 2% w/w. In some embodiments, thebinder is hydroxypropyl cellulose; and hydroxypropyl cellulose ispresent in an amount from about 0 to about 10% w/w, about 0 to about 5%w/w, about 0 to about 2% w/w, about 0.1% w/w to about 1.1% w/w, or about0.1% w/w to about 1% w/w. In some embodiments, the formulation compriseslactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose. In some embodiments, at least one excipient isa surfactant. In some embodiments, the surfactant is sodium laurylsulfate (SLS). In some embodiments, the surfactant is sodium laurylsulfate in an amount from about 0 to about 10% w/w, about 0.5 to about5% w/w, about 1 to about 4% w/w, about 4% w/w to about 8% w/w, or about5% w/w to about 6% w/w. In some embodiments, at least one excipient is aglidant. In some embodiments, the glidant is silica (colloidal silicondioxide). In some embodiments, the glidant is silica (colloidal silicondioxide) and the silica (colloidal silicon dioxide) is present in anamount from about 0 to about 5% w/w, 0.1% w/w to about 1.5% w/w, about0.4% w/w to about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, at least one excipient is a lubricant. In some embodiments,the lubricant is magnesium stearate. In some embodiments, the lubricantis magnesium stearate and the magnesium stearate is present in an amountfrom about 0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1%w/w to about 0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, the excipients comprise lactose, microcrystallinecellulose, polyvinylpyrrolidone, croscarmellose sodium, sodium laurylsulfate, colloidal silicon dioxide and magnesium stearate.

In another embodiment is a high-load solid tablet formulation comprisingat least 50% w/w of ibrutinib, and intragranular and extragranularexcipients; wherein the intragranular excipients comprise lactose,microcrystalline cellulose, croscarmellose sodium, and hydroxypropylcellulose; and the extragranular excipients comprise croscarmellosesodium, sodium lauryl sulfate, colloidal silicon dioxide, and magnesiumstearate. In another embodiment, the intragranular excipients comprise:

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0% w/w to about        10% w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about        4% w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and        the extragranular excipients comprise:    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and magnesium stearate in an amount from        about 0.1% w/w to about 1.5% w/w, about 0.4% w/w to about 0.8%        w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprisingat least 50% w/w of ibrutinib, and intragranular and extragranularexcipients; wherein the intragranular excipients comprise lactose,microcrystalline cellulose, sodium lauryl sulfate, polyvinylpyrrolidoneand croscarmellose sodium; and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment, the intragranularexcipients comprise:

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0% w/w to about 2%        w/w, about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise:    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w or about 0% w/w to about 4% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprisingabout 50% w/w to about 90% w/w of ibrutinib, and one or morepharmaceutically acceptable excipients wherein the one or moreexcipients are selected from the group consisting of diluents, binders,disintegrating agents, lubricants, glidants, and surfactants. In someembodiments, at least one excipient is a diluent. In some embodiments,the diluent is selected from the group consisting of lactose, sucrose,dextrose, dextrates, maltodextrin, mannitol, xylitol, sorbitol,cyclodextrins, calcium phosphate, calcium sulfate, starches, modifiedstarches, cellulose, microcrystalline cellulose, microcellulose, andtalc. In some embodiments, the diluent is cellulose. In someembodiments, the diluent is the diluent is lactose; and lactose ispresent in an amount from about 5% w/w to about 20% w/w, about 8% w/w toabout 20% w/w, or about 8% w/w to about 15% w/w. In some embodiments,the diluent is lactose; and lactose is present in an amount of about8.5% w/w or about 14% w/w. In some embodiments, the diluent ismicrocrystalline cellulose. In some embodiments, the diluent ismicrocrystalline cellulose and the microcrystalline cellulose is presentin an amount from about 1% w/w to about 20% w/w, about 1% w/w to about10% w/w, about 1% w/w to about 5% w/w, 1% w/w to about 2% w/w, about 5%w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w toabout 15% w/w. In some embodiments, the diluent is microcrystallinecellulose and the microcrystalline cellulose is present in an amountfrom about 1% w/w to about 6% w/w or about 8.5% w/w or about 14% w/w. Insome embodiments, the diluent comprises lactose and microcrystallinecellulose. In some embodiments, the lactose is present in an amount ofabout 10% w/w to about 15% w/w and microcrystalline cellulose is presentin an amount from about 1% w/w to about 6% w/w. In some embodiments, thelactose is present in an amount of about 14% w/w and microcrystallinecellulose is present in an amount from about 2% w/w to about 5% w/w. Insome embodiments, at least one excipient is a disintegrating agent. Insome embodiments, the disintegrating agent is selected from the groupconsisting of natural starch, a pregelatinized starch, a sodium starch,methylcrystalline cellulose, methylcellulose, croscarmellose,croscarmellose sodium, cross-linked sodium carboxymethylcellulose,cross-linked carboxymethylcellulose, cross-linked croscarmellose,cross-linked starch such as sodium starch glycolate, cross-linkedpolymer such as crospovidone, cross-linked polyvinylpyrrolidone, sodiumalginate, a clay, and a gum. In some embodiments, the disintegratingagent is croscarmellose sodium; and croscarmellose sodium is present inan amount from about 0 to about 20% w/w, about 1% w/w to about 10% w/w,about 5% w/w to about 10% w/w, about 6% w/w to about 8% w/w, about 4%w/w to about 6% w/w, or about 2% w/w to about 4% w/w. In someembodiments, at least one excipient is a binder. In some embodiments,the binder is polyvinylpyrrolidone. In some embodiments, thepolyvinylpyrrolidone is present in an amount from about 0 to about 10%w/w, about 1 to about 5% w/w, or about 2% w/w. In some embodiments, thebinder is hydroxypropyl cellulose; and hydroxypropyl cellulose ispresent in an amount from about 0 to about 10% w/w, about 0 to about 5%w/w, about 0 to about 2% w/w, about 0.1% w/w to about 1.1% w/w, or about0.1% w/w to about 1% w/w. In some embodiments, the formulation compriseslactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose. In some embodiments, at least one excipient isa surfactant. In some embodiments, the surfactant is sodium laurylsulfate. In some embodiments, the surfactant is sodium lauryl sulfate inan amount from about 0 to about 10% w/w, about 0.5 to about 5% w/w,about 1 to about 4% w/w, about 4% w/w to about 8% w/w, or about 5% w/wto about 6% w/w. In some embodiments, at least one excipient is aglidant. In some embodiments, the glidant is silica (colloidal silicondioxide). In some embodiments, the glidant is silica (colloidal silicondioxide) and the silica (colloidal silicon dioxide) is present in anamount from about 0 to about 5% w/w, 0.1% w/w to about 1.5% w/w, about0.4% w/w to about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, at least one excipient is a lubricant. In some embodiments,the lubricant is magnesium stearate. In some embodiments, the lubricantis magnesium stearate and the magnesium stearate is present in an amountfrom about 0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1%w/w to about 0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, the excipients comprise lactose, microcrystallinecellulose, polyvinylpyrrolidone, croscarmellose sodium, sodium laurylsulfate, colloidal silicon dioxide and magnesium stearate.

In another embodiment is a high-load solid tablet formulation comprisingabout 50% w/w to about 90% w/w of ibrutinib, and intragranular andextragranular excipients; wherein the intragranular excipients compriselactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose; and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment, the intragranularexcipients comprise:

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0% w/w to about        10% w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about        4% w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and        the extragranular excipients comprise:    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.1% w/w to about        1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5% w/w to        about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprisingabout 50% w/w to about 90% w/w of ibrutinib, and intragranular andextragranular excipients; wherein the intragranular excipients compriselactose, microcrystalline cellulose, sodium lauryl sulfate,polyvinylpyrrolidone and croscarmellose sodium; and the extragranularexcipients comprise croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide, and magnesium stearate. In anotherembodiment, the intragranular excipients comprise:

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0% w/w to about 2%        w/w, about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w or about 0% w/w to about 4% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprisingabout 50% w/w to about 80% w/w of ibrutinib, and one or morepharmaceutically acceptable excipients wherein the one or moreexcipients are selected from the group consisting of diluents, binders,disintegrating agents, lubricants, glidants, and surfactants. In someembodiments, at least one excipient is a diluent. In some embodiments,the diluent is selected from the group consisting of lactose, sucrose,dextrose, dextrates, maltodextrin, mannitol, xylitol, sorbitol,cyclodextrins, calcium phosphate, calcium sulfate, starches, modifiedstarches, cellulose, microcrystalline cellulose, microcellulose, andtalc. In some embodiments, the diluent is cellulose. In someembodiments, the diluent is the diluent is lactose; and lactose ispresent in an amount from about 5% w/w to about 20% w/w, about 8% w/w toabout 20% w/w, or about 8% w/w to about 15% w/w. In some embodiments,the diluent is lactose; and lactose is present in an amount of about8.5% w/w or about 14% w/w. In some embodiments, the diluent ismicrocrystalline cellulose. In some embodiments, the diluent ismicrocrystalline cellulose and the microcrystalline cellulose is presentin an amount from about 1% w/w to about 20% w/w, about 1% w/w to about10% w/w, about 1% w/w to about 5% w/w, 1% w/w to about 2% w/w, about 5%w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w toabout 15% w/w. In some embodiments, the diluent is microcrystallinecellulose and the microcrystalline cellulose is present in an amountfrom about 1% w/w to about 6% w/w or about 8.5% w/w or about 14% w/w. Insome embodiments, the diluent comprises lactose and microcrystallinecellulose. In some embodiments, the lactose is present in an amount ofabout 10% w/w to about 15% w/w and microcrystalline cellulose is presentin an amount from about 1% w/w to about 6% w/w. In some embodiments, thelactose is present in an amount of about 14% w/w and microcrystallinecellulose is present in an amount from about 2% w/w to about 5% w/w. Insome embodiments, at least one excipient is a disintegrating agent. Insome embodiments, the disintegrating agent is selected from the groupconsisting of natural starch, a pregelatinized starch, a sodium starch,methylcrystalline cellulose, methylcellulose, croscarmellose,croscarmellose sodium, cross-linked sodium carboxymethylcellulose,cross-linked carboxymethylcellulose, cross-linked croscarmellose,cross-linked starch such as sodium starch glycolate, cross-linkedpolymer such as crospovidone, cross-linked polyvinylpyrrolidone, sodiumalginate, a clay, and a gum. In some embodiments, the disintegratingagent is croscarmellose sodium; and croscarmellose sodium is present inan amount from about 0 to about 20% w/w, about 1% w/w to about 10% w/w,about 5% w/w to about 10% w/w, about 6% w/w to about 8% w/w, about 4%w/w to about 6% w/w, or about 2% w/w to about 4% w/w. In someembodiments, at least one excipient is a binder. In some embodiments,the binder is polyvinylpyrrolidone. In some embodiments, thepolyvinylpyrrolidone is present in an amount from about 0 to about 10%w/w, about 1 to about 5% w/w, or about 2% w/w. In some embodiments, thebinder is hydroxypropyl cellulose; and hydroxypropyl cellulose ispresent in an amount from about 0 to about 10% w/w, about 0 to about 5%w/w, about 0 to about 2% w/w, about 0.1% w/w to about 1.1% w/w, or about0.1% w/w to about 1% w/w. In some embodiments, the formulation compriseslactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose. In some embodiments, at least one excipient isa surfactant. In some embodiments, the surfactant is sodium laurylsulfate. In some embodiments, the surfactant is sodium lauryl sulfate inan amount from about 0 to about 10% w/w, about 0.5 to about 5% w/w,about 1 to about 4% w/w, about 4% w/w to about 8% w/w, or about 5% w/wto about 6% w/w. In some embodiments, at least one excipient is aglidant. In some embodiments, the glidant is silica (colloidal silicondioxide). In some embodiments, the glidant is silica (colloidal silicondioxide) and the silica (colloidal silicon dioxide) is present in anamount from about 0 to about 5% w/w, 0.1% w/w to about 1.5% w/w, about0.4% w/w to about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, at least one excipient is a lubricant. In some embodiments,the lubricant is magnesium stearate. In some embodiments, the lubricantis magnesium stearate and the magnesium stearate is present in an amountfrom about 0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1%w/w to about 0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, the excipients comprise lactose, microcrystallinecellulose, polyvinylpyrrolidone, croscarmellose sodium, sodium laurylsulfate, colloidal silicon dioxide and magnesium stearate.

In another embodiment is a high-load solid tablet formulation comprisingabout 50% w/w to about 80% w/w of ibrutinib, and intragranular andextragranular excipients; wherein the intragranular excipients compriselactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose; and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment the intragranularexcipients comprise:

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0% w/w to about        10% w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about        4% w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and        the extragranular excipients comprise:    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.1% w/w to about        1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5% w/w to        about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprisingabout 50% w/w to about 80% w/w of ibrutinib, and intragranular andextragranular excipients; wherein the intragranular excipients compriselactose, sodium lauryl sulfate, polyvinylpyrrolidone and croscarmellosesodium; and the extragranular excipients comprise croscarmellose sodium,sodium lauryl sulfate, microcrystalline cellulose, colloidal silicondioxide, and magnesium stearate. In another embodiment the intragranularexcipients comprise:

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0% w/w to about 2%        w/w, about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise:    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w or about 0% w/w to about 4% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprisingabout 60% w/w to about 80% w/w of ibrutinib, and one or morepharmaceutically acceptable excipients wherein the one or moreexcipients are selected from the group consisting of diluents, binders,disintegrating agents, lubricants, glidants, and surfactants. In someembodiments, at least one excipient is a diluent. In some embodiments,the diluent is selected from the group consisting of lactose, sucrose,dextrose, dextrates, maltodextrin, mannitol, xylitol, sorbitol,cyclodextrins, calcium phosphate, calcium sulfate, starches, modifiedstarches, cellulose, microcrystalline cellulose, microcellulose, andtalc. In some embodiments, the diluent is cellulose. In someembodiments, the diluent is the diluent is lactose; and lactose ispresent in an amount from about 5% w/w to about 20% w/w, about 8% w/w toabout 20% w/w, or about 8% w/w to about 15% w/w. In some embodiments,the diluent is lactose; and lactose is present in an amount of about8.5% w/w or about 14% w/w. In some embodiments, the diluent ismicrocrystalline cellulose. In some embodiments, the diluent ismicrocrystalline cellulose and the microcrystalline cellulose is presentin an amount from about 1% w/w to about 20% w/w, about 1% w/w to about10% w/w, about 1% w/w to about 5% w/w, 1% w/w to about 2% w/w, about 5%w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w toabout 15% w/w. In some embodiments, the diluent is microcrystallinecellulose and the microcrystalline cellulose is present in an amountfrom about 1% w/w to about 6% w/w or about 8.5% w/w or about 14% w/w. Insome embodiments, the diluent comprises lactose and microcrystallinecellulose. In some embodiments, the lactose is present in an amount ofabout 10% w/w to about 15% w/w and microcrystalline cellulose is presentin an amount from about 1% w/w to about 6% w/w. In some embodiments, thelactose is present in an amount of about 14% w/w and microcrystallinecellulose is present in an amount from about 2% w/w to about 5% w/w. Insome embodiments, at least one excipient is a disintegrating agent. Insome embodiments, the disintegrating agent is selected from the groupconsisting of natural starch, a pregelatinized starch, a sodium starch,methylcrystalline cellulose, methylcellulose, croscarmellose,croscarmellose sodium, cross-linked sodium carboxymethylcellulose,cross-linked carboxymethylcellulose, cross-linked croscarmellose,cross-linked starch such as sodium starch glycolate, cross-linkedpolymer such as crospovidone, cross-linked polyvinylpyrrolidone, sodiumalginate, a clay, and a gum. In some embodiments, the disintegratingagent is croscarmellose sodium; and croscarmellose sodium is present inan amount from about 0 to about 20% w/w, about 1% w/w to about 10% w/w,about 5% w/w to about 10% w/w, about 6% w/w to about 8% w/w, about 4%w/w to about 6% w/w, or about 2% w/w to about 4% w/w. In someembodiments, at least one excipient is a binder. In some embodiments,the binder is polyvinylpyrrolidone. In some embodiments, thepolyvinylpyrrolidone is present in an amount from about 0 to about 10%w/w, about 1 to about 5% w/w, or about 2% w/w. In some embodiments, thebinder is hydroxypropyl cellulose; and hydroxypropyl cellulose ispresent in an amount from about 0 to about 10% w/w, about 0 to about 5%w/w, about 0 to about 2% w/w, about 0.1% w/w to about 1.1% w/w, or about0.1% w/w to about 1% w/w. In some embodiments, the formulation compriseslactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose. In some embodiments, at least one excipient isa surfactant. In some embodiments, the surfactant is sodium laurylsulfate. In some embodiments, the surfactant is sodium lauryl sulfate inan amount from about 0 to about 10% w/w, about 0.5 to about 5% w/w,about 1 to about 4% w/w, about 4% w/w to about 8% w/w, or about 5% w/wto about 6% w/w. In some embodiments, at least one excipient is aglidant. In some embodiments, the glidant is silica (colloidal silicondioxide). In some embodiments, the glidant is silica (colloidal silicondioxide) and the silica (colloidal silicon dioxide) is present in anamount from about 0 to about 5% w/w, 0.1% w/w to about 1.5% w/w, about0.4% w/w to about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, at least one excipient is a lubricant. In some embodiments,the lubricant is magnesium stearate. In some embodiments, the lubricantis magnesium stearate and the magnesium stearate is present in an amountfrom about 0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1%w/w to about 0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, the excipients comprise lactose, microcrystallinecellulose, polyvinylpyrrolidone, croscarmellose sodium, sodium laurylsulfate, colloidal silicon dioxide and magnesium stearate.

In another embodiment is a high-load solid tablet formulation comprisingabout 60% w/w to about 80% w/w of ibrutinib, and intragranular andextragranular excipients; wherein the intragranular excipients compriselactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose; and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment the intragranularexcipients comprise

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0% w/w to about        10% w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about        4% w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and    -   the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.1% w/w to about        1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5% w/w to        about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprisingabout 60% w/w to about 80% w/w of ibrutinib, and intragranular andextragranular excipients; wherein the intragranular excipients compriselactose, microcrystalline cellulose, sodium lauryl sulfate,polyvinylpyrrolidone and croscarmellose sodium; and the extragranularexcipients comprise croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide, and magnesium stearate. In another embodimentthe intragranular excipients comprise:

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0% w/w to about 2%        w/w, about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w or about 0% w/w to about 4% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprisingabout 60% w/w to about 75% w/w of ibrutinib, and one or morepharmaceutically acceptable excipients wherein the one or moreexcipients are selected from the group consisting of diluents, binders,disintegrating agents, lubricants, glidants, and surfactants. In someembodiments, at least one excipient is a diluent. In some embodiments,the diluent is selected from the group consisting of lactose, sucrose,dextrose, dextrates, maltodextrin, mannitol, xylitol, sorbitol,cyclodextrins, calcium phosphate, calcium sulfate, starches, modifiedstarches, cellulose, microcrystalline cellulose, microcellulose, andtalc. In some embodiments, the diluent is cellulose. In someembodiments, the diluent is the diluent is lactose; and lactose ispresent in an amount from about 5% w/w to about 20% w/w, about 8% w/w toabout 20% w/w, or about 8% w/w to about 15% w/w. In some embodiments,the diluent is lactose; and lactose is present in an amount of about8.5% w/w or about 14% w/w. In some embodiments, the diluent ismicrocrystalline cellulose. In some embodiments, the diluent ismicrocrystalline cellulose and the microcrystalline cellulose is presentin an amount from about 1% w/w to about 20% w/w, about 1% w/w to about10% w/w, about 1% w/w to about 5% w/w, 1% w/w to about 2% w/w, about 5%w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w toabout 15% w/w. In some embodiments, the diluent is microcrystallinecellulose and the microcrystalline cellulose is present in an amountfrom about 1% w/w to about 6% w/w or about 8.5% w/w or about 14% w/w. Insome embodiments, the diluent comprises lactose and microcrystallinecellulose. In some embodiments, the lactose is present in an amount ofabout 10% w/w to about 15% w/w and microcrystalline cellulose is presentin an amount from about 1% w/w to about 6% w/w. In some embodiments, thelactose is present in an amount of about 14% w/w and microcrystallinecellulose is present in an amount from about 2% w/w to about 5% w/w. Insome embodiments, at least one excipient is a disintegrating agent. Insome embodiments, the disintegrating agent is selected from the groupconsisting of natural starch, a pregelatinized starch, a sodium starch,methylcrystalline cellulose, methylcellulose, croscarmellose,croscarmellose sodium, cross-linked sodium carboxymethylcellulose,cross-linked carboxymethylcellulose, cross-linked croscarmellose,cross-linked starch such as sodium starch glycolate, cross-linkedpolymer such as crospovidone, cross-linked polyvinylpyrrolidone, sodiumalginate, a clay, and a gum. In some embodiments, the disintegratingagent is croscarmellose sodium; and croscarmellose sodium is present inan amount from about 0 to about 20% w/w, about 1% w/w to about 10% w/w,about 5% w/w to about 10% w/w, about 6% w/w to about 8% w/w, about 4%w/w to about 6% w/w, or about 2% w/w to about 4% w/w. In someembodiments, at least one excipient is a binder. In some embodiments,the binder is polyvinylpyrrolidone. In some embodiments, thepolyvinylpyrrolidone is present in an amount from about 0 to about 10%w/w, about 1 to about 5% w/w, or about 2% w/w. In some embodiments, thebinder is hydroxypropyl cellulose; and hydroxypropyl cellulose ispresent in an amount from about 0 to about 10% w/w, about 0 to about 5%w/w, about 0 to about 2% w/w, about 0.1% w/w to about 1.1% w/w, or about0.1% w/w to about 1% w/w. In some embodiments, the formulation compriseslactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose. In some embodiments, at least one excipient isa surfactant. In some embodiments, the surfactant is sodium laurylsulfate. In some embodiments, the surfactant is sodium lauryl sulfate inan amount from about 0 to about 10% w/w, about 0.5 to about 5% w/w,about 1 to about 4% w/w, about 4% w/w to about 8% w/w, or about 5% w/wto about 6% w/w. In some embodiments, at least one excipient is aglidant. In some embodiments, the glidant is silica (colloidal silicondioxide). In some embodiments, the glidant is silica (colloidal silicondioxide) and the silica (colloidal silicon dioxide) is present in anamount from about 0 to about 5% w/w, 0.1% w/w to about 1.5% w/w, about0.4% w/w to about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, at least one excipient is a lubricant. In some embodiments,the lubricant is magnesium stearate. In some embodiments, the lubricantis magnesium stearate and the magnesium stearate is present in an amountfrom about 0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1%w/w to about 0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, the excipients comprise lactose, microcrystallinecellulose, polyvinylpyrrolidone, croscarmellose sodium, sodium laurylsulfate, colloidal silicon dioxide and magnesium stearate.

In another embodiment is a high-load solid tablet formulation comprisingabout 60% w/w to about 75% w/w of ibrutinib, and intragranular andextragranular excipients; wherein the intragranular excipients compriselactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose; and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment the intragranularexcipients comprise:

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0% w/w to about        10% w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about        4% w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and        the extragranular excipients comprise:    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.1% w/w to about        1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5% w/w to        about 0.6% w/w.

In another embodiment is a high-load solid tablet formulation comprisingabout 60% w/w to about 75% w/w of ibrutinib, and intragranular andextragranular excipients; wherein the intragranular excipients compriselactose, microcrystalline cellulose, sodium lauryl sulfate,polyvinylpyrrolidone and croscarmellose sodium; and the extragranularexcipients comprise croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide, and magnesium stearate. In another embodimentthe intragranular excipients comprise:

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0% w/w to about 2%        w/w, about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise:    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w or about 0% w/w to about 4% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment is a high-load solid tablet formulationcomprising:

-   -   a) about 69% w/w to about 71% w/w of ibrutinib,    -   b) about 13% w/w to about 15% w/w of lactose monohydrate,    -   c) about 2% w/w to about 5% w/w of microcrystalline cellulose,    -   d) about 1% w/w to about 3% w/w of polyvinylpyrrolidone,    -   e) about 6% w/w to about 8% w/w of croscarmellose sodium,    -   f) about 1% w/w to about 4% w/w of sodium lauryl sulfate,    -   g) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   h) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In another embodiment is a high-load solid tablet formulationcomprising:

-   -   a) about 70% w/w of ibrutinib,    -   b) about 14% w/w of lactose monohydrate,    -   c) about 5% w/w of microcrystalline cellulose,    -   d) about 2% w/w of polyvinylpyrrolidone,    -   e) about 7% w/w of croscarmellose sodium,    -   f) about 1% w/w of sodium lauryl sulfate,    -   g) about 0.5% w/w of colloidal silicon dioxide, and    -   h) about 0.5% w/w of magnesium stearate.

In one embodiment, the tablet formulation is as described above andcroscarmellose sodium is about 5% intra and about 2% extra. In anotherembodiment, sodium lauryl sulfate is about 1% intra and about 0% extra.

In another embodiment is a high-load solid tablet formulationcomprising:

-   -   a) about 70% w/w of ibrutinib,    -   b) about 14% w/w of lactose monohydrate,    -   c) about 2% w/w of microcrystalline cellulose,    -   d) about 2% w/w of polyvinylpyrrolidone,    -   e) about 7% w/w of croscarmellose sodium,    -   f) about 4% w/w of sodium lauryl sulfate,    -   g) about 0.5% w/w of colloidal silicon dioxide, and    -   h) about 0.5% w/w of magnesium stearate.

In one embodiment, the tablet formulation is as described above andcroscarmellose sodium is about 5% intra and about 2% extra. In anotherembodiment, sodium lauryl sulfate is about 1% intra and about 3% extra.

In another embodiment, the high-load solid tablet comprises lactose,polyvinylpyrrolidone, sodium lauryl sulfate, crospovidone, colloidalsilicon dioxide, and magnesium stearate. In another embodiment is ahigh-load solid tablet formulation comprising:

-   -   a) about 65% w/w to about 75% w/w, or about 70% w/w of        ibrutinib,    -   b) about 14% w/w to about 18% w/w, or about 16% w/w of lactose        monohydrate,    -   c) about 1% w/w to about 3% w/w, or about 2% w/w of        polyvinylpyrrolidone,    -   d) about 0.5% w/w to about 1.5% w/w, or about 1% w/w of sodium        lauryl sulfate,    -   e) about 5% w/w to about 15% w/w, or about 10% w/w of        crospovidone,    -   f) about 0.3% w/w to about 0.7% w/w, or about 0.5% w/w of        colloidal silicon dioxide, and    -   g) about 0.3% w/w to about 0.7% w/w, or about 0.5% w/w of        magnesium stearate.

In another embodiment is a high-load solid tablet formulationcomprising:

-   -   a) about 59% w/w to about 61% w/w of ibrutinib,    -   b) about 13% w/w to about 15% w/w of lactose,    -   c) about 13% w/w to about 15% w/w of microcrystalline cellulose,    -   d) about 4% w/w to about 6% w/w of croscarmellose sodium,    -   e) about 5% w/w to about 7% w/w of sodium lauryl sulfate,    -   f) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   g) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In some embodiments, the total weight of a tablet is about 934 mg.

In another embodiment is a high-load solid tablet formulationcomprising:

-   -   a) about 59% w/w to about 61% w/w of ibrutinib,    -   b) about 13% w/w to about 14% w/w of lactose,    -   c) about 13% w/w to about 14% w/w of microcrystalline cellulose,    -   d) about 2% w/w to about 3% w/w of croscarmellose        sodium(intragranular),    -   e) about 0.8% w/w to about 1.2% w/w of hydroxypropyl cellulose,    -   f) about 2% w/w to about 3% w/w of croscarmellose        sodium(extragranular),    -   g) about 5.5 to about 6.5% w/w of sodium lauryl sulfate,    -   h) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   i) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In some embodiments, the total weight of a tablet is about 934 mg.

In another embodiment is a high-load solid tablet formulationcomprising:

-   -   a) about 69% w/w to about 71% w/w of ibrutinib,    -   b) about 8% w/w to about 9% w/w of lactose,    -   c) about 8 to about 9% w/w of microcrystalline cellulose,    -   d) about 2.5 to about 3.5% w/w of croscarmellose sodium        (intragranular),    -   e) about 2.5 to about 3.5% w/w of croscarmellose sodium        (extragranular),    -   g) about 5.5 to about 6.5% w/w of sodium lauryl sulfate,    -   h) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   i) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In some embodiments of a tablet described herein the total weight of thetablet is about 50 mg to about 1.2 g, such as about 50 mg, about 100 mg,about 200 mg, about 400 mg, about 600 mg, about 800 mg, or about 1.2 g,or any range between any two of the values, end points inclusive. Insome embodiments, the total weight of a tablet is about 800 mg.

In some embodiments of the high-load solid tablet formulations describedherein, the ibrutinib is in an amount of about 35 mg to about 840 mg pertablet, such as about 35 mg, about 70 mg, about 140 mg, about 280 mg,about 420 mg, about 560 mg, or about 840 mg, or any range between anytwo of the values, end points inclusive. In some embodiments of thehigh-load solid tablet formulations described herein, the ibrutinib isin an amount of about 560 mg. In some embodiments of the high-load solidtablet formulations described herein, the ibrutinib is in micronizedform. In some embodiments of the high-load solid tablet formulationsdescribed herein, the formulation is used for once a day dosing. In someembodiments of the high-load solid tablet formulations described herein,the formulation is in an oral dosage form containing a therapeuticallyeffective amount of ibrutinib.

In some embodiments, the high-load solid tablet formulations describedherein are prepared by a process comprising a wet granulation method.

In another embodiment is a method of treating a disease in a patient inneed of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein.

In another embodiment is a method of treating an autoimmune disease in apatient in need of such treatment, comprising administering to thepatient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein. In some embodiments, theautoimmune disease is rheumatoid arthritis or lupus. In anotherembodiment is a method of treating rheumatoid arthritis in a patient inneed of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein. In another embodiment is a method oftreating lupus in a patient in need of such treatment, comprisingadministering to the patient a therapeutically effective amount of apharmaceutical composition or formulation described herein.

In another embodiment is a method of treating a heteroimmune disease ina patient in need of such treatment, comprising administering to thepatient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein.

In another embodiment is a method of treating cancer in a patient inneed of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein. In some embodiments, the cancer is aB-cell proliferative disorder. In some embodiments, the cancer is aB-cell proliferative disorder and the B-cell proliferative disorder isdiffuse large B cell lymphoma, follicular lymphoma or chroniclymphocytic leukemia. In some embodiments, the cancer is a B-cellproliferative disorder and the B-cell proliferative disorder is diffuselarge B cell lymphoma. In some embodiments, the cancer is a B-cellproliferative disorder and the B-cell proliferative disorder isfollicular lymphoma.

In another embodiment is a method of treating cancer in a patient inneed of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein, wherein the cancer is a B cell malignancy.In some embodiments, the cancer is a B cell malignancy and the B cellmalignancy selected from chronic lymphocytic leukemia (CLL)/smalllymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large BCell lymphoma (DLBCL), and multiple myeloma. In some embodiments, thecancer is a B cell malignancy and the B cell malignancy is chroniclymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In someembodiments, the cancer is a B cell malignancy and the B cell malignancyis mantle cell lymphoma (MCL). In some embodiments, the cancer is a Bcell malignancy and the B cell malignancy is diffuse large B Celllymphoma (DLBCL). In some embodiments, the cancer is a B cell malignancyand the B cell malignancy is multiple myeloma.

In another embodiment is a method of treating cancer in a patient inneed of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein, wherein the cancer is a lymphoma, leukemiaor a solid tumor. In another embodiment is a method of treating cancerin a patient in need of such treatment, comprising administering to thepatient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein, wherein the cancer is alymphoma. In another embodiment is a method of treating cancer in apatient in need of such treatment, comprising administering to thepatient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein, wherein the cancer is aleukemia. In another embodiment is a method of treating cancer in apatient in need of such treatment, comprising administering to thepatient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein, wherein the cancer is asolid tumor.

In another embodiment is a method of treating cancer in a patient inneed of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein, wherein the cancer is diffuse large B celllymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chroniclymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacyticlymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma,plasma cell myeloma, plasmacytoma, extranodal marginal zone B celllymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma,mediastinal (thymic) large B cell lymphoma, intravascular large B celllymphoma, primary effusion lymphoma, burkitt lymphoma/leukemia, orlymphomatoid granulomatosis. In another embodiment is a method oftreating cancer in a patient in need of such treatment, comprisingadministering to the patient a therapeutically effective amount of apharmaceutical composition or formulation described herein, wherein thecancer is diffuse large B cell lymphoma. In another embodiment is amethod of treating cancer in a patient in need of such treatment,comprising administering to the patient a therapeutically effectiveamount of a pharmaceutical composition or formulation described herein,wherein the cancer is follicular lymphoma. In another embodiment is amethod of treating cancer in a patient in need of such treatment,comprising administering to the patient a therapeutically effectiveamount of a pharmaceutical composition or formulation described herein,wherein the cancer is chronic lymphocytic lymphoma. In anotherembodiment is a method of treating cancer in a patient in need of suchtreatment, comprising administering to the patient a therapeuticallyeffective amount of a pharmaceutical composition or formulationdescribed herein, wherein the cancer is chronic lymphocytic leukemia. Inanother embodiment is a method of treating cancer in a patient in needof such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein, wherein the cancer is B-cellprolymphocytic leukemia. In another embodiment is a method of treatingcancer in a patient in need of such treatment, comprising administeringto the patient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein, wherein the cancer islymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. In anotherembodiment is a method of treating cancer in a patient in need of suchtreatment, comprising administering to the patient a therapeuticallyeffective amount of a pharmaceutical composition or formulationdescribed herein, wherein the cancer is splenic marginal zone lymphoma.In another embodiment is a method of treating cancer in a patient inneed of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein, wherein the cancer is plasma cell myeloma.In another embodiment is a method of treating cancer in a patient inneed of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein, wherein the cancer is plasmacytoma. Inanother embodiment is a method of treating cancer in a patient in needof such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein, wherein the cancer is extranodal marginalzone B cell lymphoma. In another embodiment is a method of treatingcancer in a patient in need of such treatment, comprising administeringto the patient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein, wherein the cancer is nodalmarginal zone B cell lymphoma. In another embodiment is a method oftreating cancer in a patient in need of such treatment, comprisingadministering to the patient a therapeutically effective amount of apharmaceutical composition or formulation described herein, wherein thecancer is mantle cell lymphoma. In another embodiment is a method oftreating cancer in a patient in need of such treatment, comprisingadministering to the patient a therapeutically effective amount of apharmaceutical composition or formulation described herein, wherein thecancer is mediastinal (thymic) large B cell lymphoma. In anotherembodiment is a method of treating cancer in a patient in need of suchtreatment, comprising administering to the patient a therapeuticallyeffective amount of a pharmaceutical composition or formulationdescribed herein, wherein the cancer is intravascular large B celllymphoma. In another embodiment is a method of treating cancer in apatient in need of such treatment, comprising administering to thepatient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein, wherein the cancer isprimary effusion lymphoma. In another embodiment is a method of treatingcancer in a patient in need of such treatment, comprising administeringto the patient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein, wherein the cancer isburkitt lymphoma/leukemia. In another embodiment is a method of treatingcancer in a patient in need of such treatment, comprising administeringto the patient a therapeutically effective amount of a pharmaceuticalcomposition or formulation described herein, wherein the cancer islymphomatoid granulomatosis.

In some embodiments, the composition is for use in treatment of asarcoma or carcinoma. In some embodiments, the composition is for use intreatment of a sarcoma. In some embodiments, the composition is for usein treatment of a carcinoma. In some embodiments, the sarcoma isselected from alveolar rhabdomyosarcoma; alveolar soft part sarcoma;ameloblastoma; angiosarcoma; chondrosarcoma; chordoma; clear cellsarcoma of soft tissue; dedifferentiated liposarcoma; desmoid;desmoplastic small round cell tumor; embryonal rhabdomyosarcoma;epithelioid fibrosarcoma; epithelioid hemangioendothelioma; epithelioidsarcoma; esthesioneuroblastoma; Ewing sarcoma; extrarenal rhabdoidtumor; extraskeletal myxoid chondrosarcoma; extrasketetal osteosarcoma;fibrosarcoma; giant cell tumor; hemangiopericytoma; infantilefibrosarcoma; inflammatory myofibroblastic tumor; Kaposi sarcoma;leiomyosarcoma of bone; liposarcoma; liposarcoma of bone; malignantfibrous histiocytoma (MFH); malignant fibrous histiocytoma (MFH) ofbone; malignant mesenchymoma; malignant peripheral nerve sheath tumor;mesenchymal chondrosarcoma; myxofibrosarcoma; myxoid liposarcoma;myxoinflammatory fibroblastic sarcoma; neoplasms with perivascularepitheioid cell differentiation; osteosarcoma; parosteal osteosarcoma;neoplasm with perivascular epitheioid cell differentiation; periostealosteosarcoma; pleomorphic liposarcoma; pleomorphic rhabdomyosarcoma;PNET/extraskeletal Ewing tumor; rhabdomyosarcoma; round cellliposarcoma; small cell osteosarcoma; solitary fibrous tumor; synovialsarcoma; telangiectatic osteosarcoma. In some embodiments, the carcinomais selected from an adenocarcinoma, squamous cell carcinoma,adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, orsmall cell carcinoma. In some embodiments, the solid tumor is selectedfrom anal cancer; appendix cancer; bile duct cancer (i.e.,cholangiocarcinoma); bladder cancer; brain tumor; breast cancer;HER2-amplified breast cancer; cervical cancer; colon cancer; cancer ofUnknown Primary (CUP); esophageal cancer; eye cancer; fallopian tubecancer; kidney cancer; renal cell carcinoma; liver cancer; lung cancer;medulloblastoma; melanoma; oral cancer; ovarian cancer; pancreaticcancer; pancreatic ductal cancer; parathyroid disease; penile cancer;pituitary tumor; prostate cancer; rectal cancer; skin cancer; stomachcancer; testicular cancer; throat cancer; thyroid cancer; uterinecancer; vaginal cancer; or vulvar cancer. In some embodiments, thecarcinoma is breast cancer. In some embodiments, the breast cancer isinvasive ductal carcinoma, ductal carcinoma in situ, invasive lobularcarcinoma, or lobular carcinoma in situ. In some embodiments, thecarcinoma is pancreatic cancer. In some embodiments, the pancreaticcancer is adenocarcinoma, or islet cell carcinoma. In some embodiments,the carcinoma is colorectal cancer. In some embodiments, the colorectalcancer is adenocarcinoma. In some embodiments, the solid tumor is acolon polyp. In some embodiments, the colon polyp is associated withfamilial adenomatous polyposis. In some embodiments, the carcinoma isbladder cancer. In some embodiments, the bladder cancer is transitionalcell bladder cancer, squamous cell bladder cancer, or adenocarcinoma. Insome embodiments, the carcinoma is lung cancer. In some embodiments, thelung cancer is a non-small cell lung cancer. In some embodiments, thenon-small cell lung cancer is adenocarcinoma, squamous-cell lungcarcinoma, or large-cell lung carcinoma. In some embodiments, thenon-small cell lung cancer is large cell lung cancer. In someembodiments, the lung cancer is a small cell lung cancer. In someembodiments, the carcinoma is prostate cancer. In some embodiments, theprostate cancer is adenocarcinoma or small cell carcinoma. In someembodiments, the carcinoma is ovarian cancer. In some embodiments, theovarian cancer is epithelial ovarian cancer. In some embodiments, thecarcinoma is bile duct cancer. In some embodiments, the bile duct canceris proximal bile duct carcinoma or distal bile duct carcinoma.

In another embodiment is a method of treating mastocytosis in a patientin need of such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein.

In another embodiment is a method of treating osteoporosis or boneresorption disorders in a patient in need of such treatment, comprisingadministering to the patient a therapeutically effective amount of apharmaceutical composition or formulation described herein. In anotherembodiment is a method of treating osteoporosis in a patient in need ofsuch treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein. In another embodiment is a method oftreating bone resorption disorders in a patient in need of suchtreatment, comprising administering to the patient a therapeuticallyeffective amount of a pharmaceutical composition or formulationdescribed herein.

In another embodiment is a method of treating an inflammatory disease orcondition in a patient in need of such treatment, comprisingadministering to the patient a therapeutically effective amount of apharmaceutical composition or formulation described herein.

In another embodiment is a method of treating lupus in a patient in needof such treatment, comprising administering to the patient atherapeutically effective amount of a pharmaceutical composition orformulation described herein.

In another aspect is a process for preparing a pharmaceuticalcomposition described herein wherein the process comprises a wetgranulation method.

In another aspect is a process for preparing a pharmaceuticalcomposition comprising ibrutinib, wherein ibrutinib is a compound withthe structure of Compound 1,

the process comprises a wet granulation method; and the pharmaceuticalcomposition comprises at least 50% w/w of ibrutinib.

In another embodiment is a process for preparing a pharmaceuticalcomposition comprising ibrutinib, wherein the process comprises a wetgranulation method and the pharmaceutical composition comprises about30% w/w to about 90% w/w of ibrutinib. In another embodiment is aprocess for preparing a pharmaceutical composition comprising ibrutinib,wherein the process comprises a wet granulation method and thepharmaceutical composition comprises about 40% w/w to about 90% w/w ofibrutinib. In another embodiment is a process for preparing apharmaceutical composition comprising ibrutinib, wherein the processcomprises a wet granulation method and the pharmaceutical compositioncomprises about 50% w/w to about 90% w/w of ibrutinib. In anotherembodiment is a process for preparing a pharmaceutical compositioncomprising ibrutinib, wherein the process comprises a wet granulationmethod and the pharmaceutical composition comprises about 40% w/w toabout 80% w/w of ibrutinib. In another embodiment is a process forpreparing a pharmaceutical composition comprising ibrutinib, wherein theprocess comprises a wet granulation method and the pharmaceuticalcomposition comprises about 50% w/w to about 80% w/w of ibrutinib. Inanother embodiment is a process for preparing a pharmaceuticalcomposition comprising ibrutinib, wherein the process comprises a wetgranulation method and the pharmaceutical composition comprises about60% w/w to about 80% w/w of ibrutinib. In another embodiment is aprocess for preparing a pharmaceutical composition comprising ibrutinib,wherein the process comprises a wet granulation method and thepharmaceutical composition comprises about 50% w/w to about 75% w/w ofibrutinib. In another embodiment is a process for preparing apharmaceutical composition comprising ibrutinib, wherein the processcomprises a wet granulation method and the pharmaceutical compositioncomprises about 60% w/w to about 75% w/w of ibrutinib.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising at least 50% w/w of ibrutinib, about50% w/w to about 90% w/w of ibrutinib, about 50% w/w to about 80% w/w ofibrutinib, about 60% w/w to about 80% w/w of ibrutinib, or about 60% w/wto about 75% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients, wherein the process comprises a wet granulationmethod. In another embodiment provided is a process for preparing ahigh-load solid tablet formulation comprising at least 30% w/w ofibrutinib, and one or more pharmaceutically acceptable excipients,wherein the process comprises a wet granulation method. In anotherembodiment provided is a process for preparing a high-load solid tabletformulation comprising at least 40% w/w of ibrutinib, and one or morepharmaceutically acceptable excipients, wherein the process comprises awet granulation method. In another embodiment provided is a process forpreparing a high-load solid tablet formulation comprising at least 50%w/w of ibrutinib, and one or more pharmaceutically acceptableexcipients, wherein the process comprises a wet granulation method. Inanother embodiment provided is a process for preparing a high-load solidtablet formulation comprising about 30% w/w to about 90% w/w ofibrutinib, and one or more pharmaceutically acceptable excipients,wherein the process comprises a wet granulation method. In anotherembodiment provided is a process for preparing a high-load solid tabletformulation comprising about 40% w/w to about 90% w/w of ibrutinib, andone or more pharmaceutically acceptable excipients, wherein the processcomprises a wet granulation method. In another embodiment provided is aprocess for preparing a high-load solid tablet formulation comprisingabout 50% w/w to about 90% w/w of ibrutinib, and one or morepharmaceutically acceptable excipients, wherein the process comprises awet granulation method. In another embodiment provided is a process forpreparing a high-load solid tablet formulation comprising about 40% w/wto about 80% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients, wherein the process comprises a wet granulationmethod. In another embodiment provided is a process for preparing ahigh-load solid tablet formulation comprising about 50% w/w to about 80%w/w of ibrutinib, and one or more pharmaceutically acceptableexcipients, wherein the process comprises a wet granulation method. Inanother embodiment provided is a process for preparing a high-load solidtablet formulation comprising about 60% w/w to about 80% w/w ofibrutinib, and one or more pharmaceutically acceptable excipients,wherein the process comprises a wet granulation method. In anotherembodiment provided is a process for preparing a high-load solid tabletformulation comprising about 50% w/w to about 75% w/w of ibrutinib, andone or more pharmaceutically acceptable excipients, wherein the processcomprises a wet granulation method. In another embodiment provided is aprocess for preparing a high-load solid tablet formulation comprisingabout 60% w/w to about 75% w/w of ibrutinib, and one or morepharmaceutically acceptable excipients, wherein the process comprises awet granulation method.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising at least 50% w/w of ibrutinib, about50% w/w to about 90% w/w of ibrutinib, about 50% w/w to about 80% w/w ofibrutinib, about 60% w/w to about 80% w/w of ibrutinib, or about 60% w/wto about 75% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients present in a total amount from about 10% w/w toabout 50% w/w, wherein the process comprises a wet granulation method.In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising at least 50% w/w of ibrutinib, andone or more pharmaceutically acceptable excipients present in a totalamount no more than about 50% w/w, wherein the process comprises a wetgranulation method. In another embodiment provided is a process forpreparing a high-load solid tablet formulation comprising about 50% w/wto about 90% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients present in a total amount from about 10% w/w toabout 50% w/w, wherein the process comprises a wet granulation method.In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 50% w/w to about 80% w/w ofibrutinib, and one or more pharmaceutically acceptable excipientspresent in a total amount from about 20% w/w to about 50% w/w, whereinthe process comprises a wet granulation method. In another embodimentprovided is a process for preparing a high-load solid tablet formulationcomprising about 60% w/w to about 80% w/w of ibrutinib, and one or morepharmaceutically acceptable excipients present in a total amount fromabout 20% w/w to about 40% w/w, wherein the process comprises a wetgranulation method. In another embodiment provided is a process forpreparing a high-load solid tablet formulation comprising about 60% w/wto about 75% w/w of ibrutinib, and one or more pharmaceuticallyacceptable excipients present in a total amount from about 25% w/w toabout 40% w/w, wherein the process comprises a wet granulation method.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising at least 50% w/w of ibrutinib, andone or more pharmaceutically acceptable excipients selected from thegroup consisting of diluents, binders, disintegrating agents,lubricants, glidants, and surfactants, wherein the process comprises awet granulation method. In some embodiments, at least one excipient is adiluent. In some embodiments, the diluent is selected from the groupconsisting of lactose, sucrose, dextrose, dextrates, maltodextrin,mannitol, xylitol, sorbitol, cyclodextrins, calcium phosphate, calciumsulfate, starches, modified starches, cellulose, microcrystallinecellulose, microcellulose, and talc. In some embodiments, the diluent iscellulose. In some embodiments, the diluent is the diluent is lactose;and lactose is present in an amount from about 5% w/w to about 20% w/w,about 8% w/w to about 20% w/w, or about 8% w/w to about 15% w/w. In someembodiments, the diluent is lactose; and lactose is present in an amountof about 8.5% w/w or about 14% w/w. In some embodiments, the diluent ismicrocrystalline cellulose. In some embodiments, the diluent ismicrocrystalline cellulose and the microcrystalline cellulose is presentin an amount from about 1% w/w to about 20% w/w, about 1% w/w to about10% w/w, about 1% w/w to about 5% w/w, 1% w/w to about 2% w/w, about 5%w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w toabout 15% w/w. In some embodiments, the diluent is microcrystallinecellulose and the microcrystalline cellulose is present in an amountfrom about 1% w/w to about 6% w/w or about 8.5% w/w or about 14% w/w. Insome embodiments, the diluent comprises lactose and microcrystallinecellulose. In some embodiments, the lactose is present in an amount ofabout 10% w/w to about 15% w/w and microcrystalline cellulose is presentin an amount from about 1% w/w to about 6% w/w. In some embodiments, thelactose is present in an amount of about 14% w/w and microcrystallinecellulose is present in an amount from about 2% w/w to about 5% w/w. Insome embodiments, at least one excipient is a disintegrating agent. Insome embodiments, the disintegrating agent is selected from the groupconsisting of natural starch, a pregelatinized starch, a sodium starch,methylcrystalline cellulose, methylcellulose, croscarmellose,croscarmellose sodium, cross-linked sodium carboxymethylcellulose,cross-linked carboxymethylcellulose, cross-linked croscarmellose,cross-linked starch such as sodium starch glycolate, cross-linkedpolymer such as crospovidone, cross-linked polyvinylpyrrolidone, sodiumalginate, a clay, and a gum. In some embodiments, the disintegratingagent is croscarmellose sodium; and croscarmellose sodium is present inan amount from about 0 to about 20% w/w, about 1% w/w to about 10% w/w,about 5% w/w to about 10% w/w, about 6% w/w to about 8% w/w, about 4%w/w to about 6% w/w, or about 2% w/w to about 4% w/w. In someembodiments, at least one excipient is a binder. In some embodiments,the binder is polyvinylpyrrolidone. In some embodiments, thepolyvinylpyrrolidone is present in an amount from about 0 to about 10%w/w, about 1 to about 5% w/w, or about 2% w/w. In some embodiments, thebinder is hydroxypropyl cellulose; and hydroxypropyl cellulose ispresent in an amount from about 0 to about 10% w/w, about 0 to about 5%w/w, about 0 to about 2% w/w, about 0.1% w/w to about 1.1% w/w, or about0.1% w/w to about 1% w/w. In some embodiments, the formulation compriseslactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose. In some embodiments, at least one excipient isa surfactant. In some embodiments, the surfactant is sodium laurylsulfate. In some embodiments, the surfactant is sodium lauryl sulfate inan amount from about 0 to about 10% w/w, about 0.5 to about 5% w/w,about 1 to about 4% w/w, about 4% w/w to about 8% w/w, or about 5% w/wto about 6% w/w. In some embodiments, at least one excipient is aglidant. In some embodiments, the glidant is silica (colloidal silicondioxide). In some embodiments, the glidant is silica (colloidal silicondioxide) and the silica (colloidal silicon dioxide) is present in anamount from about 0 to about 5% w/w, 0.1% w/w to about 1.5% w/w, about0.4% w/w to about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, at least one excipient is a lubricant. In some embodiments,the lubricant is magnesium stearate. In some embodiments, the lubricantis magnesium stearate and the magnesium stearate is present in an amountfrom about 0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1%w/w to about 0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In someembodiments, the excipients comprise lactose, microcrystallinecellulose, polyvinylpyrrolidone, croscarmellose sodium, sodium laurylsulfate, colloidal silicon dioxide and magnesium stearate.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising at least 50% w/w of ibrutinib, andintragranular and extragranular excipients; wherein the processcomprises a wet granulation method, the intragranular excipientscomprise lactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose, and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment provided is a process forpreparing a high-load solid tablet formulation comprising at least 50%w/w of ibrutinib, wherein the process comprises a wet granulationmethod, the intragranular excipients comprise

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0% w/w to about        10% w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about        4% w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.1% w/w to about        1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5% w/w to        about 0.6% w/w.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising at least 50% w/w of ibrutinib, andintragranular and extragranular excipients; wherein the processcomprises a wet granulation method, the intragranular excipientscomprise lactose, microcrystalline cellulose, sodium lauryl sulfate,polyvinylpyrrolidone and croscarmellose sodium, and the extragranularexcipients comprise croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide, and magnesium stearate. In another embodimentprovided is a process for preparing a high-load solid tablet formulationcomprising at least 50% w/w of ibrutinib, wherein the process comprisesa wet granulation method, the intragranular excipients comprise

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0% w/w to about 2%        w/w, about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w or about 0% w/w to about 4% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 50% w/w to about 90% w/w ofibrutinib, and one or more pharmaceutically acceptable excipientsselected from the group consisting of diluents, binders, disintegratingagents, lubricants, glidants, and surfactants. In some embodiments, atleast one excipient is a diluent, wherein the process comprises a wetgranulation method. In some embodiments, the diluent is selected fromthe group consisting of lactose, sucrose, dextrose, dextrates,maltodextrin, mannitol, xylitol, sorbitol, cyclodextrins, calciumphosphate, calcium sulfate, starches, modified starches, cellulose,microcrystalline cellulose, microcellulose, and talc. In someembodiments, the diluent is cellulose. In some embodiments, the diluentis the diluent is lactose; and lactose is present in an amount fromabout 5% w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about8% w/w to about 15% w/w. In some embodiments, the diluent is lactose;and lactose is present in an amount of about 8.5% w/w or about 14% w/w.In some embodiments, the diluent is microcrystalline cellulose. In someembodiments, the diluent is microcrystalline cellulose and themicrocrystalline cellulose is present in an amount from about 1% w/w toabout 20% w/w, about 1% w/w to about 10% w/w, about 1% w/w to about 5%w/w, 1% w/w to about 2% w/w, 5% w/w to about 20% w/w, about 8% w/w toabout 20% w/w, or about 8% w/w to about 15% w/w. In some embodiments,the diluent is microcrystalline cellulose and the microcrystallinecellulose is present in an amount from about 1% w/w to about 6% w/w orabout 8.5% w/w or about 14% w/w. In some embodiments, the diluentcomprises lactose and microcrystalline cellulose. In some embodiments,the lactose is present in an amount of about 10% w/w to about 15% w/wand microcrystalline cellulose is present in an amount from about 1% w/wto about 6% w/w. In some embodiments, the lactose is present in anamount of about 14% w/w and microcrystalline cellulose is present in anamount from about 2% w/w to about 5% w/w. In some embodiments, at leastone excipient is a disintegrating agent. In some embodiments, thedisintegrating agent is selected from the group consisting of naturalstarch, a pregelatinized starch, a sodium starch, methylcrystallinecellulose, methylcellulose, croscarmellose, croscarmellose sodium,cross-linked sodium carboxymethylcellulose, cross-linkedcarboxymethylcellulose, cross-linked croscarmellose, cross-linked starchsuch as sodium starch glycolate, cross-linked polymer such ascrospovidone, cross-linked polyvinylpyrrolidone, sodium alginate, aclay, and a gum. In some embodiments, the disintegrating agent iscroscarmellose sodium; and croscarmellose sodium is present in an amountfrom about 0 to about 20% w/w, about 1% w/w to about 10% w/w, about 5%w/w to about 10% w/w, about 6% w/w to about 8% w/w, about 4% w/w toabout 6% w/w, or about 2% w/w to about 4% w/w. In some embodiments, atleast one excipient is a binder. In some embodiments, the binder ispolyvinylpyrrolidone. In some embodiments, the polyvinylpyrrolidone ispresent in an amount from about 0 to about 10% w/w, about 1 to about 5%w/w, or about 2% w/w. In some embodiments, the binder is hydroxypropylcellulose; and hydroxypropyl cellulose is present in an amount fromabout 0 to about 10% w/w, about 0 to about 5% w/w, about 0 to about 2%w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to about 1%w/w. In some embodiments, the formulation comprises lactose,microcrystalline cellulose, croscarmellose sodium, and hydroxypropylcellulose. In some embodiments, at least one excipient is a surfactant.In some embodiments, the surfactant is sodium lauryl sulfate. In someembodiments, the surfactant is sodium lauryl sulfate in an amount fromabout 0 to about 10% w/w, about 0.5 to about 5% w/w, about 1 to about 4%w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about 6% w/w. Insome embodiments, at least one excipient is a glidant. In someembodiments, the glidant is silica (colloidal silicon dioxide). In someembodiments, the glidant is silica (colloidal silicon dioxide) and thesilica (colloidal silicon dioxide) is present in an amount from about 0to about 5% w/w, 0.1% w/w to about 1.5% w/w, about 0.4% w/w to about0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In some embodiments, atleast one excipient is a lubricant. In some embodiments, the lubricantis magnesium stearate. In some embodiments, the lubricant is magnesiumstearate and the magnesium stearate is present in an amount from about0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1% w/w to about0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In some embodiments, theexcipients comprise lactose, microcrystalline cellulose,polyvinylpyrrolidone, croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide and magnesium stearate.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 50% w/w to about 90% w/w ofibrutinib, and intragranular and extragranular excipients; wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise lactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose, and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment provided is a process forpreparing a high-load solid tablet formulation comprising about 50% w/wto about 90% w/w of ibrutinib, wherein the process comprises a wetgranulation method, the intragranular excipients comprise

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0% w/w to about        10% w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about        4% w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.1% w/w to about        1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5% w/w to        about 0.6% w/w.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 50% w/w to about 90% w/w ofibrutinib, and intragranular and extragranular excipients; wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise lactose, microcrystalline cellulose, sodium lauryl sulfate,polyvinylpyrrolidone and croscarmellose sodium, and the extragranularexcipients comprise croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide, and magnesium stearate. In another embodimentprovided is a process for preparing a high-load solid tablet formulationcomprising about 50% w/w to about 90% w/w of ibrutinib, wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0% w/w to about 2%        w/w, about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w or about 0% w/w to about 4% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 50% w/w to about 80% w/w ofibrutinib, and one or more pharmaceutically acceptable excipientsselected from the group consisting of diluents, binders, disintegratingagents, lubricants, glidants, and surfactants, wherein the processcomprises a wet granulation method. In some embodiments, at least oneexcipient is a diluent. In some embodiments, the diluent is selectedfrom the group consisting of lactose, sucrose, dextrose, dextrates,maltodextrin, mannitol, xylitol, sorbitol, cyclodextrins, calciumphosphate, calcium sulfate, starches, modified starches, cellulose,microcrystalline cellulose, microcellulose, and talc. In someembodiments, the diluent is cellulose. In some embodiments, the diluentis the diluent is lactose; and lactose is present in an amount fromabout 5% w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about8% w/w to about 15% w/w. In some embodiments, the diluent is lactose;and lactose is present in an amount of about 8.5% w/w or about 14% w/w.In some embodiments, the diluent is microcrystalline cellulose. In someembodiments, the diluent is microcrystalline cellulose and themicrocrystalline cellulose is present in an amount from about 1% w/w toabout 20% w/w, about 1% w/w to about 10% w/w, about 1% w/w to about 5%w/w, 1% w/w to about 2% w/w, about 5% w/w to about 20% w/w, about 8% w/wto about 20% w/w, or about 8% w/w to about 15% w/w. In some embodiments,the diluent is microcrystalline cellulose and the microcrystallinecellulose is present in an amount from about 1% w/w to about 6% w/w orabout 8.5% w/w or about 14% w/w. In some embodiments, the diluentcomprises lactose and microcrystalline cellulose. In some embodiments,the lactose is present in an amount of about 10% w/w to about 15% w/wand microcrystalline cellulose is present in an amount from about 1% w/wto about 6% w/w. In some embodiments, the lactose is present in anamount of about 14% w/w and microcrystalline cellulose is present in anamount from about 2% w/w to about 5% w/w. In some embodiments, at leastone excipient is a disintegrating agent. In some embodiments, thedisintegrating agent is selected from the group consisting of naturalstarch, a pregelatinized starch, a sodium starch, methylcrystallinecellulose, methylcellulose, croscarmellose, croscarmellose sodium,cross-linked sodium carboxymethylcellulose, cross-linkedcarboxymethylcellulose, cross-linked croscarmellose, cross-linked starchsuch as sodium starch glycolate, cross-linked polymer such ascrospovidone, cross-linked polyvinylpyrrolidone, sodium alginate, aclay, and a gum. In some embodiments, the disintegrating agent iscroscarmellose sodium; and croscarmellose sodium is present in an amountfrom about 0 to about 20% w/w, about 1% w/w to about 10% w/w, about 5%w/w to about 10% w/w, about 6% w/w to about 8% w/w, about 4% w/w toabout 6% w/w, or about 2% w/w to about 4% w/w. In some embodiments, atleast one excipient is a binder. In some embodiments, the binder ispolyvinylpyrrolidone. In some embodiments, the polyvinylpyrrolidone ispresent in an amount from about 0 to about 10% w/w, about 1 to about 5%w/w, or about 2% w/w. In some embodiments, the binder is hydroxypropylcellulose; and hydroxypropyl cellulose is present in an amount fromabout 0 to about 10% w/w, about 0 to about 5% w/w, about 0 to about 2%w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to about 1%w/w. In some embodiments, the formulation comprises lactose,microcrystalline cellulose, croscarmellose sodium, and hydroxypropylcellulose. In some embodiments, at least one excipient is a surfactant.In some embodiments, the surfactant is sodium lauryl sulfate. In someembodiments, the surfactant is sodium lauryl sulfate in an amount fromabout 0 to about 10% w/w, about 0.5 to about 5% w/w, about 1 to about 4%w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about 6% w/w. Insome embodiments, at least one excipient is a glidant. In someembodiments, the glidant is silica (colloidal silicon dioxide). In someembodiments, the glidant is silica (colloidal silicon dioxide) and thesilica (colloidal silicon dioxide) is present in an amount from about 0to about 5% w/w, 0.1% w/w to about 1.5% w/w, about 0.4% w/w to about0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In some embodiments, atleast one excipient is a lubricant. In some embodiments, the lubricantis magnesium stearate. In some embodiments, the lubricant is magnesiumstearate and the magnesium stearate is present in an amount from about0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1% w/w to about0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In some embodiments, theexcipients comprise lactose, microcrystalline cellulose,polyvinylpyrrolidone, croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide and magnesium stearate.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 50% w/w to about 80% w/w ofibrutinib and intragranular and extragranular excipients, wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise lactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose, and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment provided is a process forpreparing a high-load solid tablet formulation comprising about 50% w/wto about 80% w/w of ibrutinib, wherein the process comprises a wetgranulation method, the intragranular excipients comprise

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0% w/w to about        10% w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about        4% w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.1% w/w to about        1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5% w/w to        about 0.6% w/w.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 50% w/w to about 80% w/w ofibrutinib, and intragranular and extragranular excipients, wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise lactose, microcrystalline cellulose, sodium lauryl sulfate,polyvinylpyrrolidone and croscarmellose sodium, and the extragranularexcipients comprise croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide, and magnesium stearate. In another embodimentprovided is a process for preparing a high-load solid tablet formulationcomprising about 50% w/w to about 80% w/w of ibrutinib, wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0% w/w to about 2%        w/w, about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w or about 0% w/w to about 4% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 60% w/w to about 80% w/w ofibrutinib, and one or more pharmaceutically acceptable excipientsselected from the group consisting of diluents, binders, disintegratingagents, lubricants, glidants, and surfactants, wherein the processcomprises a wet granulation method. In some embodiments, at least oneexcipient is a diluent. In some embodiments, the diluent is selectedfrom the group consisting of lactose, sucrose, dextrose, dextrates,maltodextrin, mannitol, xylitol, sorbitol, cyclodextrins, calciumphosphate, calcium sulfate, starches, modified starches, cellulose,microcrystalline cellulose, microcellulose, and talc. In someembodiments, the diluent is cellulose. In some embodiments, the diluentis the diluent is lactose; and lactose is present in an amount fromabout 5% w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about8% w/w to about 15% w/w. In some embodiments, the diluent is lactose;and lactose is present in an amount of about 8.5% w/w or about 14% w/w.In some embodiments, the diluent is microcrystalline cellulose. In someembodiments, the diluent is microcrystalline cellulose and themicrocrystalline cellulose is present in an amount from about 1% w/w toabout 20% w/w, about 1% w/w to about 10% w/w, about 1% w/w to about 5%w/w, 1% w/w to about 2% w/w, about 5% w/w to about 20% w/w, about 8% w/wto about 20% w/w, or about 8% w/w to about 15% w/w. In some embodiments,the diluent is microcrystalline cellulose and the microcrystallinecellulose is present in an amount from about 1% w/w to about 6% w/w orabout 8.5% w/w or about 14% w/w. In some embodiments, the diluentcomprises lactose and microcrystalline cellulose. In some embodiments,the lactose is present in an amount of about 10% w/w to about 15% w/wand microcrystalline cellulose is present in an amount from about 1% w/wto about 6% w/w. In some embodiments, the lactose is present in anamount of about 14% w/w and microcrystalline cellulose is present in anamount from about 2% w/w to about 5% w/w. In some embodiments, at leastone excipient is a disintegrating agent. In some embodiments, thedisintegrating agent is selected from the group consisting of naturalstarch, a pregelatinized starch, a sodium starch, methylcrystallinecellulose, methylcellulose, croscarmellose, croscarmellose sodium,cross-linked sodium carboxymethylcellulose, cross-linkedcarboxymethylcellulose, cross-linked croscarmellose, cross-linked starchsuch as sodium starch glycolate, cross-linked polymer such ascrospovidone, cross-linked polyvinylpyrrolidone, sodium alginate, aclay, and a gum. In some embodiments, the disintegrating agent iscroscarmellose sodium; and croscarmellose sodium is present in an amountfrom about 0 to about 20% w/w, about 1% w/w to about 10% w/w, about 5%w/w to about 10% w/w, about 6% w/w to about 8% w/w, about 4% w/w toabout 6% w/w, or about 2% w/w to about 4% w/w. In some embodiments, atleast one excipient is a binder. In some embodiments, the binder ispolyvinylpyrrolidone. In some embodiments, the polyvinylpyrrolidone ispresent in an amount from about 0 to about 10% w/w, about 1 to about 5%w/w, or about 2% w/w. In some embodiments, the binder is hydroxypropylcellulose; and hydroxypropyl cellulose is present in an amount fromabout 0 to about 10% w/w, about 0 to about 5% w/w, about 0 to about 2%w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to about 1%w/w. In some embodiments, the formulation comprises lactose,microcrystalline cellulose, croscarmellose sodium, and hydroxypropylcellulose. In some embodiments, at least one excipient is a surfactant.In some embodiments, the surfactant is sodium lauryl sulfate. In someembodiments, the surfactant is sodium lauryl sulfate in an amount fromabout 0 to about 10% w/w, about 0.5 to about 5% w/w, about 1 to about 4%w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about 6% w/w. Insome embodiments, at least one excipient is a glidant. In someembodiments, the glidant is silica (colloidal silicon dioxide). In someembodiments, the glidant is silica (colloidal silicon dioxide) and thesilica (colloidal silicon dioxide) is present in an amount from about 0to about 5% w/w, 0.1% w/w to about 1.5% w/w, about 0.4% w/w to about0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In some embodiments, atleast one excipient is a lubricant. In some embodiments, the lubricantis magnesium stearate. In some embodiments, the lubricant is magnesiumstearate and the magnesium stearate is present in an amount from about0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1% w/w to about0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In some embodiments, theexcipients comprise lactose, microcrystalline cellulose,polyvinylpyrrolidone, croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide and magnesium stearate.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 60% w/w to about 80% w/w ofibrutinib, and intragranular and extragranular excipients, wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise lactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose, and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment provided is a process forpreparing a high-load solid tablet formulation comprising about 60% w/wto about 80% w/w of ibrutinib, wherein the process comprises a wetgranulation method, the intragranular excipients comprise

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0% w/w to about        10% w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about        4% w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.1% w/w to about        1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5% w/w to        about 0.6% w/w.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 60% w/w to about 80% w/w ofibrutinib, and intragranular and extragranular excipients, wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise lactose, microcrystalline cellulose, sodium lauryl sulfate,polyvinylpyrrolidone and croscarmellose sodium, and the extragranularexcipients comprise croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide, and magnesium stearate. In another embodimentprovided is a process for preparing a high-load solid tablet formulationcomprising about 60% w/w to about 80% w/w of ibrutinib, wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0% w/w to about 2%        w/w, about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w or about 0% w/w to about 4% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 60% w/w to about 75% w/w ofibrutinib, and one or more pharmaceutically acceptable excipientsselected from the group consisting of diluents, binders, disintegratingagents, lubricants, glidants, and surfactants, wherein the processcomprises a wet granulation method. In some embodiments, at least oneexcipient is a diluent. In some embodiments, the diluent is selectedfrom the group consisting of lactose, sucrose, dextrose, dextrates,maltodextrin, mannitol, xylitol, sorbitol, cyclodextrins, calciumphosphate, calcium sulfate, starches, modified starches, cellulose,microcrystalline cellulose, microcellulose, and talc. In someembodiments, the diluent is cellulose. In some embodiments, the diluentis the diluent is lactose; and lactose is present in an amount fromabout 5% w/w to about 20% w/w, about 8% w/w to about 20% w/w, or about8% w/w to about 15% w/w. In some embodiments, the diluent is lactose;and lactose is present in an amount of about 8.5% w/w or about 14% w/w.In some embodiments, the diluent is microcrystalline cellulose. In someembodiments, the diluent is microcrystalline cellulose and themicrocrystalline cellulose is present in an amount from about 1% w/w toabout 20% w/w, about 1% w/w to about 10% w/w, about 1% w/w to about 5%w/w, 1% w/w to about 2% w/w, about 5% w/w to about 20% w/w, about 8% w/wto about 20% w/w, or about 8% w/w to about 15% w/w. In some embodiments,the diluent is microcrystalline cellulose and the microcrystallinecellulose is present in an amount from about 1% w/w to about 6% w/w orabout 8.5% w/w or about 14% w/w. In some embodiments, the diluentcomprises lactose and microcrystalline cellulose. In some embodiments,the lactose is present in an amount of about 10% w/w to about 15% w/wand microcrystalline cellulose is present in an amount from about 1% w/wto about 6% w/w. In some embodiments, the lactose is present in anamount of about 14% w/w and microcrystalline cellulose is present in anamount from about 2% w/w to about 5% w/w. In some embodiments, at leastone excipient is a disintegrating agent. In some embodiments, thedisintegrating agent is selected from the group consisting of naturalstarch, a pregelatinized starch, a sodium starch, methylcrystallinecellulose, methylcellulose, croscarmellose, croscarmellose sodium,cross-linked sodium carboxymethylcellulose, cross-linkedcarboxymethylcellulose, cross-linked croscarmellose, cross-linked starchsuch as sodium starch glycolate, cross-linked polymer such ascrospovidone, cross-linked polyvinylpyrrolidone, sodium alginate, aclay, and a gum. In some embodiments, the disintegrating agent iscroscarmellose sodium; and croscarmellose sodium is present in an amountfrom about 0 to about 20% w/w, about 1% w/w to about 10% w/w, about 5%w/w to about 10% w/w, about 6% w/w to about 8% w/w, about 4% w/w toabout 6% w/w, or about 2% w/w to about 4% w/w. In some embodiments, atleast one excipient is a binder. In some embodiments, the binder ispolyvinylpyrrolidone. In some embodiments, the polyvinylpyrrolidone ispresent in an amount from about 0 to about 10% w/w, about 1 to about 5%w/w, or about 2% w/w. In some embodiments, the binder is hydroxypropylcellulose; and hydroxypropyl cellulose is present in an amount fromabout 0 to about 10% w/w, about 0 to about 5% w/w, about 0 to about 2%w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to about 1%w/w. In some embodiments, the formulation comprises lactose,microcrystalline cellulose, croscarmellose sodium, and hydroxypropylcellulose. In some embodiments, at least one excipient is a surfactant.In some embodiments, the surfactant is sodium lauryl sulfate. In someembodiments, the surfactant is sodium lauryl sulfate in an amount fromabout 0 to about 10% w/w, about 0.5 to about 5% w/w, about 1 to about 4%w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about 6% w/w. Insome embodiments, at least one excipient is a glidant. In someembodiments, the glidant is silica (colloidal silicon dioxide). In someembodiments, the glidant is silica (colloidal silicon dioxide) and thesilica (colloidal silicon dioxide) is present in an amount from about 0to about 5% w/w, 0.1% w/w to about 1.5% w/w, about 0.4% w/w to about0.8% w/w, or about 0.5% w/w to about 0.6% w/w. In some embodiments, atleast one excipient is a lubricant. In some embodiments, the lubricantis magnesium stearate. In some embodiments, the lubricant is magnesiumstearate and the magnesium stearate is present in an amount from about0.01% w/w to about 5% w/w, 0.01% w/w to about 2% w/w, 0.1% w/w to about0.7% w/w, or about 0.5% w/w to about 0.6% w/w. In some embodiments, theexcipients comprise lactose, microcrystalline cellulose,polyvinylpyrrolidone, croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide and magnesium stearate.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 60% w/w to about 75% w/w ofibrutinib, and intragranular and extragranular excipients; wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise lactose, microcrystalline cellulose, croscarmellose sodium, andhydroxypropyl cellulose; and the extragranular excipients comprisecroscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide,and magnesium stearate. In another embodiment provided is a process forpreparing a high-load solid tablet formulation comprising about 60% w/wto about 75% w/w of ibrutinib, wherein the process comprises a wetgranulation method, the intragranular excipients comprise

-   -   lactose in an amount from about 5% w/w to about 20% w/w, about        8% w/w to about 15% w/w, or about 8% w/w to about 14% w/w;    -   microcrystalline cellulose in an amount from about 5% w/w to        about 20% w/w, about 8% w/w to about 20% w/w, or about 8% w/w to        about 15% w/w;    -   croscarmellose sodium in an amount from about 0% w/w to about        10% w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about        4% w/w; and    -   hydroxypropyl cellulose in an amount from about 0% w/w to about        2% w/w, about 0.1% w/w to about 1.1% w/w, or about 0.1% w/w to        about 1% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 2% w/w to about 5% w/w, or about 2% w/w to about 5%        w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w, about 4% w/w to about 8% w/w, or about 5% w/w to about        6% w/w;    -   colloidal silicon dioxide in an amount from about 0.1% w/w to        about 1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5%        w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.1% w/w to about        1.5% w/w, about 0.4% w/w to about 0.8% w/w, or about 0.5% w/w to        about 0.6% w/w.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising about 60% w/w to about 75% w/w ofibrutinib, and intragranular and extragranular excipients; wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise lactose, microcrystalline cellulose, sodium lauryl sulfate,polyvinylpyrrolidone and croscarmellose sodium, and the extragranularexcipients comprise croscarmellose sodium, sodium lauryl sulfate,colloidal silicon dioxide, and magnesium stearate. In another embodimentprovided is a process for preparing a high-load solid tablet formulationcomprising about 60% w/w to about 75% w/w of ibrutinib, wherein theprocess comprises a wet granulation method, the intragranular excipientscomprise

-   -   lactose in an amount from about 10% w/w to about 20% w/w, or        about 12% w/w to about 15% w/w;    -   microcrystalline cellulose in an amount from about 1% w/w to        about 10% w/w, about 2% w/w to about 5% w/w;    -   polyvinylpyrrolidone in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   croscarmellose sodium in an amount from about 1% w/w to about        10% w/w, or about 3% w/w to about 7% w/w; and    -   sodium lauryl sulfate in an amount from about 0% w/w to about 2%        w/w, about 0.5% w/w to about 1.5% w/w; and        the extragranular excipients comprise    -   croscarmellose sodium in an amount from about 0% w/w to about 5%        w/w, about 1% w/w to about 3% w/w;    -   sodium lauryl sulfate in an amount from about 0% w/w to about        10% w/w or about 0% w/w to about 4% w/w;    -   colloidal silicon dioxide in an amount from about 0.4% w/w to        about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w; and    -   magnesium stearate in an amount from about 0.4% w/w to about        0.8% w/w, or about 0.5% w/w to about 0.6% w/w.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising ibrutinib, wherein the processcomprises a wet granulation method, and the formulation comprises:

-   -   a) about 69% w/w to about 71% w/w of ibrutinib,    -   b) about 13% w/w to about 15% w/w of lactose,    -   c) about 2% w/w to about 5% w/w of microcrystalline cellulose,    -   d) about 1% w/w to about 3% w/w of polyvinylpyrrolidone,    -   e) about 6% w/w to about 8% w/w of croscarmellose sodium,    -   f) about 1% w/w to about 4% w/w of sodium lauryl sulfate,    -   g) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   h) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising ibrutinib, wherein the processcomprises a wet granulation method, and the formulation comprises:

-   -   a) about 70% w/w of ibrutinib,    -   b) about 14% w/w of lactose,    -   c) about 5% w/w of microcrystalline cellulose,    -   d) about 2% w/w of polyvinylpyrrolidone,    -   e) about 7% w/w of croscarmellose sodium,    -   f) about 1% w/w of sodium lauryl sulfate,    -   g) about 0.5% w/w of colloidal silicon dioxide, and    -   h) about 0.5% w/w of magnesium stearate.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising ibrutinib, wherein the processcomprises a wet granulation method, and the formulation comprises:

-   -   a) about 70% w/w of ibrutinib,    -   b) about 14% w/w of lactose,    -   c) about 2% w/w of microcrystalline cellulose,    -   d) about 2% w/w of polyvinylpyrrolidone,    -   e) about 7% w/w of croscarmellose sodium,    -   f) about 4% w/w of sodium lauryl sulfate,    -   g) about 0.5% w/w of colloidal silicon dioxide, and    -   h) about 0.5% w/w of magnesium stearate.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising ibrutinib, wherein the processcomprises a wet granulation method, and wherein the formulationcomprises:

-   -   a) about 65% w/w to about 75% w/w, or about 70% w/w of        ibrutinib,    -   b) about 14% w/w to about 18% w/w, or about 16% w/w of lactose        monohydrate,    -   c) about 1% w/w to about 3% w/w, or about 2% w/w of        polyvinylpyrrolidone,    -   d) about 0.5% w/w to about 1.5% w/w, or about 1% w/w of sodium        lauryl sulfate,    -   e) about 5% w/w to about 15% w/w, or about 10% w/w of        crospovidone,    -   f) about 0.3% w/w to about 0.7% w/w, or about 0.5% w/w of        colloidal silicon dioxide, and    -   g) about 0.3% w/w to about 0.7% w/w, or about 0.5% w/w of        magnesium stearate.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising ibrutinib, wherein the processcomprises a wet granulation method, and wherein the formulationcomprises:

-   -   a) about 59% w/w to about 61% w/w of ibrutinib,    -   b) about 13% w/w to about 15% w/w of lactose,    -   c) about 13% w/w to about 15% w/w of microcrystalline cellulose,    -   d) about 4% w/w to about 6% w/w of croscarmellose sodium,    -   e) about 5% w/w to about 7% w/w of sodium lauryl sulfate,    -   f) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   g) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In some embodiments, the total weight of a tablet is about 934 mg.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising ibrutinib, wherein the processcomprises a wet granulation method, and wherein the formulationcomprises:

-   -   a) about 59% w/w to about 61% w/w of ibrutinib,    -   b) about 13% w/w to about 14% w/w of lactose,    -   c) about 13% w/w to about 14% w/w of microcrystalline cellulose,    -   d) about 2% w/w to about 3% w/w of croscarmellose        sodium(intragranular),    -   e) about 0.8% w/w to about 1.2% w/w of hydroxypropyl cellulose,    -   f) about 2% w/w to about 3% w/w of croscarmellose        sodium(extragranular),    -   g) about 5.5 to about 6.5% w/w of sodium lauryl sulfate,    -   h) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   i) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In some embodiments, the total weight of a tablet is about 934 mg.

In another embodiment provided is a process for preparing a high-loadsolid tablet formulation comprising ibrutinib, wherein the processcomprises a wet granulation method, and wherein the formulationcomprises:

-   -   a) about 69% w/w to about 71% w/w of ibrutinib,    -   b) about 8% w/w to about 9% w/w of lactose,    -   c) about 8 to about 9% w/w of microcrystalline cellulose,    -   d) about 2.5 to about 3.5% w/w of croscarmellose sodium        (intragranular),    -   e) about 2.5 to about 3.5% w/w of croscarmellose sodium        (extragranular),    -   g) about 5.5 to about 6.5% w/w of sodium lauryl sulfate,    -   h) about 0.4% w/w to about 0.6% w/w of colloidal silicon        dioxide, and    -   i) about 0.4% w/w to about 0.6% w/w of magnesium stearate.

In some embodiments, the total weight of a tablet is about 800 mg.

In some embodiments of the high-load solid tablet formulations describedherein comprising ibrutinib and prepared using a wet granulation method,the ibrutinib is in an amount of about 560 mg. In some embodiments ofthe high-load solid tablet formulations described herein comprisingibrutinib and prepared using a wet granulation method, the ibrutinib isin micronized form. In some embodiments of the high-load solid tabletformulations described herein comprising ibrutinib and prepared using awet granulation method, the formulation is used for once a day dosing.In some embodiments of the high-load solid tablet formulations describedherein comprising ibrutinib and prepared using a wet granulation method,the formulation is in an oral dosage form containing a therapeuticallyeffective amount of ibrutinib.

Moreover, the pharmaceutical compositions described herein, whichinclude Compound 1 can be formulated into any suitable dosage form,including but not limited to, solid oral dosage forms, controlledrelease formulations, fast melt formulations, effervescent formulations,tablets, powders, pills, capsules, delayed release formulations,extended release formulations, pulsatile release formulations,multiparticulate formulations, and mixed immediate release andcontrolled release formulations. In some embodiments, the tabletsdescribed herein are for immediate release and do not comprise aviscosity increasing agent, such as poloxamer or glyceryl behenate.

In some embodiments, the solid dosage forms disclosed herein may be inthe form of a tablet, including a suspension tablet, a fast-melt tablet,a bite-disintegration tablet, a rapid-disintegration tablet, aneffervescent tablet, or a caplet. In other embodiments, thepharmaceutical formulation is in the form of a powder. In still otherembodiments, the pharmaceutical formulation is in the form of a tablet,including but not limited to, a fast-melt tablet. Additionally,pharmaceutical formulations described herein may be administered as asingle capsule or in multiple capsule dosage form. In some embodiments,the pharmaceutical formulation is administered in two, or three, orfour, tablets.

In some embodiments, the compositions described herein are prepared bymixing particles of Compound 1 with one or more pharmaceuticalexcipients to form a bulk blend composition. When referring to thesebulk blend compositions as homogeneous, it is meant that the particlesof Compound 1 are dispersed evenly throughout the composition so thatthe composition may be readily subdivided into equally effective unitdosage forms, such as tablets, pills, and capsules. The individual unitdosages may also include film coatings, which disintegrate upon oralingestion or upon contact with diluent.

In some embodiments, the wet granulation method comprises granulatingthe mixture of ibrutinib and the intragranular excipients with agranulation liquid, such as purified water, under granulationconditions, such as high shear granulation conditions, to form granules.

In some embodiments, the compositions or formulations described hereinare prepared by a method comprising (1) mixing ibrutinib with theintragranular excipients such as filler, binder, disintegrant andsurfactant; (2) granulating the mixture of ibrutinib and theintragranular excipients with purified water or an aqueous bindersolution under high shear granulation conditions to form granules; (3)drying the granules to form dried granules; (4) milling the driedgranules; (5) blending the milled granules with the extragranularexcipients such as filler, disintegrant, surfactant and lubricant; and(6) compressing the mixture of milled granules and the extragranularexcipients to form tablets.

The pharmaceutical compositions or formulations described herein canfurther include a flavoring agent, sweetening agent, colorant,antioxidant, preservative, or one or more combination thereof. In stillother aspects, using standard coating procedures, such as thosedescribed in Remington's Pharmaceutical Sciences, 20th Edition (2000), afilm coating is provided around the formulation of Compound 1. In oneembodiment, some or all of the particles of the Compound 1 are coated.In another embodiment, some or all of the particles of the Compound 1are microencapsulated. In still another embodiment, the particles of theCompound 1 are not microencapsulated and are uncoated.

Suitable antioxidants for use in the compositions or formulationsdescribed herein include, for example, e.g., butylated hydroxytoluene(BHT), sodium ascorbate, and tocopherol.

It should be appreciated that there is considerable overlap betweenadditives used in the solid dosage forms described herein. Thus, theabove-listed additives should be taken as merely exemplary, and notlimiting, of the types of additives that can be included in thecompositions or formulations described herein. The amounts of suchadditives can be readily determined by one skilled in the art, accordingto the particular properties desired.

Compressed tablets are solid dosage forms prepared by compacting thebulk blend of the formulations described above. In various embodiments,compressed tablets which are designed to dissolve in the mouth willinclude one or more flavoring agents. In other embodiments, thecompressed tablets will include a film surrounding the final compressedtablet. In some embodiments, the film coating can provide a delayedrelease of Compound 1 from the formulation. In other embodiments, thefilm coating aids in patient compliance (e.g., Opadry® coatings or sugarcoating). Film coatings including Opadry® typically range from about 1%to about 3% of the tablet weight. In other embodiments, the compressedtablets include one or more excipients.

In some embodiments, the compositions or formulations described hereincan be formulated as enteric coated delayed release oral dosage forms,i.e., as an oral dosage form of a pharmaceutical composition asdescribed herein which utilizes an enteric coating to affect release inthe small intestine of the gastrointestinal tract. The enteric coateddosage form may be a compressed or molded or extruded tablet/mold(coated or uncoated) containing granules, powder, pellets, beads orparticles of the active ingredient and/or other composition components,which are themselves coated or uncoated. The enteric coated oral dosageform may also be a capsule (coated or uncoated) containing pellets,beads or granules of the solid carrier or the composition, which arethemselves coated or uncoated.

The term “delayed release” as used herein refers to the delivery so thatthe release can be accomplished at some generally predictable locationin the intestinal tract more distal to that which would have beenaccomplished if there had been no delayed release alterations. In someembodiments the method for delay of release is coating. Any coatingsshould be applied to a sufficient thickness such that the entire coatingdoes not dissolve in the gastrointestinal fluids at pH below about 5,but does dissolve at pH about 5 and above. It is expected that anyanionic polymer exhibiting a pH-dependent solubility profile can be usedas an enteric coating in the methods and compositions described hereinto achieve delivery to the lower gastrointestinal tract. In someembodiments the polymers described herein are anionic carboxylicpolymers. In other embodiments, the polymers and compatible mixturesthereof, and some of their properties, include, but are not limited to:

Shellac, also called purified lac, a refined product obtained from theresinous secretion of an insect. This coating dissolves in media of pH>7;

Acrylic polymers. The performance of acrylic polymers (primarily theirsolubility in biological fluids) can vary based on the degree and typeof substitution. Examples of suitable acrylic polymers includemethacrylic acid copolymers and ammonium methacrylate copolymers. TheEudragit series E, L, S, RL, RS and NE (Rohm Pharma) are available assolubilized in organic solvent, aqueous dispersion, or dry powders. TheEudragit series RL, NE, and RS are insoluble in the gastrointestinaltract but are permeable and are used primarily for colonic targeting.The Eudragit series E dissolve in the stomach. The Eudragit series L,L-30D and S are insoluble in stomach and dissolve in the intestine;

Cellulose Derivatives. Examples of suitable cellulose derivatives are:ethyl cellulose; reaction mixtures of partial acetate esters ofcellulose with phthalic anhydride. The performance can vary based on thedegree and type of substitution. Cellulose acetate phthalate (CAP)dissolves in pH >6. Aquateric (FMC) is an aqueous based system and is aspray dried CAP psuedolatex with particles <1 m. Other components inAquateric can include pluronics, Tweens, and acetylated monoglycerides.Other suitable cellulose derivatives include: cellulose acetatetrimellitate (Eastman); methylcellulose (Pharmacoat, Methocel);hydroxypropylmethyl cellulose phthalate (HPMCP); hydroxypropylmethylcellulose succinate (HPMCS); and hydroxypropylmethylcellulose acetatesuccinate (e.g., AQOAT (Shin Etsu)). The performance can vary based onthe degree and type of substitution. For example, HPMCP such as, HP-50,HP-55, HP-55S, HP-55F grades are suitable. The performance can varybased on the degree and type of substitution. For example, suitablegrades of hydroxypropylmethylcellulose acetate succinate include, butare not limited to, AS-LG (LF), which dissolves at pH 5, AS-MG (MF),which dissolves at pH 5.5, and AS-HG (HF), which dissolves at higher pH.These polymers are offered as granules, or as fine powders for aqueousdispersions; Poly Vinyl Acetate Phthalate (PVAP). PVAP dissolves inpH >5, and it is much less permeable to water vapor and gastric fluids.

In some embodiments, the coating can, and usually does, contain aplasticizer and possibly other coating excipients such as colorants,talc, and/or magnesium stearate, which are well known in the art.Suitable plasticizers include triethyl citrate (Citroflex 2), triacetin(glyceryl triacetate), acetyl triethyl citrate (Citroflec A2), Carbowax400 (polyethylene glycol 400), diethyl phthalate, tributyl citrate,acetylated monoglycerides, glycerol, fatty acid esters, propyleneglycol, and dibutyl phthalate. In particular, anionic carboxylic acrylicpolymers usually will contain 10-25% by weight of a plasticizer,especially dibutyl phthalate, polyethylene glycol, triethyl citrate andtriacetin. Conventional coating techniques such as spray or pan coatingare employed to apply coatings. The coating thickness must be sufficientto ensure that the oral dosage form remains intact until the desiredsite of topical delivery in the intestinal tract is reached.

Colorants, detackifiers, surfactants, antifoaming agents, lubricants(e.g., camuba wax or PEG) may be added to the coatings besidesplasticizers to solubilize or disperse the coating material, and toimprove coating performance and the coated product.

In other embodiments, the formulations described herein, which includeCompound 1, are delivered using a pulsatile dosage form. A pulsatiledosage form is capable of providing one or more immediate release pulsesat predetermined time points after a controlled lag time or at specificsites. Many other types of controlled release systems known to those ofordinary skill in the art and are suitable for use with the formulationsdescribed herein. Examples of such delivery systems include, e.g.,polymer-based systems, such as polylactic and polyglycolic acid,plyanhydrides and polycaprolactone; porous matrices, nonpolymer-basedsystems that are lipids, including sterols, such as cholesterol,cholesterol esters and fatty acids, or neutral fats, such as mono-, di-and triglycerides; hydrogel release systems; silastic systems;peptide-based systems; wax coatings, bioerodible dosage forms,compressed tablets using conventional binders and the like. See, e.g.,Liberman et al., Pharmaceutical Dosage Forms, 2 Ed., Vol. 1, pp. 209-214(1990); Singh et al., Encyclopedia of Pharmaceutical Technology, 2^(nd)Ed., pp. 751-753 (2002); U.S. Pat. Nos. 4,327,725, 4,624,848, 4,968,509,5,461,140, 5,456,923, 5,516,527, 5,622,721, 5,686,105, 5,700,410,5,977,175, 6,465,014 and 6,932,983, each of which is specificallyincorporated by reference.

In some embodiments, pharmaceutical formulations are provided thatinclude particles of Compound 1 and at least one dispersing agent orsuspending agent for oral administration to a subject. The formulationsmay be a powder and/or granules for suspension, and upon admixture withwater, a substantially uniform suspension is obtained.

It is to be appreciated that there is overlap between the above-listedadditives used in the aqueous dispersions or suspensions describedherein, since a given additive is often classified differently bydifferent practitioners in the field, or is commonly used for any ofseveral different functions. Thus, the above-listed additives should betaken as merely exemplary, and not limiting, of the types of additivesthat can be included in formulations described herein. The amounts ofsuch additives can be readily determined by one skilled in the art,according to the particular properties desired.

Dosing and Treatment Regimens

In some embodiments, the amount of Compound 1 that is administered to amammal is from 300 mg/day up to, and including, 1000 mg/day. In someembodiments, the amount of Compound 1 that is administered to a mammalis from 420 mg/day up to, and including, 840 mg/day. In someembodiments, the amount of Compound 1 that is administered to a mammalis about 420 mg/day, about 560 mg/day, or about 840 mg/day. In someembodiments, the amount of Compound 1 that is administered to a mammalis about 420 mg/day. In some embodiments, the amount of Compound 1 thatis administered to a mammal is about 560 mg/day. In some embodiments,the AUC₀₋₂₄ of Compound 1 is between about 150 and about 3500 ng*h/mL.In some embodiments, the AUC₀₋₂₄ of Compound 1 is between about 500 andabout 1100 ng*h/mL. In some embodiments, Compound 1 is administeredorally. In some embodiments, Compound 1 is administered once per day,twice per day, or three times per day. In some embodiments, Compound 1is administered daily. In some embodiments, Compound 1 is administeredonce daily. In some embodiments, Compound 1 is administered every otherday. In some embodiments, the Compound 1 is a maintenance therapy.

Compound 1 can be used in the preparation of medicaments for theinhibition of Btk or a homolog thereof, or for the treatment of diseasesor conditions that would benefit, at least in part, from inhibition ofBtk or a homolog thereof, including a subject diagnosed with ahematological malignancy. In addition, a method for treating any of thediseases or conditions described herein in a subject in need of suchtreatment, involves administration of pharmaceutical compositionscontaining Compound 1, or a pharmaceutically acceptable salt,pharmaceutically acceptable N-oxide, pharmaceutically active metabolite,pharmaceutically acceptable prodrug, or pharmaceutically acceptablesolvate thereof, in therapeutically effective amounts to said subject.

The compositions containing Compound 1 can be administered forprophylactic, therapeutic, or maintenance treatment. In someembodiments, compositions containing Compound 1 are administered fortherapeutic applications (e.g., administered to a subject diagnosed witha hematological malignancy). In some embodiments, compositionscontaining Compound 1 are administered for therapeutic applications(e.g., administered to a subject susceptible to or otherwise at risk ofdeveloping a hematological malignancy). In some embodiments,compositions containing Compound 1 are administered to a patient who isin remission as a maintenance therapy.

Amounts of Compound 1 will depend on the use (e.g., therapeutic,prophylactic, or maintenance). Amounts of Compound 1 will depend onseverity and course of the disease or condition, previous therapy, thepatient's health status, weight, and response to the drugs, and thejudgment of the treating physician. It is considered well within theskill of the art for one to determine such therapeutically effectiveamounts by routine experimentation (including, but not limited to, adose escalation clinical trial). In some embodiments, the amount ofCompound 1 is from 300 mg/day up to, and including, 1000 mg/day. In someembodiments, the amount of Compound 1 is from 420 mg/day up to, andincluding, 840 mg/day. In some embodiments, the amount of Compound 1 isfrom 400 mg/day up to, and including, 860 mg/day. In some embodiments,the amount of Compound 1 is about 360 mg/day. In some embodiments, theamount of Compound 1 is about 420 mg/day. In some embodiments, theamount of Compound 1 is about 560 mg/day. In some embodiments, theamount of Compound 1 is about 840 mg/day. In some embodiments, theamount of Compound 1 is from 2 mg/kg/day up to, and including, 13mg/kg/day. In some embodiments, the amount of Compound 1 is from 2.5mg/kg/day up to, and including, 8 mg/kg/day. In some embodiments, theamount of Compound 1 is from 2.5 mg/kg/day up to, and including, 6mg/kg/day. In some embodiments, the amount of Compound 1 is from 2.5mg/kg/day up to, and including, 4 mg/kg/day. In some embodiments, theamount of Compound 1 is about 2.5 mg/kg/day. In some embodiments, theamount of Compound 1 is about 8 mg/kg/day.

In one embodiment, the tablet formulation of the invention with 140 mgof dose in dogs produces C_(max) of about 260 to 400 ng/mL (Fed), andabout 300 to 400 ng/mL (Fasted). In another embodiment, the formulationproduces C_(max) of about 280 to 380 ng/mL (Fed), and about 360 to 380ng/mL (Fasted). In a particular embodiment, the formulation producesC_(max) of about 290 ng/mL (Fed), and about 370 ng/mL (Fasted). Inanother particular embodiment, the formulation produces C_(max) of about370 ng/mL (Fed), and about 370 ng/mL (Fasted). In one embodiment, theformulation is a wet granulation formulation. In one embodiment, thetablet formulation is Formulation BK02, BK21A, or BK21B. In a particularembodiment, the tablet formulation is Formulation BK21A. In anotherparticular embodiment, the tablet formulation is Formulation BK21B.(Table 1E and 1F).

In one embodiment, the tablet formulation of the invention with 140 mgof dose in dogs produces AUC of about 850 to 1050 ng*h/mL (Fed), andabout 850 to 1050 ng*h/mL (Fasted). In another embodiment, theformulation produces AUC of about 870 to 1050 ng*h/mL (Fed), and about840 to 1000 ng*h/mL (Fasted). In a particular embodiment, theformulation produces AUC of about 875 ng*h/mL (Fed), and about 1000ng*h/mL (Fasted). In another particular embodiment, the formulationproduces AUC of about 1000 ng*h/mL (Fed), and about 850 ng*h/mL(Fasted). In one embodiment, the formulation is a wet granulationformulation. In one embodiment, the tablet formulation is FormulationBK02, BK21A, or BK21B. In a particular embodiment, the tabletformulation is Formulation BK21A. In another particular embodiment, thetablet formulation is Formulation BK21B. (Table 1E and 1F).

In one embodiment, the tablet formulation of the invention with 140 mgof dose in dogs produces % F_(rel) (tablet/capsule) (C_(max)) value ofabout 150-250 (Fed) and 100-160 (Fasted). In a particular embodiment,the formulation produces % F_(rel) (tablet/capsule) (C_(max)) value ofabout 170 (Fed) and about 110 (Fasted). In another particularembodiment, the formulation produces % F_(rel) (tablet/capsule)(C_(max)) value of about 230 (Fed) and about 150 (Fasted). In oneembodiment, the formulation is a wet granulation formulation. In oneembodiment, the tablet formulation is Formulation BK02, BK21A, or BK21B.In a particular embodiment, the tablet formulation is Formulation BK21A.In another particular embodiment, the tablet formulation is FormulationBK21B. (Table 1E and 1F).

In one embodiment, the tablet formulation of the invention with 140 mgof dose in dogs produces % F_(rel) (tablet/capsule) (AUC) value of about110-150 (Fed) and 100-140 (Fasted). In a particular embodiment, theformulation produces % F_(rel) (tablet/capsule) (AUC) value of about 120(Fed) and about 110 (Fasted). In another particular embodiment, theformulation produces % F_(rel) (tablet/capsule) (AUC) value of about 150(Fed) and about 130 (Fasted). In one embodiment, the formulation is awet granulation formulation. In one embodiment, the tablet formulationis Formulation BK02, BK21A, or BK21B. In a particular embodiment, thetablet formulation is Formulation BK21A. In another particularembodiment, the tablet formulation is Formulation BK21B. (Table 1E and1F).

In one embodiment, the tablet formulation of the invention with 140 mgof dose in dogs produces % F_(rel) (Fed/Fasted) (C_(max)) value of about90-105. In a particular embodiment, the formulation produces % F_(rel)(Fed/Fasted) (C_(max)) value of about 95. In another particularembodiment, the formulation produces % F_(rel) (Fed/Fasted) (C_(max))value of about 100. In one embodiment, the formulation is a wetgranulation formulation. In one embodiment, the tablet formulation isFormulation BK02, BK21A, or BK21B. In a particular embodiment, thetablet formulation is Formulation BK21A. In another particularembodiment, the tablet formulation is Formulation BK21B. (Table 1E and1F).

In one embodiment, the tablet formulation of the invention with 140 mgof dose in dogs produces % F_(rel) (Fed/Fasted) (AUC) value of about90-140. In a particular embodiment, the formulation produces % F_(rel)(Fed/Fasted) (AUC) value of about 100. In one embodiment, theformulation is a wet granulation formulation. In one embodiment, thetablet formulation is Formulation BK02, BK21A, or BK21B. In a particularembodiment, the tablet formulation is Formulation BK21A. In anotherparticular embodiment, the tablet formulation is Formulation BK21B.(Table 1E and 1F).

In some embodiments, pharmaceutical compositions described hereininclude about 140 mg of Compound 1. In some embodiments, a tabletformulation is prepared that includes about 140 mg of Compound 1. Insome embodiments, 2, 3, 4, or 5 of the tablet formulations areadministered daily. In some embodiments, 3 or 4 of the capsules areadministered daily. In some embodiments tablet are administered oncedaily. In some embodiments, the capsules are administered once daily. Inother embodiments, the tablet are administered multiple times a day.

In another aspect is a high-load solid tablet formulation comprisingibrutinib, wherein ibrutinib is a compound with the structure ofCompound 1,

and the tablet comprises about 560 mg of ibrutinib.

In another embodiment is a high-load solid tablet formulation, whereinthe tablet is used for once a day oral dosing. The high-load solidtablet formulations described herein make it possible for one tablet aday administration and contain a large amount of ibrutinib per tablet ofabout 420 mg to about 840 mg, such as about 420 mg, about 560 mg, orabout 840 mg, or any range between any two of the values, end pointsinclusive. In another embodiment is a high-load solid tabletformulation, wherein the tablet comprises 560 mg of ibrutinib. Inanother embodiment is a high-load solid tablet formulation, whereinibrutinib is in micronized form.

In some embodiments, Compound 1 is administered daily. In someembodiments, Compound 1 is administered every other day.

In some embodiments, Compound 1 is administered once per day. In someembodiments, Compound 1 is administered twice per day. In someembodiments, Compound 1 is administered three times per day. In someembodiments, Compound 1 is administered four times per day.

In some embodiments, Compound 1 is administered until diseaseprogression, unacceptable toxicity, or individual choice. In someembodiments, Compound 1 is administered daily until disease progression,unacceptable toxicity, or individual choice. In some embodiments,Compound 1 is administered every other day until disease progression,unacceptable toxicity, or individual choice.

In the case wherein the patient's status does improve, upon the doctor'sdiscretion the administration of the compounds may be givencontinuously; alternatively, the dose of drug being administered may betemporarily reduced or temporarily suspended for a certain length oftime (i.e., a “drug holiday”). The length of the drug holiday can varybetween 2 days and 1 year, including by way of example only, 2 days, 3days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days,180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or365 days. The dose reduction during a drug holiday may be from 10%-100%,including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%,45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

Once improvement of the patient's conditions has occurred, a maintenancedose is administered if necessary. Subsequently, the dosage or thefrequency of administration, or both, can be reduced, as a function ofthe symptoms, to a level at which the improved disease, disorder orcondition is retained. Patients can, however, require intermittenttreatment on a long-term basis upon any recurrence of symptoms.

The amount of a given agent that will correspond to such an amount willvary depending upon factors such as the particular compound, theseverity of the disease, the identity (e.g., weight) of the subject orhost in need of treatment, but can nevertheless be routinely determinedin a manner known in the art according to the particular circumstancessurrounding the case, including, e.g., the specific agent beingadministered, the route of administration, and the subject or host beingtreated. In general, however, doses employed for adult human treatmentwill typically be in the range of 0.02-5000 mg per day, or from about1-1500 mg per day. The desired dose may conveniently be presented in asingle dose or as divided doses administered simultaneously (or over ashort period of time) or at appropriate intervals, for example as two,three, four or more sub-doses per day.

The pharmaceutical compositions or formulations described herein may bein unit dosage forms suitable for single administration of precisedosages. In unit dosage form, the formulation is divided into unit dosescontaining appropriate quantities of one or more compound. The unitdosage may be in the form of a package containing discrete quantities ofthe formulation. Non-limiting examples are packaged tablets or capsules,and powders in vials or ampoules. Aqueous suspension compositions can bepackaged in single-dose non-reclosable containers. Alternatively,multiple-dose reclosable containers can be used, in which case it istypical to include a preservative in the composition. In someembodiments, each unit dosage form comprises 140 mg of Compound 1. Insome embodiments, an individual is administered 1 unit dosage form perday. In some embodiments, an individual is administered 2 unit dosageforms per day. In some embodiments, an individual is administered 3 unitdosage forms per day. In some embodiments, an individual is administered4 unit dosage forms per day.

The foregoing ranges are merely suggestive, as the number of variablesin regard to an individual treatment regime is large, and considerableexcursions from these recommended values are not uncommon. Such dosagesmay be altered depending on a number of variables, not limited to theactivity of the compound used, the disease or condition to be treated,the mode of administration, the requirements of the individual subject,the severity of the disease or condition being treated, and the judgmentof the practitioner.

Toxicity and therapeutic efficacy of such therapeutic regimens can bedetermined by standard pharmaceutical procedures in cell cultures orexperimental animals, including, but not limited to, the determinationof the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (thedose therapeutically effective in 50% of the population). The dose ratiobetween the toxic and therapeutic effects is the therapeutic index andit can be expressed as the ratio between LD₅₀ and ED₅₀. Compoundsexhibiting high therapeutic indices are preferred. The data obtainedfrom cell culture assays and animal studies can be used in formulating arange of dosage for use in human. The dosage of such compounds liespreferably within a range of circulating concentrations that include theED₅₀ with minimal toxicity. The dosage may vary within this rangedepending upon the dosage form employed and the route of administrationutilized.

Combination Therapy

In certain instances, it is appropriate to administer Compound 1 incombination with another therapeutic agent.

In one embodiment, the compositions and methods described herein arealso used in conjunction with other therapeutic reagents that areselected for their particular usefulness against the condition that isbeing treated. In general, the compositions described herein and, inembodiments where combinational therapy is employed, other agents do nothave to be administered in the same pharmaceutical composition, and are,because of different physical and chemical characteristics, administeredby different routes. In one embodiment, the initial administration ismade according to established protocols, and then, based upon theobserved effects, the dosage, modes of administration and times ofadministration, further modified.

In various embodiments, the compounds are administered concurrently(e.g., simultaneously, essentially simultaneously or within the sametreatment protocol) or sequentially, depending upon the nature of thedisease, the condition of the patient, and the actual choice ofcompounds used. In certain embodiments, the determination of the orderof administration, and the number of repetitions of administration ofeach therapeutic agent during a treatment protocol, is based uponevaluation of the disease being treated and the condition of thepatient.

For combination therapies described herein, dosages of theco-administered compounds vary depending on the type of co-drugemployed, on the specific drug employed, on the disease or conditionbeing treated and so forth.

The individual compounds of such combinations are administered eithersequentially or simultaneously in separate or combined pharmaceuticalformulations. In one embodiment, the individual compounds will beadministered simultaneously in a combined pharmaceutical formulation.Appropriate doses of known therapeutic agents will be appreciated bythose skilled in the art.

The combinations referred to herein are conveniently presented for usein the form of a pharmaceutical compositions together with apharmaceutically acceptable diluent(s) or carrier(s).

Disclosed herein, in certain embodiments, is a method for treating acancer in an individual in need thereof, comprising: administering tothe individual an amount of Compound 1. In some embodiments, the methodfurther comprises administering a second cancer treatment regimen.

In some embodiments, administering a Btk inhibitor before a secondcancer treatment regimen reduces immune-mediated reactions to the secondcancer treatment regimen. In some embodiments, administering Compound 1before ofatumumab reduces immune-mediated reactions to ofatumumab.

In some embodiments, the second cancer treatment regimen comprises achemotherapeutic agent, a steroid, an immunotherapeutic agent, atargeted therapy, or a combination thereof. In some embodiments, thesecond cancer treatment regimen comprises a B cell receptor pathwayinhibitor. In some embodiments, the B cell receptor pathway inhibitor isa CD79A inhibitor, a CD79B inhibitor, a CD19 inhibitor, a Lyn inhibitor,a Syk inhibitor, a PI3K inhibitor, a Blnk inhibitor, a PLCγ inhibitor, aPKCβ inhibitor, or a combination thereof. In some embodiments, thesecond cancer treatment regimen comprises an antibody, B cell receptorsignaling inhibitor, a PI3K inhibitor, an IAP inhibitor, an mTORinhibitor, an immunochemotherapy, a radioimmunotherapeutic, a DNAdamaging agent, a proteosome inhibitor, a Cyp3A4 inhibitor, a histonedeacetylase inhibitor, a protein kinase inhibitor, a hedgehog inhibitor,an Hsp90 inhibitor, a telomerase inhibitor, a Jak1/2 inhibitor, aprotease inhibitor, a PKC inhibitor, a PARP inhibitor, or a combinationthereof.

In some embodiments, the second cancer treatment regimen compriseschlorambucil, ifosphamide, doxorubicin, mesalazine, thalidomide,lenalidomide, temsirolimus, everolimus, fludarabine, fostamatinib,paclitaxel, docetaxel, ofatumumab, rituximab, dexamethasone, prednisone,CAL-101, ibritumomab, tositumomab, bortezomib, pentostatin, endostatin,EPOCH-R, DA-EPOCH-R, rifampin, selinexor, gemcitabine, obinutuzumab,carmustine, cytarabine, melphalan, ublituximab, palbociclib, ACP-196(Acerta Pharma BV), TGR-1202 (TG Therapeutics, Inc.), TEDDI, TEDD,MEDI4736 (AstraZeneca), ABT-0199 (AbbVie), CC-122 (Celgene Corporation),LD-AraC, ketoconazole, etoposide, carboplatin, moxifloxacin, citrovorum,methotrexate, filgrastim, mesna, vincristine, cyclophosphamide,erythromycin, voriconazole, nivolumab, or a combination thereof.

In some embodiments, the second cancer treatment regimen comprisescyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone, andoptionally, rituximab.

In some embodiments, the second cancer treatment regimen comprisesbendamustine, and rituximab.

In some embodiments, the second cancer treatment regimen comprisesfludarabine, cyclophosphamide, and rituximab.

In some embodiments, the second cancer treatment regimen comprisescyclophosphamide, vincristine, and prednisone, and optionally,rituximab.

In some embodiments, the second cancer treatment regimen comprisesetoposide, doxorubicin, vinristine, cyclophosphamide, prednisolone, andoptionally, rituximab.

In some embodiments, the second cancer treatment regimen comprisesdexamethasone and lenalidomide.

In some embodiments, the second cancer treatment comprises a proteasomeinhibitor. In some embodiments, the second treatment comprisesbortezomib. In some embodiments, the second cancer treatment comprisesan epoxyketone. In some embodiments, the second cancer treatmentcomprises epoxomicin. In some embodiments, the second cancer treatmentcomprises a tetrapeptide epoxyketone In some embodiments, the secondcancer treatment comprises carfilzomib. In some embodiments, the secondcancer treatment comprises disulfram, epigallocatechin-3-gallate,salinosporamide A, ONX 0912m CEP-18770, MLN9708, or MG132.

In some embodiments, the second cancer treatment comprises a Cyp3A4inhibitor. In some embodiments, the second cancer treatment comprisesindinavir, nelfinavir, ritonavir, clarithromycin, itraconazole,ketoconazole, nefazodone. In some embodiments, the second cancertreatment comprises ketoconazole.

In some embodiments, the second cancer treatment comprises a JanusKinase (JAK) inhibitor. In some embodiments, the second treatmentcomprises Lestaurtinib, Tofacitinib, Ruxolitinib, CYT387, Baricitinib orPacritinib.

In some embodiments, the second cancer treatment comprises a histonedeacetylase inhibitor (HDAC inhibitor, HDI). In some embodiments, thesecond cancer treatment comprises a hydroxamic acid (or hydroxamate),such as trichostatin A, vorinostat (SAHA), belinostat (PXD101), LAQ824,and panobinostat (LBH589), a cyclic tetrapeptide, such as trapoxin B, adepsipeptide, a benzamide, such as entinostat (MS-275), CI994, andmocetinostat (MGCD0103), an electrophilic ketone, or an aliphatic acidcompound, such as phenylbutyrate and valproic acid,

Additional cancer treatment regimens include Nitrogen Mustards such asfor example, bendamustine, chlorambucil, chlormethine, cyclophosphamide,ifosfamide, melphalan, prednimustine, trofosfamide; Alkyl Sulfonateslike busulfan, mannosulfan, treosulfan; Ethylene Imines like carboquone,thiotepa, triaziquone; Nitrosoureas like carmustine, fotemustine,lomustine, nimustine, ranimustine, semustine, streptozocin; Epoxidessuch as for example, etoglucid; Other Alkylating Agents such as forexample dacarbazine, mitobronitol, pipobroman, temozolomide; Folic AcidAnalogues such as for example methotrexate, permetrexed, pralatrexate,raltitrexed; Purine Analogs such as for example cladribine, clofarabine,fludarabine, mercaptopurine, nelarabine, tioguanine; Pyrimidine Analogssuch as for example azacitidine, capecitabine, carmofur, cytarabine,decitabine, fluorouracil, gemcitabine, tegafur; Vinca Alkaloids such asfor example vinblastine, vincristine, vindesine, vinflunine,vinorelbine; Podophyllotoxin Derivatives such as for example etoposide,teniposide; Colchicine derivatives such as for example demecolcine;Taxanes such as for example docetaxel, paclitaxel, paclitaxelpoliglumex; Other Plant Alkaloids and Natural Products such as forexample trabectedin; Actinomycines such as for example dactinomycin;Antracyclines such as for example aclarubicin, daunorubicin,doxorubicin, epirubicin, idarubicin, mitoxantrone, pirarubicin,valrubicin, zorubincin; Other Cytotoxic Antibiotics such as for examplebleomycin, ixabepilone, mitomycin, plicamycin; Platinum Compounds suchas for example carboplatin, cisplatin, oxaliplatin, satraplatin;Methylhydrazines such as for example procarbazine; Sensitizers such asfor example aminolevulinic acid, efaproxiral, methyl aminolevulinate,porfimer sodium, temoporfin; Protein Kinase Inhibitors such as forexample dasatinib, erlotinib, everolimus, gefitinib, imatinib,lapatinib, nilotinib, pazonanib, sorafenib, sunitinib, temsirolimus;Other Antineoplastic Agents such as for example alitretinoin,altretamine, amzacrine, anagrelide, arsenic trioxide, asparaginase,bexarotene, bortezomib, celecoxib, denileukin diftitox, estramustine,hydroxycarbamide, irinotecan, lonidamine, masoprocol, miltefosein,mitoguazone, mitotane, oblimersen, pegaspargase, pentostatin,romidepsin, sitimagene ceradenovec, tiazofurine, topotecan, tretinoin,vorinostat; Estrogens such as for example diethylstilbenol,ethinylestradiol, fosfestrol, polyestradiol phosphate; Progestogens suchas for example gestonorone, medroxyprogesterone, megestrol; GonadotropinReleasing Hormone Analogs such as for example buserelin, goserelin,leuprorelin, triptorelin; Anti-Estrogens such as for examplefulvestrant, tamoxifen, toremifene; Anti-Androgens such as for examplebicalutamide, flutamide, nilutamide; Enzyme Inhibitors,aminoglutethimide, anastrozole, exemestane, formestane, letrozole,vorozole; Other Hormone Antagonists such as for example abarelix,degarelix; Immunostimulants such as for example histaminedihydrochloride, mifamurtide, pidotimod, plerixafor, roquinimex,thymopentin; Immunosuppressants such as for example everolimus,gusperimus, leflunomide, mycophenolic acid, sirolimus; CalcineurinInhibitors such as for example ciclosporin, tacrolimus; OtherImmunosuppressants such as for example azathioprine, lenalidomide,methotrexate, thalidomide; and Radiopharmaceuticals such as for example,iobenguane.

Additional cancer treatment regimens include interferons, interleukins,Tumor Necrosis Factors, Growth Factors, or the like.

Additional cancer treatment regimens include Immunostimulants such asfor example ancestim, filgrastim, lenograstim, molgramostim,pegfilgrastim, sargramostim; Interferons such as for example interferonalfa natural, interferon alfa-2a, interferon alfa-2b, interferonalfacon-1, interferon alfa-n1, interferon beta natural, interferonbeta-1a, interferon beta-1b, interferon gamma, peginterferon alfa-2a,peginterferon alfa-2b; Interleukins such as for example aldesleukin,oprelvekin; Other Immunostimulants such as for example BCG vaccine,glatiramer acetate, histamine dihydrochloride, immunocyanin, lentinan,melanoma vaccine, mifamurtide, pegademase, pidotimod, plerixafor, polyI:C, poly ICLC, roquinimex, tasonermin, thymopentin; Immunosuppressantssuch as for example abatacept, abetimus, alefacept, antilymphocyteimmunoglobulin (horse), antithymocyte immunoglobulin (rabbit),eculizumab, efalizumab, everolimus, gusperimus, leflunomide,muromab-CD3, mycophenolic acid, natalizumab, sirolimus; TNF alphaInhibitors such as for example adalimumab, afelimomab, certolizumabpegol, etanercept, golimumab, infliximab; Interleukin Inhibitors such asfor example anakinra, basiliximab, canakinumab, daclizumab, mepolizumab,rilonacept, tocilizumab, ustekinumab; Calcineurin Inhibitors such as forexample ciclosporin, tacrolimus; Other Immunosuppressants such as forexample azathioprine, lenalidomide, methotrexate, thalidomide.

Additional cancer treatment regimens include Adalimumab, Alemtuzumab,Basiliximab, Bevacizumab, Cetuximab, Certolizumab pegol, Daclizumab,Eculizumab, Efalizumab, Gemtuzumab, Ibritumomab tiuxetan, Infliximab,Muromonab-CD3, Natalizumab, Panitumumab, Ranibizumab, Rituximab,Tositumomab, Trastuzumab, or the like, or a combination thereof.

Additional cancer treatment regimens include Monoclonal Antibodies suchas for example alemtuzumab, bevacizumab, catumaxomab, cetuximab,edrecolomab, gemtuzumab, ofatumumab, panitumumab, rituximab,trastuzumab, Immunosuppressants, eculizumab, efalizumab, muromab-CD3,natalizumab; TNF alpha Inhibitors such as for example adalimumab,afelimomab, certolizumab pegol, golimumab, infliximab, InterleukinInhibitors, basiliximab, canakinumab, daclizumab, mepolizumab,tocilizumab, ustekinumab, Radiopharmaceuticals, ibritumomab tiuxetan,tositumomab; Others Monoclonal Antibodies such as for exampleabagovomab, adecatumumab, alemtuzumab, anti-CD30 monoclonal antibodyXmab2513, anti-MET monoclonal antibody MetMab, apolizumab, apomab,arcitumomab, basiliximab, bispecific antibody 2B1, blinatumomab,brentuximab vedotin, capromab pendetide, cixutumumab, claudiximab,conatumumab, dacetuzumab, denosumab, eculizumab, epratuzumab,epratuzumab, ertumaxomab, etaracizumab, figitumumab, fresolimumab,galiximab, ganitumab, gemtuzumab ozogamicin, glembatumumab, ibritumomab,inotuzumab ozogamicin, ipilimumab, lexatumumab, lintuzumab, lintuzumab,lucatumumab, mapatumumab, matuzumab, milatuzumab, monoclonal antibodyCC49, necitumumab, nimotuzumab, ofatumumab, oregovomab, pertuzumab,ramacurimab, ranibizumab, siplizumab, sonepcizumab, tanezumab,tositumomab, trastuzumab, tremelimumab, tucotuzumab celmoleukin,veltuzumab, visilizumab, volociximab, zalutumumab.

Additional cancer treatment regimens include agents that affect thetumor micro-environment such as cellular signaling network (e.g.phosphatidylinositol 3-kinase (PI3K) signaling pathway, signaling fromthe B-cell receptor and the IgE receptor). In some embodiments, thesecond agent is a PI3K signaling inhibitor or a syc kinase inhibitor. Inone embodiment, the syk inhibitor is R788. In another embodiment is aPKCγ inhibitor such as by way of example only, enzastaurin.

In some embodiments, the additional therapeutic agent comprises ananalgesic such as acetaminophen.

In some embodiments, the additional therapeutic agent comprises an agentselected from: an inhibitor of LYN, SYK, JAK, PI3K, PLCγ, MAPK, MEK orNFκB.

Examples of agents that affect the tumor micro-environment include PI3Ksignaling inhibitor, syc kinase inhibitor, Protein Kinase Inhibitorssuch as for example dasatinib, erlotinib, everolimus, gefitinib,imatinib, lapatinib, nilotinib, pazonanib, sorafenib, sunitinib,temsirolimus; Other Angiogenesis Inhibitors such as for example GT-111,JI-101, R1530; Other Kinase Inhibitors such as for example AC220, AC480,ACE-041, AMG 900, AP24534, Arry-614, AT7519, AT9283, AV-951, axitinib,AZD1152, AZD7762, AZD8055, AZD8931, bafetinib, BAY 73-4506, BGJ398,BGT226, BI811283, BI6727, BIBF 1120, BIBW 2992, BMS-690154, BMS-777607,BMS-863233, BSK-461364, CAL-101, CEP-11981, CYC116, DCC-2036,dinaciclib, dovitinib lactate, E7050, EMD 1214063, ENMD-2076,fostamatinib disodium, GSK2256098, GSK690693, INCB18424, INNO-406,JNJ-26483327, JX-594, KX2-391, linifanib, LY2603618, MGCD265, MK-0457,MK1496, MLN8054, MLN8237, MP470, NMS-1116354, NMS-1286937, ON 01919.Na,OSI-027, OSI-930, Btk inhibitor, PF-00562271, PF-02341066, PF-03814735,PF-04217903, PF-04554878, PF-04691502, PF-3758309, PHA-739358, PLC3397,progenipoietin, R547, R763, ramucirumab, regorafenib, RO5185426,SAR103168, SCH 727965, SGI-1176, SGX523, SNS-314, TAK-593, TAK-901,TKI258, TLN-232, TTP607, XL147, XL228, XL281RO5126766, XL418, XL765.

Further examples of anti-cancer agents for use in combination with a Btkinhibitor compound include inhibitors of mitogen-activated proteinkinase signaling, e.g., U0126, PD98059, PD184352, PD0325901,ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002;Syk inhibitors; mTOR inhibitors; and antibodies (e.g., rituxan).

Other anti-cancer agents that can be employed in combination with a Btkinhibitor compound include Adriamycin, Dactinomycin, Bleomycin,Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride;acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantroneacetate; aminoglutethimide; amsacrine; anastrozole; anthramycin;asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat;benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate;bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan;cactinomycin; calusterone; caracemide; carbetimer; carboplatin;carmustine; carubicin hydrochloride; carzelesin; cedefingol;chlorambucil; cirolemycin; cladribine; crisnatol mesylate;cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride;decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate;diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene;droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate;eflomithine hydrochloride; elsamitrucin; enloplatin; enpromate;epipropidine; epirubicin hydrochloride; erbulozole; esorubicinhydrochloride; estramustine; estramustine phosphate sodium; etanidazole;etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride;fazarabine; fenretinide; floxuridine; fludarabine phosphate;fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine;gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride;ifosfamide; iimofosine; interleukin Il (including recombinantinterleukin II, or rlL2), interferon alfa-2a; interferon alfa-2b;interferon alfa-n1; interferon alfa-n3; interferon beta-1 a; interferongamma-1 b; iproplatin; irinotecan hydrochloride; lanreotide acetate;letrozole; leuprolide acetate; liarozole hydrochloride; lometrexolsodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine;mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate;melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium;metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin;mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride;mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran;pegaspargase; peliomycin; pentamustine; peplomycin sulfate;perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride;plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine;procarbazine hydrochloride; puromycin; puromycin hydrochloride;pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride;semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermaniumhydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin;sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantronehydrochloride; temoporfin; teniposide; teroxirone; testolactone;thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifenecitrate; trestolone acetate; triciribine phosphate; trimetrexate;trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracilmustard; uredepa; vapreotide; verteporfin; vinblastine sulfate;vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate;vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate;vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin;zinostatin; zorubicin hydrochloride.

Other anti-cancer agents that can be employed in combination with a Btkinhibitor compound include: 20-epi-1, 25 dihydroxyvitamin D3;5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol;adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine;amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine;anagrelide; anastrozole; andrographolide; angiogenesis inhibitors;antagonist D; antagonist G; antarelix; anti-dorsalizing morphogeneticprotein-1; antiandrogen, prostatic carcinoma; antiestrogen;antineoplaston; antisense oligonucleotides; aphidicolin glycinate;apoptosis gene modulators; apoptosis regulators; apurinic acid;ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane;atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron;azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat;BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactamderivatives; beta-alethine; betaclamycin B; betulinic acid; bFGFinhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide;bistratene A; bizelesin; breflate; bropirimine; budotitane; buthioninesulfoximine; calcipotriol; calphostin C; camptothecin derivatives;canarypox IL-2; capecitabine; carboxamide-amino-triazole;carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor;carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropinB; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost;cis-porphyrin; cladribine; clomifene analogues; clotrimazole;collismycin A; collismycin B; combretastatin A4; combretastatinanalogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8;cryptophycin A derivatives; curacin A; cyclopentanthraquinones;cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor;cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin;dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone;didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine;9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron;doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen;ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefur;epirubicin; epristeride; estramustine analogue; estrogen agonists;estrogen antagonists; etanidazole; etoposide phosphate; exemestane;fadrozole; fazarabine; fenretinide; filgrastim; finasteride;flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicinhydrochloride; forfenimex; formestane; fostriecin; fotemustine;gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix;gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam;heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid;idarubicin; idoxifene; idramantone; ilmofosine; ilomastat;imidazoacridones; imiquimod; immunostimulant peptides; insulin-such asfor example growth factor-1 receptor inhibitor; interferon agonists;interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-;iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron;jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide;leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole;leukemia inhibiting factor; leukocyte alpha interferon;leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole;linear polyamine analogue; lipophilic disaccharide peptide; lipophilicplatinum compounds; lissoclinamide 7; lobaplatin; lombricine;lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine;lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides;maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysininhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone;meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone;miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone;mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growthfactor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonalantibody, human chorionic gonadotrophin; monophosphoryl lipidA+myobacterium cell wall sk; mopidamol; multiple drug resistance geneinhibitor; multiple tumor suppressor 1-based therapy; mustard anticanceragent; mycaperoxide B; mycobacterial cell wall extract; myriaporone;N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip;naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin;nemorubicin; neridronic acid; neutral endopeptidase; nilutamide;nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn;O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone;ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin;osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin;pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine;pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin;pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin;phenylacetate; phosphatase inhibitors; picibanil; pilocarpinehydrochloride; pirarubicin; piritrexim; placetin A; placetin B;plasminogen activator inhibitor; platinum complex; platinum compounds;platinum-triamine complex; porfimer sodium; porfiromycin; prednisone;propyl bis-acridone; prostaglandin J2; proteasome inhibitors; proteinA-based immune modulator; protein kinase C inhibitor; protein kinase Cinhibitors, microalgal; protein tyrosine phosphatase inhibitors; purinenucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine;pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists;raltitrexed; ramosetron; ras famesyl protein transferase inhibitors; rasinhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide;rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol;saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics;semustine; senescence derived inhibitor 1; sense oligonucleotides;signal transduction inhibitors; signal transduction modulators; singlechain antigen-binding protein; sizofiran; sobuzoxane; sodiumborocaptate; sodium phenylacetate; solverol; somatomedin bindingprotein; sonermin; sparfosic acid; spicamycin D; spiromustine;splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-celldivision inhibitors; stipiamide; stromelysin inhibitors; sulfinosine;superactive vasoactive intestinal peptide antagonist; suradista;suramin; swainsonine; synthetic glycosaminoglycans; tallimustine;tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium;tegafur; tellurapyrylium; telomerase inhibitors; temoporfin;temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine;thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic;thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroidstimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocenebichloride; topsentin; toremifene; totipotent stem cell factor;translation inhibitors; tretinoin; triacetyluridine; triciribine;trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinaseinhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenitalsinus-derived growth inhibitory factor; urokinase receptor antagonists;vapreotide; variolin B; vector system, erythrocyte gene therapy;velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine;vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatinstimalamer.

Yet other anticancer agents that can be employed in combination with aBtk inhibitor compound include alkylating agents, antimetabolites,natural products, or hormones, e.g., nitrogen mustards (e.g.,mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkylsulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne,ete.), or triazenes (decarbazine, etc.). Examples of antimetabolitesinclude but are not limited to folic acid analog (e.g., methotrexate),or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g.,mercaptopurine, thioguanine, pentostatin).

Examples of alkylating agents that can be employed in combination a Btkinhibitor compound include, but are not limited to, nitrogen mustards(e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan,etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine,thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g.,carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes(decarbazine, ete.). Examples of antimetabolites include, but are notlimited to folic acid analog (e.g., methotrexate), or pyrimidine analogs(e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g.,mercaptopurine, thioguanine, pentostatin.

Examples of hormones and antagonists include, but are not limited to,adrenocorticosteroids (e.g., prednisone), progestins (e.g.,hydroxyprogesterone caproate, megestrol acetate, medroxyprogesteroneacetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol),antiestrogen (e.g., tamoxifen), androgens (e.g., testosteronepropionate, fluoxymesterone), antiandrogen (e.g., flutamide),gonadotropin releasing hormone analog (e.g., leuprolide).

Other agents that can be used in the methods and compositions describedherein for the treatment or prevention of cancer include platinumcoordination complexes (e.g., cisplatin, carboblatin), anthracenedione(e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methylhydrazine derivative (e.g., procarbazine), adrenocortical suppressant(e.g., mitotane, aminoglutethimide).

Examples of anti-cancer agents which act by arresting cells in the G2-Mphases due to stabilized microtubules and which can be used incombination with a Btk inhibitor compound include without limitation thefollowing marketed drugs and drugs in development: Erbulozole (alsoknown as R-55104), Dolastatin 10 (also known as DLS-10 and NSC-376128),Mivobulin isethionate (also known as CI-980), Vincristine, NSC-639829,Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also knownas E-7010), Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C),Spongistatins (such as Spongistatin 1, Spongistatin 2, Spongistatin 3,Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7,Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (also knownas LU-103793 and NSC-D-669356), Epothilones (such as Epothilone A,Epothilone B, Epothilone C (also known as desoxyepothilone A or dEpoA),Epothilone D (also referred to as KOS-862, dEpoB, and desoxyepothiloneB), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone AN-oxide, 16-aza-epothilone B, 21-aminoepothilone B (also known asBMS-310705), 21-hydroxyepothilone D (also known as Desoxyepothilone Fand dEpoF), 26-fluoroepothilone), Auristatin PE (also known asNSC-654663), Soblidotin (also known as TZT-1027), LS-4559-P (Pharmacia,also known as LS-4577), LS-4578 (Pharmacia, also known as LS-477-P),LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis),Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, also knownas WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academyof Sciences), BSF-223651 (BASF, also known as ILX-651 and LU-223651),SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97(Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko),IDN-5005 (Indena), Cryptophycin 52 (also known as LY-355703), AC-7739(Ajinomoto, also known as AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto,also known as AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A),Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (also known asNSC-106969), T-138067 (Tularik, also known as T-67, TL-138067 andTI-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 andWHI-261), H10 (Kansas State University), H16 (Kansas State University),Oncocidin A1 (also known as BTO-956 and DIME), DDE-313 (Parker HughesInstitute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute),SPA-1 (Parker Hughes Institute, also known as SPIKET-P), 3-IAABU(Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-569),Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica),A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai Schoolof Medicine, also known as MF-191), TMPN (Arizona State University),Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, lnanocine(also known as NSC-698666), 3-1AABE (Cytoskeleton/Mt. Sinai School ofMedicine), A-204197 (Abbott), T-607 (Tularik, also known as T-900607),RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin,Desaetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin),Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica),D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350(Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott),Diozostatin, (−)-Phenylahistin (also known as NSCL-96F037), D-68838(Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris,also known as D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286(also known as SPA-110, trifluoroacetate salt) (Wyeth), D-82317(Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphatesodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411(Sanofi).

The formulations may be used in any combination with one or more otheranti-thromboembolic agents to treat or prevent thromboembolic disorder(e.g., stroke). Examples of anti-thromboembolic agents include, but arenot limited any of the following: thrombolytic agents (e.g., alteplaseanistreplase, streptokinase, urokinase, or tissue plasminogenactivator), heparin, tinzaparin, warfarin, dabigatran (e.g., dabigatranetexilate), factor Xa inhibitors (e.g., fondaparinux, draparinux,rivaroxaban, DX-9065a, otamixaban, LY517717, or YM150), ticlopidine,clopidogrel, CS-747 (prasugrel, LY640315), ximelagatran, or BIBR 1048.

In some embodiments, the additional anti-cancer agent that is a Bcl-2inhibitor.

In some embodiments, the additional anti-cancer agent is immunecheckpoint inhibitor. In some embodiments, the immune checkpointinhibitor is an inhibitor of Programmed Death-Ligand 1 (PD-L1, alsoknown as B7-H1, CD274), Programmed Death 1 (PD-1), CTLA-4, PD-L2 (B7-DC,CD273), LAG3, TIM3, 2B4, A2aR, B7H1, B7H3, B7H4, BTLA, CD2, CD27, CD28,CD30, CD40, CD70, CD80, CD86, CD137,CD160, CD226, CD276, DR3, GAL9,GITR, HAVCR2, HVEM, IDO1, IDO2, ICOS (inducible T cell costimulator),KIR, LAIR1, LIGHT, MARCO (macrophage receptor with collageneousstructure), PS (phosphatidylserine), OX-40, SLAM, TIGHT, VISTA, VTCN1,or any combinations thereof. In some embodiments, the immune checkpointinhibitor is an inhibitor of PD-L1, PD-1, CTLA-4, LAG3, or TIM3. In someembodiments, the immune checkpoint inhibitor is an inhibitor of PD-L1.In some embodiments, the immune checkpoint inhibitor is an inhibitor ofPD-1. In some embodiments, the immune checkpoint inhibitor is aninhibitor of CTLA-4. In some embodiments, the immune checkpointinhibitor is an inhibitor of LAG3. In some embodiments, the immunecheckpoint inhibitor is an inhibitor of TIM3. In some embodiments, theimmune checkpoint inhibitor is an inhibitor of PD-L2.

In some embodiments, the formulations are administered in combinationwith a CD20 inhibitor. Exemplary CD20 inhibitors include, but are notlimited to, ibritumomab tiuxetan, ofatumumab, rituximab, tositumomab,and obinutuzumab.

In some embodiments, the additional anticancer agent used in combinationwith the formulations described herein include CDK4 inhibitors (e.g.,palbociclib).

In some embodiments, the additional cancer agent is a proteosomeinhibitor. In some embodiments, the proteasome inhibitor is selectedfrom bortezomib or carfilzomib

In some embodiments, the additional cancer agent that can beadministered in combination with the formulations is an HDAC inhibitor.In some embodiments, the HDAC inhibitor is abexinostat or a saltthereof. In some embodiments, the abexinostat or a salt thereof isabexinostat HCl. In some embodiments, the abexinostat or a salt thereofis abexinostat tosylate.

In some embodiments, the additional cancer agent that can beadministered in combination with the formulations is a MALT1 inhibitor,MCL-1 inhibitor, IDH1inhibitor, TLR inhibitor, or PIM inhibitor.

In some embodiments, the additional anti-cancer agent that can beadministered in combination with the formulations is an immunomodulatoryagent. Exemplary immunomodulatory agents include, but are not limitedto, lenalidomide, thalidomide, and pomalidomide.

Where the individual is suffering from or at risk of suffering from anautoimmune disease, an inflammatory disease, or an allergy disease,Compound 1 can be used in with one or more of the following therapeuticagents in any combination: immunosuppressants (e.g., tacrolimus,cyclosporin, rapamycin, methotrexate, cyclophosphamide, azathioprine,mercaptopurine, mycophenolate, or FTY720), glucocorticoids (e.g.,prednisone, cortisone acetate, prednisolone, methylprednisolone,dexamethasone, betamethasone, triamcinolone, beclometasone,fludrocortisone acetate, deoxycorticosterone acetate, aldosterone),non-steroidal anti-inflammatory drugs (e.g., salicylates, arylalkanoicacids, 2-arylpropionic acids, N-arylanthranilic acids, oxicams, coxibs,or sulphonanilides), Cox-2-specific inhibitors (e.g., valdecoxib,celecoxib, or rofecoxib), leflunomide, gold thioglucose, goldthiomalate, aurofin, sulfasalazine, hydroxychloroquinine, minocycline,TNF-α binding proteins (e.g., infliximab, etanercept, or adalimumab),abatacept, anakinra, interferon-β, interferon-γ, interleukin-2, allergyvaccines, antihistamines, antileukotrienes, beta-agonists, theophylline,or anticholinergics.

Kits/Articles of Manufacture

For use in the therapeutic methods of use described herein, kits andarticles of manufacture are also described herein. Such kits include acarrier, package, or container that is compartmentalized to receive oneor more containers such as vials, tubes, and the like, each of thecontainer(s) comprising one of the separate elements to be used in amethod described herein. Suitable containers include, for example,bottles, vials, syringes, and test tubes. In one embodiment, thecontainers are formed from a variety of materials such as glass orplastic.

The articles of manufacture provided herein contain packaging materials.Packaging materials for use in packaging pharmaceutical productsinclude, e.g., U.S. Pat. No. 5,323,907. Examples of pharmaceuticalpackaging materials include, but are not limited to, blister packs,bottles, tubes, bags, containers, bottles, and any packaging materialsuitable for a selected formulation and intended mode of administrationand treatment.

In some embodiments, the compounds or compositions described herein, arepresented in a package or dispenser device which may contain one or moreunit dosage forms containing the active ingredient. The compound orcomposition described herein is packaged alone, or packaged with anothercompound or another ingredient or additive. In some embodiments, thepackage contains one or more containers filled with one or more of theingredients of the pharmaceutical compositions. In some embodiments, thepackage comprises metal or plastic foil, such as a blister pack. In someembodiments, the package or dispenser device is accompanied byinstructions for administration, such as instructions for administeringthe compounds or compositions for treating a neoplastic disease. In someembodiments, the package or dispenser is accompanied with a noticeassociated with the container in form prescribed by a governmentalagency regulating the manufacture, use, or sale of pharmaceuticals,which notice is reflective of approval by the agency of the form of thedrug for human or veterinary administration. In some embodiments, suchnotice, for example, is the labeling approved by the U.S. Food and DrugAdministration for prescription drugs, or the approved product insert.In some embodiments, compositions include a compound described hereinformulated in a compatible pharmaceutical carrier are prepared, placedin an appropriate container, and labeled for treatment of an indicatedcondition.

For example, the container(s) include Compound 1, optionally in acomposition or in combination with another agent as disclosed herein.Such kits optionally include an identifying description or label orinstructions relating to its use in the methods described herein.

A kit typically includes labels listing contents and/or instructions foruse, and package inserts with instructions for use. A set ofinstructions will also typically be included.

In one embodiment, a label is on or associated with the container. Inone embodiment, a label is on a container when letters, numbers or othercharacters forming the label are attached, molded or etched into thecontainer itself; a label is associated with a container when it ispresent within a receptacle or carrier that also holds the container,e.g., as a package insert. In one embodiment, a label is used toindicate that the contents are to be used for a specific therapeuticapplication. The label also indicates directions for use of thecontents, such as in the methods described herein.

In certain embodiments, the pharmaceutical compositions are presented ina pack or dispenser device which contains one or more unit dosage formscontaining a compound provided herein. The pack, for example, containsmetal or plastic foil, such as a blister pack. In one embodiment, thepack or dispenser device is accompanied by instructions foradministration. In one embodiment, the pack or dispenser is alsoaccompanied with a notice associated with the container in formprescribed by a governmental agency regulating the manufacture, use, orsale of pharmaceuticals, which notice is reflective of approval by theagency of the form of the drug for human or veterinary administration.Such notice, for example, is the labeling approved by the U.S. Food andDrug Administration for prescription drugs, or the approved productinsert. In one embodiment, compositions containing a compound providedherein formulated in a compatible pharmaceutical carrier are alsoprepared, placed in an appropriate container, and labeled for treatmentof an indicated condition.

EXAMPLES

The following ingredients, formulations, processes and procedures forpracticing the methods disclosed herein correspond to that describedabove.

Example 1: Wet Granulation Method for the Preparation of High-LoadTablet Formulations of Ibrutinib

A high shear mixer is charged with ibrutinib, intragranular components,such as lactose monohydrate, optionally microcrystalline cellulose, andoptionally croscarmellose sodium and hydroxypropylcellulose, in W/Wproportions as described in Tables 1A-1F. The ingredients were thenmixed and water (or an aqueous binder solution) was added gradually.Once granulated, the wet granules were dried in a fluid bed dryer withan inlet temperature at 60° C. until the loss on drying (LOD) was <1.5%.The dried granulated material was then passed through a comil equippedwith a 0.04 inch screen. The extragranular components, such ascroscarmellose sodium, sodium lauryl sulfate and colloidal silicondioxide were then mixed with the granules in a blender for 20 minutes.Magnesium stearate was charged to the blender. The final mixture wasblended for another two minutes. The final blend was then discharged andcompressed into tablets. The tablets are stored at room temperatureuntil they are used.

Wet granulation tablet formulations W1-W19, W22, W23-W24, and BK01-BK02,BK04, BK06-BK09, BK21A and BK21B shown below in Tables 1A-1F wereprepared as or similarly to that described above.

TABLE 1A Wet Granulation Tablet Formulations w1 w2 w3 w4 w5 w6 w7 Wt mg/Wt mg/ Wt mg/ Wt mg/ Wt mg/ Wt mg/ Wt mg/ % Tab % Tab % Tab % Tab % Tab% Tab % Tab Ibrutinib 60.0 560.0 60.0 560.0 60.0 560.0 60.0 560.0 60.0560.0 60.0 560.0 70.0 560.0 MCC (Avicel PH101) 12.5 116.7 12.5 116.710.75 100.3 25.0 233.3 — 12.5 116.7 15.0 120.0 Lactose Mono (Fast 12.5116.6 12.5 116.6 10.75 100.3 — — 25.0 233.3 — — — — Flo 316) Mannitol(Pearlitol 100 — — — — — — — — — 12.5 116.6 — — SD)Hydroxypropylcellulose 3.0 28.0 3.0 28.0 — — 3.0 28.0 3.0 28.0 3.0 28.03.0 24.0 (Klucel EXF) PVP K30 — — — — 6.5 60.7 — — — — — — — — SLS(Kolliphor Fine) — 3.0 28.0 — — — — — — — — — — Subtotal (Intra) 88.0821.3 91.0 849.3 88.0 821.3 88.0 821.3 88.0 821.3 88.0 821.3 88.0 704.0SLS (Kolliphor Fine) 6.0 56.0 3.0 28.0 6.0 56.0 6.0 56.0 6.0 56.0 6.056.0 6.0 48.0 Croscarmellose Na (Ac- 5.0 46.7 5.0 46.7 5.0 46.7 5.0 46.75.0 46.7 5.0 46.7 5.0 40.0 Di-Sol) Silicon Dioxide 0.5 4.7 0.5 4.7 0.54.7 0.5 4.7 0.5 4.7 0.5 4.7 0.5 4.0 (Cabosil M5P) Magnesium Stearate 0.54.6 0.5 4.6 0.5 4.6 0.5 4.6 0.5 4.6 0.5 4.6 0.5 4.0 Total 100 933.3 100933.3 100 933.3 100 933.3 100 933.3 100 933.3 100% 800.0

TABLE 1B Wet Granulation Tablet Formulations W8 W10 W9 W11 Ibrutinib60.0% 60.0% 70.0% 70.0% MCC (Avicel PH101) 14.0% 13.5% 9.0% 8.5% LactoseMono (Fast Flo 316) 14.0% 13.5% 9.0% 8.5% Croscarmellose Na (Ac-Di-Sol)— 2.5% — 3.0% Hydroxypropylcellulose — 1.0% — — (Klucel EXF) Subtotal(Intra) 88.0% 90.5% 88.0% 90.0% SLS (Kolliphor Fine) 6.0% 6.0% 6.0% 6.0%Croscarmellose Na (Ac-Di-Sol) 5.0% 2.5% 5.0% 3.0% Silicon Dioxide(Cabosil M5P) 0.5% 0.5% 0.5% 0.5% Magnesium Stearate 0.5% 0.5% 0.5% 0.5%Total 100.0%

TABLE 1C Wet Granulation Tablet Formulations W12 W13 W14 W15 W16Ibrutinib 60.0% 60.0% 70.0% 70.0% 70.0% MCC (Avicel PH101) 12.0% 12.0%7.0% 7.0% — Lactose Mono 12.0% 12.0% 7.0% 7.0% 14.0% (Fast Flo 316)Croscarmellose Na 5.0% 5.0% 5.0% 5.0% 5.0% (Ac-Di-Sol)Hydroxypropylcellulose 2.0% — 2.0% — — (SSL) Povidone (K25) — 2.0% —2.0% 2.0% Subtotal (Intra) 91.0% SLS (Kolliphor Fine) 6.0% 6.0% 6.0%6.0% 6.0% Croscarmellose Na 2.0% 2.0% 2.0% 2.0% 2.0% (Ac-Di-Sol) SiliconDioxide 0.5% 0.5% 0.5% 0.5% 0.5% (Cabosil M5P) Magnesium Stearate 0.5%0.5% 0.5% 0.5% 0.5% Total 100.0%

TABLE 1D Wet Granulation Tablet Formulations Blend Component W17 W18 W19W21 W23 W24 Intragranular Ibrutinib 70.00% 70.00% 70.00%   70%   70%  70% Lactose (Fast Flo 14.00% 14.00% 14.00% 13.00% 13.00% 14.00% 316)PVP K25  2.00%  2.00%  2.00%  3.00%  3.00%  2.00% Croscarmellose Na 5.00%  5.00%  5.00%  5.00%  5.00%  5.00% (Ac-Di-Sol) SLS (Kolliphor 1.00%  0.00%  0.00%  1.00%  1.00%  1.00% Fine) Poloxamer  1.00% Tween80  0.50% Subtotal (Intra) 92.00% 91.50% 92.00% 92.00% 92.00% 92.00%Water   35%   35%   35%   35%   40%   40% Extragranular 17A 17B 17CLactose (Fast Flo 5.00% 0.00% 0.00%  5.50%  5.00%  5.00%  5.00%  5.00%316) Citric Acid 5.00% Poloxamer 5.00% Croscarmellose Na 2.00% 2.00%2.00%  2.00%  2.00%  2.00%  2.00%  2.00% (Ac-Di-Sol) Silicon Dioxide0.50% 0.50% 0.50%  0.50%  0.50%  0.50%  0.50%  0.50% (Cabosil M5P)Magnesium 0.50% 0.50% 0.50%  0.50%  0.50%  0.50%  0.50%  0.50% StearateTotal 100.00%  100.00%  100.00%  100.00%  100.00%  100.00%  100.00% 100.00% 

TABLE 1E Wet Granulation Tablet Formulations Component BK01 BK02 BK04BK06 BK07 BK08 BK09 BK10 Intragranular Ibrutinib 70.00% 70.00% 70.00%70.00%   70%   70%   70%   70% Lactose (Fast 14.00% 14.00% 14.00% 13.00%14.00%  6.00%  5.00%   16% Flo 316) Povidone (PVP 2.00% 2.00% 2.00%3.00%  2.00%  2.00%  2.00%  2.0% K25) Cropovidone 5.00% 10.00% 0 5.00% 5.00%  15.0%  15.0% 10.0% Sodium Starch Glycolate 0 0 5.00% 0 0   0  0   0   SLS (Kolliphor 1.00% 1.00% 0.00% 1.0%  3.00%  1.00%  3.00%  1.0%Fine) Subtotal (Intra) 92.00% 97.00% 92.0% 92.00% 94.00% 94.00% 95.00%99.0% Extragranular BK01A BK01B Lactose (Fast 5.00% 2.00% 2.00% 5.0%5.0%  3.00%  5.00%  4.00% 0   Flo 316) Crospovidone 2.00% 5.00% 0 02.00%  2.00% 0   0   0   Sodium Starch 0 0 0 2.00% 0 0   0   0   0  Glycolate Silicon 0.50% 0.50% 0.50% 0.50% 0.50%  0.50%  0.50%  0.50%0.50% Dioxide (Cabosil M5P) Magnesium 0.50% 0.50% 0.50% 0.50% 0.50% 0.50%  0.50%  0.50% 0.50% Stearate Total 100.00% 100.00% 100.00%100.00% 100.00% 100.00%  100.00%  100.00%  100.0% 

TABLE 1F Wet Granulation Tablet Formulations Ingredients BK21A BK21BIbrutinib (Intra)  70%  70% Lactose Monohydrate (Intra)  14%  14%Microcrystalline Cellulose (Extra)   5%   2% Binder (PVP K25) (Intra)  2%   2% SLS (% Intra/% Extra) 1% (1/0) 4% (1/3) Croscarmellose Sodium(% intra/Extra) 7% (5/2) 7% (5/2) Colloidal Silicon Dioxide (Extra) 0.5%0.5% Mg Stearate (Extra) 0.5% 0.5%

Example 2: Dry Granulation Method for the Preparation of IbrutinibTablet Formulations

Ibrutinib, microcrystalline cellulose, croscarmellose sodium, sodiumlauryl sulfate and optionally magnesium stearate were passed through a1000 microns sieve. The mixture was then blended for 10 minutes. Thepre-blending was charged to a roller compactor and compacted at 0.6kN/cm. The resulting ribbon was passed through an oscillating millequipped with a 0.8 mm screen. The milled granules were then combinedwith the extragranular components: microcrystalline cellulose,croscarmellose sodium, sodium lauryl sulfate and optionally magnesiumstearate and blended for 10 minutes. The blend was then compressed intotablets using a single station manual press.

Dry granulation tablet formulations D1 and D5 shown below in Table 2were prepared as described above.

TABLE 2 Dry Granulation Tablet Formulations D1 D5 Component Wt % mg/TabWt % mg/Tab Ibrutinib 50.00 560.0 42.42 560.0 MCC (Avicel PH101) 30.00336.0 45.88 605.7 Croscarmellose Na (Ac-Di-Sol) 4.00 44.8 3.97 52.4 SLS(Kolliphor Fine) 3.40 38.1 2.85 37.6 Magnesium Stearate — — 0.24 3.2Subtotal (Intra) 87.40 978.9 95.36 1258.9 MCC (Avicel PH200) 7.50 84.0 —— SLS (Kolliphor Fine) 1.60 17.9 1.39 18.3 Croscarmellose Na (Ac-Di-Sol)3.00 33.6 3.00 39.6 Magnesium Stearate 0.50 5.6 0.24 3.2 Total 100.001120.0 100.00 1320.1

Example 3: Preparation of Immediate Release High-Load TabletFormulations of Ibrutinib

Immediate release tablet formulations are prepared using the componentsshown in Table 3 following the procedure from Example 1.

TABLE 3 Components of Immediate Release Tablet Formulation IngredientRange Ibrutinib 80 to 90% Lactose 0 to 10% Croscarmellose sodium 1 to10% Microcrystalline cellulose 0 to 10% Colloidal Silicon Dioxide 0 to1% Magnesium stearate 0.25% to 2.5% Total Tablet weight range: 622 mg to700 mg

Example 4: Preparation of Capsule Formulations of Ibrutinib

The capsule Formulation A manufacturing process includes the followingsteps: weigh the indicated amount of the components, mix together andadd into an appropriate size capsule, and close capsule. The capsulesare stored at room temperature until they are used.

Example 5: In Vivo Evaluation of High-Load, Wet and Dry GranulationTablet Formulations of Ibrutinib and Ibrutinib Capsule Formulation

The pharmacokinetics of ibrutinib in capsule (Formulation A) versusdifferent wet granulation (Formulations B, C and D which correspond toFormulations W8, W10, and W11 in Example 1, respectively) and drygranulation (Formulations E and F which correspond to Formulations D1and D5 in Example 2, respectively) tablet formulations was studied infasted male beagle dogs following single oral administration of 140 mgibrutinib formulations administered in a Latin square crossover design.The wet granulation (Formulations B, C and D) and dry granulation(Formulations E and F) tablets were studied in two parallel groups withcapsule as internal control in each of the group. The tabletformulations composition and drug load are presented in Table 4.

TABLE 4 Ibrutinib Tablet Formulations - Drug Load and CompositionFormulation A B C D E F Process — Wet Wet Wet Dry Dry w/w w/w w/w w/ww/w w/w Component % % % % % % Ibrutinib 42.0 60.0 60.0 70.0 50.0 42.0Lactose Mono- 0 14 13.5 8.5 0 0 hydrate NF Microcrystalline 46.5 14 13.58.5 37.5 46.5 cellulose NF Hydroxypropyl 0 0 1.0 0 0 0 Cellulose NFCroscarmellose 7.0 5.0 5.0 6.0 7.0 7.0 sodium NF Sodium lauryl 4.0 6.06.0 6.0 5.0 4.0 sulfate NF Colloidal Silicon 0 0.5 0.5 0.5 0 0 DioxideNF Magnesium 0.5 0.5 0.5 0.5 0.5 0.5 stearate NF Tablet Weight 333.3233.3 233.3 200.0 280.0 333.3

FIG. 1 and FIG. 2 shows mean plasma concentration-time profiles ofibrutinib following single oral dose administration of three differentwet and two dry ibrutinib tablet formulations, respectively to fastedbeagle dogs (Dose=140 mg). In general, all the wet granulationformulation tablets (B, C and D) tested showed comparable concentrationsto the capsule formulation. Specifically, wet granulation tabletformulations B, C and D showed average % F_(rel) values ranging from 72to 110% (Table 5). However, dry granulation tablet formulations, E and Fshowed lower concentrations compared to capsule with average % F_(rel)values ranging from 43 to 52% (Table 6). Furthermore, reducedvariability in ibrutinib exposure was observed with wet granulationformulations when compared to capsule formulation (Tables 5 and 7). Insome embodiments, the tablet formulation provides unexpected lowvariability in ibrutinib exposure in terms of % CV for both C_(max) andAUC when administered under fasted and fed conditions, see, e.g.,Formulation BK21B as compared to the capsule formulation A and tabletformulations BK02 and BK21A (Table 7). In some embodiments, the tabletformulation provides unexpected absence of food effect in C_(max) andT_(max) when administered under fed conditions compared to fastedconditions, which is contemplated to lead to more predictabletherapeutic efficacy and side effects when taking with or without food,see, e.g., Table 7.

TABLE 5 Mean (% CV) Ibrutinib Plasma PK Parameters Following Single DoseAdministration of Three Different Wet Tablet Ibrutinib Formulations toFasted Beagle Dogs (n = 7) Dose C_(max) T_(max) T_(1/2) AUC Formulation(mg) (ng/mL) (h) (h) (ng * h/mL) F_(rel) (%) A (Capsule) 140 32.1 2.36ND 146 (106) N/A (93.7) B (Wet W8) 140 20.7 1.64 ND 63.2 (37.7) 96(63.1) (54.1) C (Wet 140 22.6 1.46 1.10^(a) 72.6 (66.1) 72 (53.2) W10)(86.1) D (Wet 140 23.0 2.00 6.50^(b) 93.3 (92.8) 110 (83.3)  W11) (86.9)(36.5) F_(rel): for each dog, which has received both capsule and tabletformulations in a cross-over fashion(AUC_(Formulation B, C, D, E or F)/AUC_(Formulation A)) * 100; ^(a)n =1; ^(b)n = 3; N/A: not applicable; ND: not determined

TABLE 6 Mean (% CV) Ibrutinib Plasma PK Parameters Following Single DoseAdministration of Two Different Dry Tablet Ibrutinib Formulations toFasted Beagle Dogs (n = 8) Dose C_(max) T_(max) T_(1/2) AUC Formulation(mg) (ng/mL) (h) (h) (ng * h/mL) F_(rel) (%) A (Capsule) 140 29.9 (90.2)5.81 ND 161 (105) N/A E (Dry D1) 140 10.2 (78.9) 2.72 ND 45.1 (43.7)42.6 (64.7) F (Dry D5) 140 10.1 (49.5) 2.50 ND 59.9 (77.3) 51.6 (66.5)F_(rel): for each dog, which has received both capsule and tabletformulations in a cross-over fashion(AUC_(Formulation B, C, D, E or F)/AUC_(Formulation A)) * 100; N/A: notapplicable; ND: not determined

TABLE 7 Comparison of Capsule and Three Tablet Formulations (140 mgdose) in Dogs under Fasted and Fed States F_(rel) ^(b) F_(rel)tablet/capsule Fed/Fasted C_(max) T_(max) T_(1/2) AUC^(a) (%) (%)Formulation (ng/mL) (h) (h) (ng * h/mL) C_(max) AUC C_(max) AUC AFed^(c,d) 251 3.20 1.74  892 NA NA 89.7 117 (Capsule)  (78.6)^(e) (70.7)Fasted^(f,g) 419 1.63 2.23 1010 NA NA (57.1) (52.7) BK02 Fed^(h) 3522.00 1.92  991 236 146 84.1 107 (54.3) (42.2) Fasted 494 1.19 2.20 1000150 112 (54.0) (52.9) BK21A Fed 287 2.93 1.63  878 172 119 92.1 99.2(75.5) (60.5) Fasted 370 1.47 2.47 1000 111 108 (73.5) (64.6) BK21B Fed367 1.80 1.73 1014 227 146 104 136 (51.1) (37.5) Fasted 363 1.44 1.85 840 152 134 (45.6) (36.3) ^(a)AUC_(last) ^(b)calculated for each dog,which has received both capsule and tablet formulations in a cross-overfashion ^(c)fed dogs were administered with liquid concentrated diet 15minutes prior to dosing ^(d)n = 15 ^(e)% coefficient of variation (CV),values are presented as mean (% CV) ^(f)fasted dogs were administered 12mg/kg sub-cutaneous pentagastrin 45 minutes prior to dosing ^(g)n = 16^(h)n = 14

Example 6: A Single-Dose, Open-Label, Randomized, Crossover Study toAssess the Pharmacokinetics of Ibrutinib Tablet Formulations in HealthyAdult Subjects Compared to the Ibrutinib Capsule Formulation a

This is a single-center, open-label, randomized, crossover, single-dosestudy in healthy adults. After providing written informed consent,subjects were screened within 21 days (Day −21 to −2).

Main Criteria for Inclusion:

Healthy men and women between 18 and 55 years of age, inclusive; bodymass index (BMI) between 18 and 30 kg/m², inclusive, and a body weightof not less than 50 kg. Women must be post-menopausal or surgicallysterile.

Eligible subjects received a single oral dose of ibrutinib 560 mg (ineither capsule formulation A comprising 140 mg ibrutinib per capsule ora tablet formulation comprising 560 mg ibrutinib per tablet) with 240 mLof noncarbonated water on Day 1 of each treatment period after fastingat least 10 hours before each dose. Water was allowed ad libitumbeginning 2 hours after each dose, and lunch was provided beginning 4hours after each dose.

Blood samples for pharmacokinetic (PK) analysis of ibrutinib werecollected before dosing and over 48 hours after dosing in each treatmentperiod.

Total duration of the study was approximately 70 days (21-day screeningperiod, 4×3-day treatment periods with 7-day washouts between periods,and a 7-day follow-up phase).

PK parameters including the following were calculated and the resultsare in Table 8:

-   -   C_(max): Maximum observed concentration    -   T_(max): Time to reach the maximum observed concentration    -   AUC_(last): Area under the concentration-time curve from time 0        to last time point    -   AUC_(∞): Area under the concentration-time curve from time 0 to        infinite time    -   t_(1/2): Apparent elimination half-life associated with the        terminal slope of the semilogarithmic drug concentration-time        curve

TABLE 8 Pharmacokinetics Parameters and Results C_(max) T_(max)AUC_(last) AUC_(inf) T_(1/2) Treatment N (ng/mL) (h) (ng * h/mL) (ng *h/mL) (h) Ibrutinib 32 Mean 48.6 1.64 379  465^(a) 9.5^(a) capsule SD36.0 1.09 248 248 3.5 Formulation Range 7.50-184 0.5-4   118-1100206-1120 5.9-20.0 A (4 × 140 mg/ % CV 74.1 66.2 62.4 53.4 36.9 capsule)Ibrutinib 22 Mean 47.7 2.80 413  472^(b) 8.3^(b) Tablet SD 43.7 4.88 227246 1.9 Formulation Range 7.50-181  1-24 135-1040 155-1060 5.9-13.1BK21A % CV 91.6 174 55.0 52.0 22.8 coated with a cosmetic film coatingagent - Opadry II white (560 mg/ tablet) Ibrutinib 21 Mean 35.5 1.90 355 411^(c) 7.8^(c) Tablet SD 21.9 1.28 135 130 2.0 Formulation Range 7.90-96.0 1-6 74.2-692   182-696 5.3-13.2 BK21B % CV 61.6 67.2 38.131.7 26.1 coated with a cosmetic film coating agent - Opadry II white(560 mg/ tablet) ^(a)n = 22; ^(b)n = 16; ^(c)n = 13

In some embodiments, the high load tablet formulations possess bothpharmaceutically acceptable properties and desired PK properties, suchas a high C_(max), similar to that of a capsule formulation (e.g.,BK21A).

Example 7: Safety and Tolerability Study of Compound 1 in ChronicLymphocytic Leukemia

Purpose: The purpose of this study is to establish the safety andoptimal dose of orally administered Compound 1 (420 mg/day) high-loadtablets in patients with B-cell chronic lymphocytic leukemia/smalllymphocytic lymphoma/diffuse well-differentiated lymphocytic lymphoma.

Primary Outcome Measures: Safety and tolerability of Compound 1(frequency, severity, and relatedness of adverse events).

Secondary Outcome Measures: Pharmacokinetic/Pharmacodynamic assessments.Tumor response—overall response rate as defined by recent guidelines onCLL and SLL (B cell lymphoma) and duration of response.

Eligibility: 18 Years and older; both genders are eligible.

Inclusion Criteria: 1. For treatment-naive group only: Men and women ≥65years of age with confirmed diagnosis of CLL/SLL, who require treatmentper NCI or International Working Group guidelines 11-14. 2. Forrelapsed/refractory group only: Men and women ≥18 years of age with aconfirmed diagnosis of relapsed/refractory CLL/SLL unresponsive totherapy (ie, failed ≥2 previous treatments for CLL/SLL and at least 1regimen had to have had a purine analog [eg, fludarabine] for subjectswith CLL). 3. Body weight ≥40 kg. 4. ECOG performance status of ≤2. 5.Agreement to use contraception during the study and for 30 days afterthe last dose of study drug if sexually active and able to bearchildren. 6. Willing and able to participate in all required evaluationsand procedures in this study protocol including swallowing tabletswithout difficulty. 7. Ability to understand the purpose and risks ofthe study and provide signed and dated informed consent andauthorization to use protected health information (in accordance withnational and local subject privacy regulations).

Exclusion Criteria: 1. A life-threatening illness, medical condition ororgan system dysfunction which, in the investigator's opinion, couldcompromise the subject's safety, interfere with the absorption ormetabolism of Compound 1 PO, or put the study outcomes at undue risk. 2.Any immunotherapy, chemotherapy, radiotherapy, or experimental therapywithin 4 weeks before first dose of study drug (corticosteroids fordisease-related symptoms allowed but require 1-week washout before studydrug administration). 3. Central nervous system (CNS) involvement bylymphoma. 4. Major surgery within 4 weeks before first dose of studydrug. 5. Creatinine >1.5×institutional upper limit of normal (ULN);total bilirubin >1.5×ULN (unless due to Gilbert's disease); andaspartate aminotransferase (AST) or alanine aminotransferase(ALT) >2.5×ULN unless disease related. 6. Concomitant use of medicinesknown to cause QT prolongation or torsades de pointes. 7. Significantscreening electrocardiogram (ECG) abnormalities including left bundlebranch block, 2nd degree AV block type II, 3rd degree block,bradycardia, and QTc >470 msec. 8. Lactating or pregnant.

Example 8: Safety and Efficacy of Compound 1 in Subjects withRelapsed/Refractory Mantle Cell Lymphoma (MCL)

The primary objective of this trial is to evaluate the efficacy ofCompound 1 in relapsed/refractory subjects with Mantle Cell Lymphoma(MCL). The secondary objective is to evaluate the safety of a fixeddaily dosing regimen of Compound 1 (560 mg/day in the form of tablets)in this population.

Primary Outcome Measures: To measure the number of participants with aresponse to Compound 1.

Secondary Outcome Measures: To measure the number of participants withadverse events as a measure of safety and tolerability. To measurepharmacokinetics to assist in determining how the body responds to thestudy drug. Patient reported outcomes (to measure the number ofparticipants reported outcomes in determining the health related qualityof life).

Eligibility: 18 Years and older; both genders are eligible.

Inclusion Criteria: Men and women ≥18 years of age. ECOG performancestatus of ≤2. Pathologically confirmed MCL, with documentation of eitheroverexpression of cyclin D1 or t(11;14), and measurable disease on crosssectional imaging that is ≥2 cm in the longest diameter and measurablein 2 perpendicular dimensions. Documented failure to achieve at leastpartial response (PR) with, or documented disease progression diseaseafter, the most recent treatment regimen. At least 1, but no more than5, prior treatment regimens for MCL (Note: Subjects having received ≥2cycles of prior treatment with bortezomib, either as a single agent oras part of a combination therapy regimen, will be considered to bebortezomib-exposed.). Willing and able to participate in all requiredevaluations and procedures in this study protocol including swallowingtablets without difficulty. Ability to understand the purpose and risksof the study and provide signed and dated informed consent andauthorization to use protected health information (in accordance withnational and local subject privacy regulations).

Major exclusion criteria: Prior chemotherapy within 3 weeks,nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4weeks, radio- or toxin-immunoconjugates within 10 weeks, radiationtherapy within 3 weeks, or major surgery within 2 weeks of first dose ofstudy drug. Any life-threatening illness, medical condition or organsystem dysfunction which, in the investigator's opinion, couldcompromise the subject's safety, interfere with the absorption ormetabolism of Compound 1 high-load tablets, or put the study outcomes atundue risk. Clinically significant cardiovascular disease such asuncontrolled or symptomatic arrhythmias, congestive heart failure, ormyocardial infarction within 6 months of screening, or any Class 3 or 4cardiac disease as defined by the New York Heart Association FunctionalClassification. Malabsorption syndrome, disease significantly affectinggastrointestinal function, or resection of the stomach or small bowel orulcerative colitis, symptomatic inflammatory bowel disease, or partialor complete bowel obstruction. Any of the following laboratoryabnormalities: 1. Absolute neutrophil count (ANC)<750 cells/mm3(0.75×109/L) unless there is documented bone marrow involvement. 2.Platelet count <50,000 cells/mm3 (50×109/L) independent of transfusionsupport unless there is documented bone marrow involvement. 3. Serumaspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT)≥3.0×upper limit of normal (ULN). 4. Creatinine >2.0×ULN.

Example 9: Phase 2 Study of the Combination of Compound 1 and Rituximabin High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaPatients

Purpose: The goal of this clinical research study is to learn ifCompound 1 combined with rituximab can help to control chroniclymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Thesafety of this combination will also be studied.

Rituximab (375 mg/m²) will be given intravenously (IV) on Day 1, Day 8,Day 15, and Day 22, then continued once every 4 weeks only on Days 1during cycles 2-6. Compound 1 will be started on Day 2 of cycle 1 at adose of 420 mg (one 420 mg tablet) orally daily and will be continueddaily.

Primary Outcome Measures: Progression free survival (PFS) [Time Frame: 3months]—progression free survival defined as the time interval fromtreatment to progressive disease or death, whichever happens earlier.Patients in complete remission (CR), partial remission (PR) or stabledisease (SD) are all counted as progression-free. Survival or times toprogression functions estimated using the Kaplan-Meier method.

Secondary Outcome Measures: Toxicity [Time Frame: 3 months]—toxicityreported by type, frequency and severity. Worst toxicity grades perpatient tabulated for selected adverse events and laboratorymeasurements. Toxicity (grade 3 or 4) monitored based on the Bayesianmodel (beta-binomial) by assuming a priori probability of toxicityfollowing beta(1,1).

Eligibility: 18 Years and older; both genders are eligible.

Inclusion Criteria: 1. Patients must have a diagnosis of high-riskCLL/SLL and be previously treated with up to 3 lines of prior therapy.High-risk CLL and high-risk SLL is defined by the presence of a 17pdeletion or 11q deletion or TP53 mutation. Any CLL and SLL patient whohas a short remission duration of less than 3 years after priorfirst-line chemo-immunotherapy, such as the FCR regimen, also fulfillscriteria of high-risk CLL/SLL, regardless of the presence or absence ofcytogenetic abnormalities. 2. CLL and SLL patients with 17p deletion orTP53 mutation will not be required to have received any prior therapy,given the poor outcome of CLL/SLL patients to standard frontlinechemo-immunotherapy, such patients will be eligible if they areuntreated or if they have received up to 3 lines of prior therapy. 3.Patients must have an indication for treatment by 2008 IWCLL Criteria.4. Patients age >18 years at the time of signing informed consent.Understand and voluntarily sign an informed consent. Be able to complywith study procedures and follow-up examinations. 5. ECOG/WHOperformance status of 0-1. 6. Patients of childbearing potential must bewilling to practice highly effective birth control (e.g., condoms,implants, injectables, combined oral contraceptives, some intrauterinedevices [IUDs], sexual abstinence, or sterilized partner) during thestudy and for 30 days after the last dose of study drug. Women ofchildbearing potential include any female who has experienced menarcheand who has not undergone successful surgical sterilization(hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) oris not postmenopausal. Post menopause is defined as follows:Amenorrhea >/=12 consecutive months without another cause and adocumented serum follicle stimulating hormone (FSH) level >35 mIU/mL; amale of childbearing potential is any male that has not been surgicallysterilized. 7. Adequate renal and hepatic function as indicated by allof the following: Total bilirubin </=1.5×institutional Upper Limit ofNormal (ULN) except for patients with bilirubin elevation due toGilbert's disease who will be allowed to participate; an ALT </=2.5×ULN;and an estimated creatinine clearance (CrCl) of >30 mL/min, ascalculated by the Cockroft-Gault equation unless disease related. 8.Free of prior malignancies for 3 years with exception of currentlytreated basal cell, squamous cell carcinoma of the skin, or carcinoma insitu of the cervix or breast. 9. A urine pregnancy test (within 7 daysof Day 1) is required for women with childbearing potential.

Exclusion Criteria: 1. Pregnant or breast-feeding females. 2. Treatmentincluding chemotherapy, chemo-immunotherapy, monoclonal antibodytherapy, radiotherapy, high-dose corticosteroid therapy (more than 60 mgPrednisone or equivalent daily), or immunotherapy within 21 days priorto enrollment or concurrent with this trial. 3. Investigational agentreceived within 30 days prior to the first dose of study drug or havepreviously taken Compound 1. If received any investigational agent priorto this time point, drug-related toxicities must have recovered to Grade1 or less prior to first dose of study drug. 4. Systemic fungal,bacterial, viral, or other infection not controlled (defined asexhibiting ongoing signs/symptoms related to the infection and withoutimprovement, despite appropriate antibiotics or other treatment). 5.Patients with uncontrolled Autoimmune Hemolytic Anemia (AIHA) orautoimmune thrombocytopenia (ITP). 6. Patients with severe hematopoieticinsufficiency, as defined by an absolute neutrophil count of less than500/micro-L and/or a platelet count of less than 30,000/micro-L at timeof screening for this protocol. 7. Any other severe concurrent disease,or have a history of serious organ dysfunction or disease involving theheart, kidney, liver or other organ system that may place the patient atundue risk to undergo therapy with Compound 1 and rituximab. 8.Significant cardiovascular disease such as uncontrolled or symptomaticarrhythmias, congestive heart failure, or myocardial infarction within 6months of screening, or any Class 3 or 4 cardiac disease as defined bythe New York Heart Association Functional Classification. 9. Significantscreening ECG abnormalities including left bundle branch block, 2nddegree AV block type II, 3rd degree block, bradycardia, and QTc >470msec. 10. Any serious medical condition, laboratory abnormality, orpsychiatric illness that places the subject at unacceptable risk ifhe/she were to participate in the study. 11. History of stroke orcerebral hemorrhage within 6 months. 12. Evidence of bleeding diathesisor coagulopathy. 13. Major surgical procedure, open biopsy, orsignificant traumatic injury within 28 days prior to Day 1, anticipationof need for major surgical procedure during the course of the study. 14.Minor surgical procedures, fine needle aspirations or core biopsieswithin 7 days prior to Day 1. Bone marrow aspiration and/or biopsy areallowed. 15. Serious, non-healing wound, ulcer, or bone fracture. 16.Treatment with Coumadin. Patients who recently received Coumadin must beoff Coumadin for at least 7 days prior to start of the study. 17. Anychemotherapy (e.g., bendamustine, cyclophosphamide, pentostatin, orfludarabine), immunotherapy (e.g., alemtuzumab, or ofatumumab), bonemarrow transplant, experimental therapy, or radiotherapy is prohibitedduring therapy on this study. 18. Use of medications known to prolongQTc interval or that may be associated with Torsades de Pointes (referto Appendix F) are prohibited within 7 days of starting study drug andduring study-drug treatment.

The examples and embodiments described herein are illustrative andvarious modifications or changes suggested to persons skilled in the artare to be included within this disclosure. As will be appreciated bythose skilled in the art, the specific components listed in the aboveexamples may be replaced with other functionally equivalent components,e.g., diluents, binders, lubricants, fillers, and the like.

What is claimed is:
 1. A solid tablet formulation comprising ibrutiniband one or more pharmaceutically acceptable excipients, whereinibrutinib is a compound with the structure of Compound 1,

wherein the ibrutinib is in micronized form; and wherein ibrutinib is inan amount of about 140 mg, about 280 mg, about 420 mg, or about 560 mgin the tablet.
 2. The solid tablet formulation of claim 1, wherein theparticle size of micronized ibrutinib is about or less than 30 microns.3. The solid tablet formulation of claim 1, wherein the particle size ofmicronized ibrutinib is about or less than 10 microns.
 4. The solidtablet formulation of claim 1, wherein the particle size of micronizedibrutinib is less than about 1 micron.
 5. The solid tablet formulationof claim 1 further comprising one or more diluents.
 6. The solid tabletformulation of claim 5, wherein the one or more diluents are selectedfrom the group consisting of lactose, sucrose, dextrose, dextrates,maltodextrin, mannitol, xylitol, sorbitol, cyclodextrins, calciumphosphate, calcium sulfate, starches, modified starches, cellulose,microcrystalline cellulose, microcellulose, and talc.
 7. The solidtablet formulation of claim 5, wherein the one or more diluents arelactose, cellulose, microcrystalline cellulose, or a combinationthereof.
 8. The solid tablet formulation of claim 5 further comprisingone or more lubricants.
 9. The solid tablet formulation of claim 8,wherein the one or more lubricants are a stearate, a polyethylene glycol(PEG), or a wax.
 10. The solid tablet formulation of claim 8 furthercomprising one or more disintegrating agents.
 11. The solid tabletformulation of claim 10, wherein the one or more disintegrating agentsare selected from the group consisting of natural starch, apregelatinized starch, a sodium starch, methylcrystalline cellulose,methylcellulose, croscarmellose, croscarmellose sodium, cross-linkedsodium carboxymethylcellulose, cross-linked carboxymethylcellulose,cross-linked croscarmellose, cross-linked starch, cross-linked polymer,cross-linked polyvinylpyrrolidone, sodium alginate, a clay, and a gum.12. The solid tablet formulation of claim 10, wherein the one or moredisintegrating agents are selected from the group consisting of naturalstarch, a pregelatinized starch, a sodium starch, methylcrystallinecellulose, methylcellulose, croscarmellose, croscarmellose sodium,cross-linked sodium carboxymethylcellulose, cross-linkedcarboxymethylcellulose, cross-linked croscarmellose, sodium starchglycolate, crospovidone, cross-linked polyvinylpyrrolidone, sodiumalginate, a clay, and a gum.
 13. The solid tablet formulation of claim 8further comprising one or more binders.
 14. The solid tablet formulationof claim 13, wherein the one or more binders are polyvinylpyrrolidone orhydroxypropyl cellulose.
 15. The solid tablet formulation of claim 1comprising: a. at least 50% w/w of ibrutinib; b. one or more diluents;and c. one or more lubricants.
 16. The solid tablet formulation of claim1 comprising: a. about 50% w/w to about 90% w/w of ibrutinib; b. about5% w/w to about 20% w/w of one or more diluents; and c. about 0.1% w/wto about 1.5% w/w of one or more lubricants.
 17. The solid tabletformulation of claim 1, wherein the excipients comprise intragranularand extragranular excipients; and the intragranular excipients compriseone or more diluents; and the extragranular excipients comprise one ormore lubricants.
 18. The solid tablet formulation of claim 1, whereinthe excipients comprise intragranular and extragranular excipients; andthe intragranular excipients comprise lactose and microcrystallinecellulose; and the extragranular excipients comprise magnesium stearate.19. The solid tablet formulation of claim 1, wherein the excipientscomprise lactose in an amount from about 5% w/w to about 20% w/w, about10% w/w to about 20% w/w, about 8% w/w to about 15% w/w, about 8.5% w/wto about 14% w/w, or about 12% w/w to about 15% w/w.
 20. The solidtablet formulation of claim 1, wherein the excipients comprisemicrocrystalline cellulose in an amount from about 5% w/w to about 20%w/w, about 8% w/w to about 20% w/w, about 8% w/w to about 15% w/w, about1% w/w to about 10% w/w, or about 2% w/w to about 5% w/w.
 21. The solidtablet formulation of claim 1, wherein the excipients comprise magnesiumstearate in an amount from about 0.1% w/w to about 1.5% w/w, about 0.4%w/w to about 0.8% w/w, or about 0.5% w/w to about 0.6% w/w.
 22. Thesolid tablet formulation of claim 1, wherein the excipients compriseintragranular and extragranular excipients; and the intragranularexcipients comprise lactose, microcrystalline cellulose, croscarmellosesodium, and hydroxypropyl cellulose; and the extragranular excipientscomprise croscarmellose sodium and magnesium stearate.
 23. The solidtablet formulation of claim 1, wherein the excipients comprisecroscarmellose sodium in an amount from about 0 to about 10% w/w, about0 to about 5% w/w, about 1% w/w to about 10% w/w, about 2% w/w to about5% w/w, about 2% w/w to about 4% w/w, about 3% w/w to about 7% w/w, orabout 1% w/w to about 3% w/w.
 24. The solid tablet formulation of claim1, wherein the excipients comprise hydroxypropyl cellulose in an amountfrom about 0 to about 2% w/w, about 0.1% w/w to about 1.1% w/w, or about0.1% w/w to about 1% w/w.
 25. The solid tablet formulation of claim 1,wherein the excipients comprise intragranular and extragranularexcipients; and the intragranular excipients comprise lactose,polyvinylpyrrolidone, and croscarmellose sodium; and the extragranularexcipients comprise croscarmellose sodium, microcrystalline cellulose,and magnesium stearate.
 26. The solid tablet formulation of claim 1,wherein the excipients comprise polyvinylpyrrolidone in an amount fromabout 0% w/w to about 5% w/w, or about 1% w/w to about 3% w/w.
 27. Thesolid tablet formulation of claim 1, wherein the high-load solid tabletformulation is used for one tablet once a day dosing.
 28. The solidtablet formulation of claim 1, wherein the formulation comprises about60% w/w to about 80% w/w of ibrutinib.